<?xml version="1.0" encoding="UTF-8"?>
<projectSnippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4246609/results/search/funders/results.xml">
   <result pre="was clinically and radiologically classified as cT3cNxcM0 according to the" exact="World Health Organization" post="International Classification of Tumors ( 5). Computed tomography of"/>
   <result pre="2005, SDC was defined as an independent entity by the" exact="World Health Organization," post="labeling it as ‘an aggressive adenocarcinoma, which resembled high-grade"/>
   <result pre="Nagao T Salivary duct carcinoma Tumours of the Salivary Glands" exact="World Health Organization" post="Classification of Tumours Pathology and Genetics of Head and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4261061/results/search/funders/results.xml">
   <result pre="[6], *To whom correspondence should be addressed: Address: Dana 1538," exact="Dana-Farber Cancer Institute," post="450 Brookline Ave., Boston, MA 02115, William_Hahn@dfci.harvard.edu, Tel: 617-632-2641,"/>
   <result pre="Toronto Research Chemicals, and trastuzumab (Herceptin) was purchased from the" exact="Dana-Farber Cancer Institute" post="pharmacy. Luminescence Assays For ATP-based viability assays, 40 ul"/>
   <result pre="samples with associated clinical information were obtained for analysis under" exact="Dana-Farber Cancer Institute" post="Institutional Review Board Protocols 93-085 and 11-264. All subjects"/>
   <result pre="purchased from U.S. Biomax. PRKACA immunohistochemistry was performed by the" exact="Dana-Farber/Harvard Cancer Center" post="Research Pathology core using standard protocols. The PRKACA primary"/>
   <result pre="Grant W81XWH-10-1-0575 and Komen Grant CCR13262292 (to S.E.M.), by the" exact="Breast Cancer Research Foundation" post="(to Z.C.W), and by NIH grants R01 CA130988, U01"/>
   <result pre="W81XWH-10-1-0575 and Komen Grant CCR13262292 (to S.E.M.), by the Breast" exact="Cancer Research Foundation" post="(to Z.C.W), and by NIH grants R01 CA130988, U01"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4293298/results/search/funders/results.xml">
   <result pre="short life expectancy. Mastectomy or BCS Concerning surgery, the randomized" exact="European Organisation for Research and Treatment of Cancer" post="(EORTC) 10850 trial found no difference in terms of"/>
   <result pre="with lumpectomy, tangential whole breast irradiation, and systemic therapy, the" exact="American College of Surgeons" post="Oncology Group Z0011 Phase III study showed that axillary"/>
   <result pre="from 30 to 65 years 67 and validated by the" exact="American Society of Clinical Oncology" post="Clinical Practice Guideline Update. 68 An alternative to axillary"/>
   <result pre="Sentinel lymph node biopsy for patients with early-stage breast cancer:" exact="American Society of Clinical Oncology" post="Clinical Practice Guideline Update J Clin Oncol 2014 32"/>
   <result pre="Inst 1996 88 21 1529 1542 8901851 80 Kunkler IH" exact="Williams" post="LW Jack W et al. The PRIME II trial:"/>
   <result pre="conservative surgery Cancer 2012 118 19 4642 4651 22890779 85" exact="Williams" post="LJ Kunkler IH King CC Jack W van der"/>
   <result pre="(RESPECT) Available from: http://clinicaltrials.gov/show/NCT01104935 Accessed August 15, 2014 192 collab:" exact="European Organisation for Research and Treatment of Cancer" post="Elderly metastatic breast cancer: pertuzumab-herceptin vs pertuzumab-herceptin-metronomic chemotherapy, followed"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4303336/results/search/funders/results.xml">
   <result pre="radiotherapy in the ESMO guidelines. 91 The guidelines from the" exact="American Society of Echocardiography" post="(ASE) and the European Association of Cardiovascular Imaging (EACVI)"/>
   <result pre="The only medication that has been approved by the US" exact="Food and Drug Administration" post="for the prevention of anthracycline-related cardiotoxicity is dexrazoxane. Its"/>
   <result pre="LJ et al. Postmastectomy radiotherapy: clinical practice guidelines of the" exact="American Society of Clinical Oncology" post="J Clin Oncol 2001 19 5 1539 1569 11230499"/>
   <result pre="report from the European Association of Cardiovascular Imaging and the" exact="American Society of Echocardiography" post="Eur Heart J Cardiovasc Imaging 2013 14 8 721"/>
   <result pre="148 1 33 39 25266130 27 Prescott RJ Kunkler IH" exact="Williams" post="LJ et al. A randomised controlled trial of postoperative"/>
   <result pre="patients during and after cancer therapy: a report from the" exact="American Society of Echocardiography" post="and the European Association of Cardiovascular Imaging Eur Heart"/>
   <result pre="124 5 642 650 21810673 141 Haykowsky MJ Mackey JR" exact="Thompson" post="RB Jones LW Paterson DI Adjuvant trastuzumab induces ventricular"/>
   <result pre="Task Force on Practice Guidelines Developed in Collaboration With the" exact="International Society for Heart and Lung Transplantation" post="J Am Coll Cardiol 2009 53 15 e1 e90"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4307685/results/search/funders/results.xml">
   <result pre="responsibility for final content. Acknowledgements This work was supported by" exact="National Natural Science Foundation of China" post="(No. 81172110), National High Technology Research and Development Program"/>
   <result pre="Natural Science Foundation of China (No. 81172110), National High Technology" exact="Research and Development" post="Program (No. 2012AA02A504), Beijing Municipal Science &amp;amp; Technology Commission"/>
   <result pre="Commission Program (No. Z11110706730000), Beijing Natural Science Foundation (7142034), and" exact="China Postdoctoral Science Foundation" post="(2013 M530494). References References 1. Jemal A Bray F"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4309158/results/search/funders/results.xml">
   <result pre="Program, Lowy Cancer Research Centre, Prince of Wales Clinical School," exact="University of New South Wales" post="(UNSW) Sydney, NSW Australia [], 2 Department of Surgery,"/>
   <result pre="of New South Wales (UNSW) Sydney, NSW Australia [], 2" exact="Department of Surgery," post="Prince of Wales Clinical School, University of New South"/>
   <result pre="[], 2 Department of Surgery, Prince of Wales Clinical School," exact="University of New South Wales" post="(UNSW) Sydney, NSW Australia [], 3 Department of Medical"/>
   <result pre="3 Department of Medical Oncology, Prince of Wales Clinical School," exact="University of New South Wales" post="(UNSW) Sydney, NSW Australia Edited by: Francois X. Claret,"/>
   <result pre="X. Claret, University of Texas, USA Reviewed by: Ruth Keri," exact="Case Western Reserve University," post="USA; Nune Markosyan, University of Pennsylvania, USA; Anastasia Pazaiti,"/>
   <result pre="by: Ruth Keri, Case Western Reserve University, USA; Nune Markosyan," exact="University of Pennsylvania," post="USA; Anastasia Pazaiti, emBIO Medical Center, Greece *Correspondence: Jia-Lin"/>
   <result pre="*Correspondence: Jia-Lin Yang, Adult Cancer Program, Lowy Cancer Research Centre," exact="University of New South Wales" post="(UNSW), Room 209, Building C25, Sydney, NSW 2052, Australia"/>
   <result pre="or exon 21 ( L858R) substitution mutations by the US" exact="Food and Drug Administration" post="( 104). panHER combination therapy Combination therapy involving panHER"/>
   <result pre="2009) 135( 9): 1137– 48. 10.1007/s00432-009-0622-4 19533170 15 Mor A" exact="Philips" post="MR . Compartmentalized Ras/MAPK signaling. Annu Rev Immunol ("/>
   <result pre="The ErbB signaling network: receptor heterodimerization in development and cancer." exact="EMBO" post="J ( 2000) 19( 13): 3159– 67 10.1093/emboj/19.13.3159 10880430"/>
   <result pre="2012) 69( 4): 1051– 61. 10.1007/s00280-011-1803-9 22200729 104 Afatinib US" exact="Food and Drug Administration." post="( 2013). Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm360574.htm 105 Huang Z Brdlik"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4310719/results/search/funders/results.xml">
   <result pre="exposure. 7 Treatment with third-generation AIs, including letrozole (Femara ®;" exact="Novartis" post="Pharmaceuticals Corporation, East Hanover, NJ, USA), anastrozole (Arimidex ®;"/>
   <result pre="Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA), anastrozole (Arimidex ®;" exact="AstraZeneca" post="Pharmaceuticals LP, Wilmington, DE, USA), and exemestane (Aromasin ®;"/>
   <result pre="AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA), and exemestane (Aromasin ®;" exact="Pfizer" post="Inc., New York, NY, USA), has become the standard"/>
   <result pre="example, second-line treatment with anastrozole vs megestrol acetate (Megace ®;" exact="Bristol-Myers Squibb" post="Company, Princeton, NJ, USA) in two Phase III trials"/>
   <result pre="Other endocrine therapies The selective ER downregulator fulvestrant (Faslodex ®;" exact="AstraZeneca" post="Pharmaceuticals LP) is believed to delay resistance to endocrine"/>
   <result pre="inhibitors In preclinical studies, the mTOR inhibitor everolimus (Afinitor ®;" exact="Novartis" post="Pharmaceuticals Corporation) in combination with endocrine therapy, including AIs"/>
   <result pre="studies evaluated the oral tyrosine kinase inhibitor gefitinib (Iressa ®;" exact="AstraZeneca" post="Pharmaceuticals LP) in combination with anastrozole or tamoxifen vs"/>
   <result pre="(ApotheCom, Yardley, PA, USA). This editorial support was funded by" exact="Novartis" post="Pharmaceuticals Corporation. Disclosure The author reports no conflicts of"/>
   <result pre="J Clin 2011 61 2 69 90 21296855 2 collab:" exact="American Cancer Society" post="Cancer Facts and Figures 2014 Atlanta, GA American Cancer"/>
   <result pre="American Cancer Society Cancer Facts and Figures 2014 Atlanta, GA" exact="American Cancer Society" post="2014 3 Setiawan VW Monroe KR Wilkens LR Kolonel"/>
   <result pre="Clin Invest 2011 121 10 3797 3803 21965336 14 collab:" exact="American Cancer Society" post="Breast Cancer Facts and Figures: 2013–2014 Atlanta, GA American"/>
   <result pre="Cancer Society Breast Cancer Facts and Figures: 2013–2014 Atlanta, GA" exact="American Cancer Society" post="2013 15 Johnson RH Chien FL Bleyer A Incidence"/>
   <result pre="mg tablets, 10 mg tablets [package insert] East Hanover, NJ" exact="Novartis" post="Pharmaceuticals Corporation 2014 59 Kardinal CG Perry MC Weinberg"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4315003/results/search/funders/results.xml">
   <result pre="Sun, Department of Breast and Thyroid Surgery, Renmin Hospital of" exact="Wuhan University," post="238 Jiefang Road, Wuhan, Hubei 430060, P.R. China, E-mail:"/>
   <result pre="was approved by the ethics committee of Renmin Hospital of" exact="Wuhan University" post="(Wuhan, China). Search strategy MEDLINE (National Library of Medicine,"/>
   <result pre="Science Center San Antonio, San Antonio, TX, USA) and the" exact="American Society of Clinical Oncology" post="Annual Meeting (American Society of Clinical Oncology, Alexandria, VA,"/>
   <result pre="Project. Table I Characteristics of eligible trials. Clinical trial (reference)" exact="Total" post="number of patients, n HER2 status assessment Number of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4316710/results/search/funders/results.xml">
   <result pre="Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital," exact="McGill University" post="Montreal, QC, Canada [], 2 Department of Otolaryngology-Head and"/>
   <result pre="Otolaryngology-Head and Neck Surgery, Sir Mortimer B. Davis-Jewish General Hospital," exact="McGill University" post="Montreal, QC, Canada Edited by: Marcelo Rizzatti Luizon, University"/>
   <result pre="McGill University Montreal, QC, Canada Edited by: Marcelo Rizzatti Luizon," exact="University of California," post="San Francisco, USA Reviewed by: Juergen Reichardt, James Cook"/>
   <result pre="Reviewed by: Juergen Reichardt, James Cook Univerrsity, Australia; Wanqing Liu," exact="Purdue University," post="USA *Correspondence: Moulay A. Alaoui-Jamali and Sabrina Daniela da"/>
   <result pre="Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital," exact="McGill University," post="3755 Côte Ste-Catherine Road, Montreal, QC H3T 1E2, Canada"/>
   <result pre="molecule inhibitors under clinical trials or approved by the US" exact="Food and Drug Administration" post="(FDA) are either reversible or irreversible inhibitors that bind"/>
   <result pre="the Quebec Breast Cancer Foundation and the Canadian Institutes for" exact="Health Research." post="Grégoire B. Morand is supported by the Swiss Cancer"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4322830/results/search/funders/results.xml">
   <result pre="disease and the association with secondary malignancies Journal of the" exact="American College of Surgeons" post="2003 196 1 45 50 10.1016/s1072-7515(02)01619-8 12517548 2 Paget"/>
   <result pre="disease: prognosis and relationship to internal malignancy Journal of the" exact="American Academy of Dermatology" post="1985 13 6 1009 1014 10.1016/s0190-9622(85)70254-x 3001158 9 Hegarty"/>
   <result pre="Micallef R. A. Barrett-Lee P. J. Donovan K. Ashraf M." exact="Williams" post="L. Trastuzumab in patients on haemodialysis for renal failure"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4323263/results/search/funders/results.xml">
   <result pre="Walter and Eliza Hall Institute, which receives commercial income from" exact="Genentech" post="and Abbvie. The authors declare that they have no"/>
   <result pre="preparing the figures. This work was supported by the Australian" exact="National Health and Medical Research Council" post="(NHMRC) grants #1016701 and #1040978, the NHMRC IRIISS, and"/>
   <result pre="This work was supported by the Australian National Health and" exact="Medical Research Council" post="(NHMRC) grants #1016701 and #1040978, the NHMRC IRIISS, and"/>
   <result pre="G. Komen Foundation grant KG120001, NIH/NCI grant U54 CA149196, and" exact="Baylor College of Medicine" post="Cancer Center grant P30 CA125123. GJL is supported by"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4325954/results/search/funders/results.xml">
   <result pre="Acknowledgements CP was funded by the Hewlett charitable bequest to" exact="Aston University." post="There was no involvement from the funder in design,"/>
   <result pre="472 82 10.1016/j.ccr.2008.05.005 18538731 10. Vander Heiden MG Cantley LC" exact="Thompson" post="CB Understanding the Warburg effect: the metabolic requirements of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4330173/results/search/funders/results.xml">
   <result pre="First Hospital of Zibo City 2013 Natural Scientific Foundation of" exact="Shandong Province" post="ZR2010CQ031 INTRODUCTION In females, breast cancer (BC) is the"/>
   <result pre="2. Isolation of total RNA and real-time quantitative (RQ)-PCR analysis" exact="Total" post="RNA was extracted from tumors, adjacent normal tissues, and"/>
   <result pre="Hospital of Zibo City, and the Natural Scientific Foundation of" exact="Shandong Province" post="(grant No. ZR2010CQ031). No potential conflicts of interest relevant"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4331616/results/search/funders/results.xml">
   <result pre="therapy or death. Adverse events were assessed according to the" exact="National Cancer Institute" post="Common Terminology Criteria for Adverse Events (CTCAE version 3.0)."/>
   <result pre="SAS ® System (SAS is a registered trademark of the" exact="SAS Institute," post="Inc., Cary, NC, USA) was used to analyze the"/>
   <result pre="n (%) Grade 1 Grade 2 Grade 3 Grade 4" exact="Total" post="PPE syndrome 18 (35) 16 (31) 5 (10) 0"/>
   <result pre="at all the study centers. This work was sponsored by" exact="GlaxoSmithKline" post="K.K. Part of this work was previously presented at"/>
   <result pre="was previously presented at the Eighth Annual Meeting of the" exact="Japanese Society of Medical Oncology" post="in 2010. References References 1. Ross JS Slodkowska EA"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4333494/results/search/funders/results.xml">
   <result pre="6 * [1], Department of Breast Medical Oncology at The" exact="University of Texas, MD Anderson Cancer Center" post="USA [2], Department of Systems Biology at The University"/>
   <result pre="Cancer Center USA [2], Department of Systems Biology at The" exact="University of Texas, MD Anderson Cancer Center" post="USA [3], Department of Biostatistics at The University of"/>
   <result pre="Anderson Cancer Center USA [3], Department of Biostatistics at The" exact="University of Texas, MD Anderson Cancer Center" post="USA [4], Department of Surgical Oncology at The University"/>
   <result pre="Cancer Center USA [4], Department of Surgical Oncology at The" exact="University of Texas, MD Anderson Cancer Center" post="USA [5], Department of Pathology at The University of"/>
   <result pre="Anderson Cancer Center USA [5], Department of Pathology at The" exact="University of Texas, MD Anderson Cancer Center" post="USA [6], Department of Health Services Research at The"/>
   <result pre="The University of Texas, MD Anderson Cancer Center USA [6]," exact="Department of Health" post="Services Research at The University of Texas, MD Anderson"/>
   <result pre="Center USA [6], Department of Health Services Research at The" exact="University of Texas, MD Anderson Cancer Center" post="USA *E-mail: mchavez1@mdanderson.org ppub: 2015-02-02 epub: 2015-01-01 112 4"/>
   <result pre="4 630 635 received: 2014-07-25 rev-recd: 2014-11-21 accepted: 2014-12-06 (C)" exact="Cancer Research UK," post="2015 From twelve months after its original publication, this"/>
   <result pre="review of the Breast Medical Oncology Institutional database at The" exact="University of Texas MD Anderson Cancer Center" post="was performed. Women with HER2-positive primary invasive breast cancer"/>
   <result pre="( Pritchard, 2010). This work was supported in part by" exact="American Cancer Society" post="Research Scholar Grant 121329-RSG-11-187-01-TBG (AMG) and The Commonwealth Foundation"/>
   <result pre="American Cancer Society Research Scholar Grant 121329-RSG-11-187-01-TBG (AMG) and The" exact="Commonwealth Foundation" post="for Cancer Research (AMG). DHHS–NIH–National Cancer Institute: 2P30 CA016672"/>
   <result pre="of this study were presented in part at the 2014" exact="American Society of Clinical Oncology," post="Chicago, IL, June, 2014. GNH, VV, and AMG have"/>
   <result pre="2014. GNH, VV, and AMG have received research funding from" exact="Genentech" post="and GSK. All remaining authors have declared no conflicts"/>
   <result pre="G Royce M McCall LM Ewer MS Hunt KK collab:" exact="American College of Surgeons" post="Oncology Group, investigators 2013 Fluorouracil, epirubicin, and cyclophosphamide (FEC-75)"/>
   <result pre="MF Spears PA Vance GH Viale G Hayes DF collab:" exact="American Society of Clinical Oncology;" post="College of American Pathologists 2013 Recommendations for human epidermal"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4335966/results/search/funders/results.xml">
   <result pre="latest advancements in this field. Dr Ian Krop from the" exact="Dana-Farber Cancer Institute," post="Boston, MA on behalf of his colleagues commenced the"/>
   <result pre="identify small differences between treatment arms. Dr Kerin Adelson from" exact="Yale University" post="School of Medicine, New Haven, CT presented results of"/>
   <result pre="differences between treatment arms. Dr Kerin Adelson from Yale University" exact="School of Medicine," post="New Haven, CT presented results of a randomised phase"/>
   <result pre="to endocrine therapy with fulvestrant. Dr Rinath Jeselsohn from the" exact="Dana-Farber Cancer Institute," post="Boston, MA on behalf of her colleagues presented the"/>
   <result pre="treatments (PARP inhibition). HER-2+ disease: Dr Teema Juntilla from the" exact="University of Washington" post="discussed on behalf of his colleagues the potential application"/>
   <result pre="of the cell lines (17/21). Dr Sara Hurvitz from the" exact="University of California," post="Los Angeles, CA and colleagues discussed the results of"/>
   <result pre="in the absence of hormonal therapy. Dr M Rimawi from" exact="Baylor College of Medicine," post="Houston, TX discussed on behalf of the Translational Breast"/>
   <result pre="adjuvant setting. Triple negative disease: Dr Rita Nanda from the" exact="University of Chicago," post="IL described on behalf of colleagues the use of"/>
   <result pre="dual compared to single agent treatment. Dr Kathy Albain from" exact="Loyola University, Chicago" post="IL on behalf of colleagues described how the addition"/>
   <result pre="considered high priorities for pharmacological interventions. Pascal Gellert from the" exact="Institute of Cancer Research," post="London and colleagues assessed exome sequencing of post-menopausal ER-positive"/>
   <result pre="phenotype on AI therapy. Dr Ryan J Hartmaier from the" exact="University of Pittsburgh" post="with colleagues performed a comprehensive analysis of genomic alterations"/>
   <result pre="potentially the vast majority of cancers. Dr Shailja Pathania from" exact="Dana-Farber Cancer Institute," post="Boston, MA and colleagues focused their research on replication"/>
   <result pre="a careful assessment of risk and benefits. Dr Chlebowsky from" exact="University of California," post="Los Angeles (UCLA), CA and colleagues presented the results"/>
   <result pre="translates to better DFS and OS. Professor Andrew Tutt from" exact="King’s College London," post="UK on behalf of colleagues discussed the treating of"/>
   <result pre="Prognostic indicators of adjuvant therapy Dr Edith Perez from the" exact="Mayo Clinic," post="Jacksonville, Florida, presenting on behalf of her colleagues upon"/>
   <result pre="therapy including pathological complete response. Dr Katherine Hoardley from the" exact="University of North Carolina" post="and colleagues presented the mutational analysis of CALGB 40601"/>
   <result pre="pCR to chemotherapy plus HER-2-targeting. Dr Bruce Tromberg from the" exact="University of California," post="Irvine, CA on behalf of colleagues discussed the role"/>
   <result pre="4.667, 95% CI: 0.945 to 23.038). Dr William Sikov from" exact="Brown University," post="Providence, RI on behalf of colleagues presented their assessment"/>
   <result pre="= 0.031, 0.0017, 0.0002, respectively). Dr Justin Balko from the" exact="Vanderbilt University," post="Nashville, TN presented on behalf of colleagues their assessment"/>
   <result pre="and cost assessment was planned. Dr J Lipson from the" exact="Stanford University" post="School of Medicine further discussed the role of supplemental"/>
   <result pre="assessment was planned. Dr J Lipson from the Stanford University" exact="School of Medicine" post="further discussed the role of supplemental screening for women"/>
   <result pre="and much less for tomosynthesis. Professor Eilen Rakovitch from the" exact="University of Toronto," post="ON presented on behalf of colleagues a population-based validation"/>
   <result pre="are highlighted form the conference. Professor Mary-Claire King from the" exact="University of Washington," post="Seattle, WA gave a thought-provoking lecture on the genomic"/>
   <result pre="measures and patient-satisfaction within breast conservation. Dr Muneer Ahmed from" exact="King’s College London," post="UK discussed the use of a handheld magnetometer and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4339844/results/search/funders/results.xml">
   <result pre="mechanisms. Funding This work was supported by the German Federal" exact="Ministry of Education" post="and Research in the platform MedSys via the project"/>
   <result pre="addition of trastuzumab or fresh full growth media. RNA sequencing" exact="Total" post="RNA was isolated from the cell lines BT474, HCC1954"/>
   <result pre="association between nuclear HER2 and the PTGS2 promoter. Flowers and" exact="Thompson" post="treated SKBR3 with t10c12 conjugated linoleic acid (CLA) and"/>
   <result pre="Genome Biol 11( 10): R106 doi: 10.1186/gb-2010-11-10-r106 20979621 24 R" exact="Core" post="Team (2013) R: A Language and Environment for Statistical"/>
   <result pre="gene expression data using real-time quantitative PCR and the 2(-Delta" exact="Delta" post="C(T)) method . Methods 25( 4): 402– 408. doi:"/>
   <result pre="3): 251– 261. doi: 10.1016/j.ccr.2004.07.012 15380516 41 Flowers M ," exact="Thompson" post="PA ( 2009) t10c12 conjugated linoleic acid suppresses HER2"/>
   <result pre="The ErbB signaling network: receptor heterodimerization in development and cancer." exact="EMBO" post="J 19( 13): 3159– 3167. doi: 10.1093/emboj/19.13.3159 10880430 46"/>
   <result pre="49 Mann M , Sheng H , Shao J ," exact="Williams" post="CS , Pisacane PI , et al. ( 2001)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4341429/results/search/funders/results.xml">
   <result pre="Jacobson Natalie 1 † Redfern Andrew 2 Dowling Anthony 3" exact="Thompson" post="Erik W. 4 5 6 ‡ Saunders Christobel M."/>
   <result pre="M. 1 * ‡ [], 1 School of Surgery, The" exact="University of Western Australia" post="Perth, WA Australia [], 2 Medical Oncology, Royal Perth"/>
   <result pre="Institute of Health and Biomedical Innovation, School of Biomedical Sciences," exact="Queensland University of Technology" post="Brisbane, QLD Australia [], 5 St. Vincent’s Institute Melbourne,"/>
   <result pre="[], 5 St. Vincent’s Institute Melbourne, VIC Australia [], 6" exact="Department of Surgery," post="St Vincent’s Hospital, University of Melbourne Melbourne, VIC Australia"/>
   <result pre="VIC Australia [], 6 Department of Surgery, St Vincent’s Hospital," exact="University of Melbourne" post="Melbourne, VIC Australia Edited by: Robin Anderson, Peter MacCallum"/>
   <result pre="University of Melbourne Melbourne, VIC Australia Edited by: Robin Anderson," exact="Peter MacCallum Cancer Centre," post="Australia Reviewed by: Keith R. Laderoute, SRI International, USA;"/>
   <result pre="Reviewed by: Keith R. Laderoute, SRI International, USA; Navneet Momi," exact="Boston Medical Center," post="USA *Correspondence: Christobel M. Saunders, School of Surgery, The"/>
   <result pre="Center, USA *Correspondence: Christobel M. Saunders, School of Surgery, The" exact="University of Western Australia," post="Mailbox M581, 35 Stirling Highway, Crawley, WA 6009, Australia"/>
   <result pre="9736035 8 Bonnomet A Brysse A Tachsidis A Waltham M" exact="Thompson" post="EW Polette M et al. Epithelial-to-mesenchymal transitions and circulating"/>
   <result pre="Mennel R Norton L Ravdin P Taube S et al." exact="American Society of Clinical Oncology" post="2007 update of recommendations for the use of tumor"/>
   <result pre="2014) 158( 5): 1110– 22. 10.1016/j.cell.2014.07.013 25171411 19 Tomaskovic-Crook E" exact="Thompson" post="EW Thiery JP . Epithelial to mesenchymal transition and"/>
   <result pre="19909494 20 Kokkinos MI Wafai R Wong MK Newgreen DF" exact="Thompson" post="EW Waltham M . Vimentin and epithelial-mesenchymal transition in"/>
   <result pre="( 2010) 9: 179. 10.1186/1476-4598-9-179 20609236 32 van Denderen BJ" exact="Thompson" post="EW . Cancer: the to and fro of tumour"/>
   <result pre="23201165 37 Bonnomet A Syne L Brysse A Feyereisen E" exact="Thompson" post="EW Noel A et al. A dynamic in vivo"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4342830/results/search/funders/results.xml">
   <result pre="the approval and in accordance with the guidelines of the" exact="Medical University of South Carolina" post="IACUC. For orthotopic tumor analysis, 5 × 10 6"/>
   <result pre="approval and in accordance with the guidelines of the Medical" exact="University of South Carolina" post="IACUC. For orthotopic tumor analysis, 5 × 10 6"/>
   <result pre="kb) The Yeh lab is supported by start-up funding from" exact="Medical University of South Carolina," post="by pilot research funding from an American Cancer Society"/>
   <result pre="The Yeh lab is supported by start-up funding from Medical" exact="University of South Carolina," post="by pilot research funding from an American Cancer Society"/>
   <result pre="University of South Carolina, by pilot research funding from an" exact="American Cancer Society" post="Institutional Research Grant (IRG-97-219-14) from the American Cancer Society"/>
   <result pre="an American Cancer Society Institutional Research Grant (IRG-97-219-14) from the" exact="American Cancer Society" post="awarded to the Hollings Cancer Center, Medical University of"/>
   <result pre="Grant (IRG-97-219-14) from the American Cancer Society awarded to the" exact="Hollings Cancer Center, Medical University of South Carolina," post="by pilot research funding from a Department of Defense"/>
   <result pre="the American Cancer Society awarded to the Hollings Cancer Center," exact="Medical University of South Carolina," post="by pilot research funding from a Department of Defense"/>
   <result pre="American Cancer Society awarded to the Hollings Cancer Center, Medical" exact="University of South Carolina," post="by pilot research funding from a Department of Defense"/>
   <result pre="funding from a Department of Defense grant (W81XWH-11-2-0229) at the" exact="Medical University of South Carolina," post="and by an award from the Concern Foundation. These"/>
   <result pre="from a Department of Defense grant (W81XWH-11-2-0229) at the Medical" exact="University of South Carolina," post="and by an award from the Concern Foundation. These"/>
   <result pre="University of South Carolina, and by an award from the" exact="Concern Foundation." post="These studies were also supported by the Biostatistics Shared"/>
   <result pre="These studies were also supported by the Biostatistics Shared Resource," exact="Hollings Cancer Center, Medical University of South Carolina" post="(P30 CA138313). ESY designed experiments, performed experiments, and wrote"/>
   <result pre="also supported by the Biostatistics Shared Resource, Hollings Cancer Center," exact="Medical University of South Carolina" post="(P30 CA138313). ESY designed experiments, performed experiments, and wrote"/>
   <result pre="supported by the Biostatistics Shared Resource, Hollings Cancer Center, Medical" exact="University of South Carolina" post="(P30 CA138313). ESY designed experiments, performed experiments, and wrote"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4346363/results/search/funders/results.xml">
   <result pre="Disease and Tumor Microenvironment, Center for Cancer and Cell Biology," exact="Van Andel Research Institute," post="333 Bostwick Ave NE, Grand Rapids, MI 49503, USA,"/>
   <result pre="mRNA signatures, including the 21-mRNA recurrence score from which US" exact="Food and Drug Administration" post="(FDA)-cleared Oncotype Dx is derived. High miR-210 expression was"/>
   <result pre="M Garshell J et al. SEER Cancer Statistics Review, 1975–2011" exact="National Cancer Institute" post="2014 Available from: http://seer.cancer.gov/csr/1975_2011/ Accessed October 31, 2014 17"/>
   <result pre="2012 7 7 e41561 22859996 26 Leidner RS Li L" exact="Thompson" post="CL Dampening enthusiasm for circulating microRNA in breast cancer"/>
   <result pre="45 Wolff AC Hammond ME Schwartz JN et al. collab:" exact="American Society of Clinical Oncology" post="collab: College of American Pathologists American Society of Clinical"/>
   <result pre="and 55 healthy controls Serum SYBR green qRT-PCR assay (Hoffman-La" exact="Roche" post="Ltd) Increased circulating levels of miR-21 in BC cases."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4346691/results/search/funders/results.xml">
   <result pre="the p53 gene in human esophageal cancer Proceedings of the" exact="National Academy of Sciences" post="of the United States of America 1990 87 24"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4353460/results/search/funders/results.xml">
   <result pre="Brigham and Women’s and Massachusetts General Hospitals (Boston, MA, USA)," exact="Duke University" post="Medical Center (Durham, NC, USA, the National Disease Research"/>
   <result pre="1]. Gene expression profiling was performed by the Dana-Farber Microarray" exact="Core" post="Facility using Affymetrix U133 Plus 2.0 chip following the"/>
   <result pre="KP receives research support from and is a consultant to" exact="Novartis" post="Pharmaceuticals, Inc. Authors’ contributions JEB and KP conceived and"/>
   <result pre="to Akihiko Kimura for providing the G-81 anti-DCD antibody and" exact="Genentech" post="Inc. for providing Herceptin antibody (OR-208654). We thank Dr"/>
   <result pre="We thank Dr Maria M Brentani, University of Sao Paulo" exact="School of Medicine," post="and Dr Victor Piana Andrade, AC Camargo Cancer Center"/>
   <result pre="FAPESP fellowships (MGM, COF, and DFM), NIH (DP), and by" exact="Novartis" post="(KP). References References 1. Porter D Weremowicz S Chin"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4353882/results/search/funders/results.xml">
   <result pre="of the coordinating centers (Medical University of Gdańsk, Poland and" exact="Indiana University," post="USA). Two patient cohorts were derived from a consecutive"/>
   <result pre="and scraped off from the slide into a microcentrifuge tube." exact="Total" post="RNA was extracted from three 10 μm thick whole"/>
   <result pre="μm thick whole tissue sections from each sample using the" exact="Roche" post="high pure RNA paraffin kit according to manufacturer’s instructions"/>
   <result pre="( GAPDH) were used as endogenous reference controls for normalization." exact="Delta" post="threshold cycle (ΔC t) values for each of the"/>
   <result pre="Additional support was from the Intramural Research Programs of the" exact="National Cancer Institute" post="in Bethesda, USA and Medical University of Gdańsk, Poland."/>
   <result pre="32 3663 3680 10.1128/MCB.00406-12 22778135 24. Graeser M McCarthy A" exact="Lord" post="C Savage K Hills M Salter J Orr N"/>
   <result pre="Pathol 2012 228 158 169 10.1002/path.3988 22247069 30. Bangs PL" exact="Sparks" post="CA Odgren PR Fey EG Product of the oncogene-activating"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4358700/results/search/funders/results.xml">
   <result pre="and degradation. Using this platform, we screened a library of" exact="Food and Drug Administration" post="(FDA) and foreign regulatory agency-approved drugs, and identified that"/>
   <result pre="in-frame into pcDNA3.1-mYFP vector (a gift from Roger Y Tsien," exact="University of California" post="at San Diego, USA). The primers used for PCR"/>
   <result pre="paraformaldehyde. HEK293 cells grown in microwell dishes were transfected (Fugene6;" exact="Roche" post="Diagnostics Corp., Indianapolis, IN, USA) with Flag-HER3ΔNLS2, and 24"/>
   <result pre="(to WC). WC is a V Foundation Scholar and an" exact="American Cancer Society" post="Scholar. References References 1. Lemmon MA Schlessinger J Cell"/>
   <result pre="mammary tumors in transgenic mice: implications for human breast cancer" exact="EMBO" post="J 1999 18 2149 64 10.1093/emboj/18.8.2149 10205169 7. Schade"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4359299/results/search/funders/results.xml">
   <result pre="papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels Journal of the" exact="National Cancer Institute" post="2013 105 175 201 23297039 2 Parkin DM Bray"/>
   <result pre="esophageal cancer Journal of clinical oncology: official journal of the" exact="American Society of Clinical Oncology" post="1999 17 3270 3275 10506629 12 Enzinger PC Mayer"/>
   <result pre="colorectal cancer Journal of clinical oncology: official journal of the" exact="American Society of Clinical Oncology" post="2008 26 1626 1634 18316791 20 Karapetis CS Khambata-Ford"/>
   <result pre="junction cancer Journal of thoracic oncology: official publication of the" exact="International Association for the Study of Lung Cancer" post="2010 5 229 235 31 Adelstein DJ Rodriguez CP"/>
   <result pre="SWOG 0127 Journal of clinical oncology: official journal of the" exact="American Society of Clinical Oncology" post="2006 24 4922 4927 17050876 34 King CR Kraus"/>
   <result pre="breast cancer Journal of clinical oncology: official journal of the" exact="American Society of Clinical Oncology" post="1996 14 737 744 8622019 39 Ross JS McKenna"/>
   <result pre="to crizotinib Journal of clinical oncology: official journal of the" exact="American Society of Clinical Oncology" post="2011 29 4803 4810 22042947 48 Iveson T Donehower"/>
   <result pre="and angiogenesis Journal of clinical oncology: official journal of the" exact="American Society of Clinical Oncology" post="2005 23 1011 1027 15585754 51 Kleespies A Guba"/>
   <result pre="junction adenocarcinoma Journal of clinical oncology: official journal of the" exact="American Society of Clinical Oncology" post="2006 24 5201 5206 17114652 54 Shah MA Jhawer"/>
   <result pre="gastroesophageal adenocarcinoma Journal of clinical oncology: official journal of the" exact="American Society of Clinical Oncology" post="2011 29 868 874 21189380 55 Ramucirumab approved for"/>
   <result pre="ECOG 5203 Journal of clinical oncology: official journal of the" exact="American Society of Clinical Oncology" post="2010 28 2947 2951 20458043 59 Lemke G Biology"/>
   <result pre="of breast cancer metastasis and patient survival Proceedings of the" exact="National Academy of Sciences" post="of the United States of America 2010 107 1124"/>
   <result pre="Mer receptor tyrosine kinases in colon cancer Proceedings of the" exact="National Academy of Sciences" post="of the United States of America 2013 110 13091"/>
   <result pre="esophagus Cancer epidemiology, biomarkers &amp;amp; prevention: a publication of the" exact="American Association for Cancer Research," post="cosponsored by the American Society of Preventive Oncology 2008"/>
   <result pre="cell carcinoma Clinical cancer research: an official journal of the" exact="American Association for Cancer Research" post="2004 10 7304 7310 15534106 79 Jeng YM Peng"/>
   <result pre="hepatocellular carcinoma Clinical cancer research: an official journal of the" exact="American Association for Cancer Research" post="2004 10 2065 2071 15041727 80 Zhou H Kuang"/>
   <result pre="Gastric Cancer Clinical cancer research: an official journal of the" exact="American Association for Cancer Research" post="2014 20 76 86 24240108 90 Asiedu MK Beauchamp-Perez"/>
   <result pre="of EMT Clinical cancer research: an official journal of the" exact="American Association for Cancer Research" post="2013 19 3 5 23172883 92 Katsha A Soutto"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4361905/results/search/funders/results.xml">
   <result pre="RA Sorensen AG Bullitt E Harris GJ Morganstern D Schneider" exact="BP" post="Krop IE Winer EP Phase II trial of carboplatin"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4362606/results/search/funders/results.xml">
   <result pre="of targeted radionuclide therapy Speer TW Targeted radionuclide therapy Lippincott" exact="Williams" post="&amp;amp; Wilkins Philadelphia 2011 Chapter 6, 71 87 978-0-7817-9693-4"/>
   <result pre="Nucl Med Mol Imaging 2010 37 212 25 19727718 61." exact="Williams" post="SP Tissue distribution studies of protein therapeutics using molecular"/>
   <result pre="for targeted radionuclide therapy Speer TW Targeted radionuclide therapy Lippincott" exact="Williams" post="&amp;amp; Wilkins 2011 Chapter 4, 49 58 64. Gomes"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4368842/results/search/funders/results.xml">
   <result pre="The HER2 Pathvysion probe has been approved by the US" exact="Food and Drug Administration" post="for selection of patients for trastuzumab and pertuzumab therapy."/>
   <result pre="ISH DNA Probe Cocktail has been approved by the US" exact="Food and Drug Administration" post="for selection of patients to HER2 targeted therapies in"/>
   <result pre="( N = 37,992) Malignancy type HER2 positive (IHC 3+) samples (N)" exact="Total" post="no. of samples Percentage of HER2 positivity (%) •"/>
   <result pre="all ErbB receptors, is a mediator of lateral signaling The" exact="EMBO" post="Journal 1997 16 7 1647 1655 10.1093/emboj/16.7.1647 9130710 3."/>
   <result pre="ErbB3 to drive breast tumor cell proliferation Proceedings of the" exact="National Academy of Sciences" post="of the United States of America 2003 100 15"/>
   <result pre="patient treatment. Clinical Cancer Research: An Official Journal of the" exact="American Association for Cancer Research" post=", 19(2), 480–490. doi:10.1158/1078-0432.CCR-12-1842 12. Williams MD Roberts DB"/>
   <result pre="American Association for Cancer Research , 19(2), 480–490. doi:10.1158/1078-0432.CCR-12-1842 12." exact="Williams" post="MD Roberts DB Kies MS Mao L Weber RS"/>
   <result pre="therapeutic significance Clinical Cancer Research: An Official Journal of the" exact="American Association for Cancer Research" post="2010 16 8 2266 2274 10.1158/1078-0432.CCR-09-0238 20371674 13. Yan,"/>
   <result pre="breast cancer. Journal of Clinical Oncology: Official Journal of the" exact="American Society of Clinical Oncology" post=", 25(1), 118–145. doi:10.1200/JCO.2006.09.2775 15. Falchook GS Janku F"/>
   <result pre="combination treatment Journal of Thoracic Oncology: official Publication of the" exact="International Association for the Study of Lung Cancer" post="2013 8 2 e19 e20 10.1097/JTO.0b013e31827ce38e 16. Falchook GS"/>
   <result pre="continually targeted Journal of Clinical Oncology: Official Journal of the" exact="American Society of Clinical Oncology" post="2012 30 26 3318 3319 10.1200/JCO.2012.43.4902 22649146 19. Wolff,"/>
   <result pre="guideline update. Journal of Clinical Oncology: Official Journal of the" exact="American Society of Clinical Oncology" post=", 31(31), 3997–4013. doi:10.1200/JCO.2013.50.9984. 20. Ruschoff, J., Dietel, M.,"/>
   <result pre="in 1005 patients Annals of Oncology: Official Journal of the" exact="European Society for Medical Oncology" post="/ ESMO 2010 21 4 815 819 10.1093/annonc/mdp488 19889613"/>
   <result pre="methodologic considerations Journal of Clinical Oncology: Official Journal of the" exact="American Society of Clinical Oncology" post="2009 27 8 1323 1333 10.1200/JCO.2007.14.8197 19204209 40. Perez"/>
   <result pre="Center initiative. Clinical Cancer Research: An Official Journal of the" exact="American Association for Cancer Research" post=", 18(22), 6373–6383. doi:10.1158/1078-0432.CCR-12-1627. 47. Heinrich, M. C., Joensuu,"/>
   <result pre="tyrosine kinases. Clinical Cancer Research: An Official Journal of the" exact="American Association for Cancer Research" post=", 14(9), 2717–2725. doi:10.1158/1078-0432.CCR-07-4575. 48. Janku, F., Hong, D."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4376930/results/search/funders/results.xml">
   <result pre="Statement Prof. Stephen R.D. Johnson has received honoraria from GlaxoSmithKline," exact="Roche" post="and Novartis, and research funding from AstraZeneca and Pfizer."/>
   <result pre="honoraria from GlaxoSmithKline, Roche and Novartis, and research funding from" exact="AstraZeneca" post="and Pfizer. Acknowledgment The authors have received support from"/>
   <result pre="and Pfizer. Acknowledgment The authors have received support from the" exact="National Institute for Health Research" post="Biomedical Research Centre at The Royal Marsden Hospital. References"/>
   <result pre="The authors have received support from the National Institute for" exact="Health Research" post="Biomedical Research Centre at The Royal Marsden Hospital. References"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4381292/results/search/funders/results.xml">
   <result pre="Skaar T. Baumann K. Leonessa F. James M. Lippman J." exact="Thompson" post="E.W. Freter C. Brunner N. Hormonal carcinogenesis in breast"/>
   <result pre="23 Suppl. 6 VI13 VI18 10.1093/annonc/mds188 23012296 47 Ward P.S." exact="Thompson" post="C.B. Signaling in control of cell growth and metabolism"/>
   <result pre="Perspect. Biol. 2012 4 a006783 10.1101/cshperspect.a006783 22687276 48 Ward P.S." exact="Thompson" post="C.B. Metabolic reprogramming: A cancer hallmark even warburg did"/>
   <result pre="308 10.1016/j.ccr.2012.02.014 22439925 49 Clarke R. Shajahan A.N. Wang Y." exact="Tyson" post="J.J. Riggins R.B. Weiner L.M. Bauman W.T. Xuan J."/>
   <result pre="Hu R. Facey C.O. Tavassoly I. Schwartz J.L. Baumann W.T." exact="Tyson" post="J.J. Xuan J. Wang Y. et al. Endoplasmic reticulum"/>
   <result pre="cancer NMR Biomed. 2014 27 80 89 10.1002/nbm.2979 23828638 72" exact="Williams" post="M.D. Reeves R. Resar L.S. Hill H.H. Jr. Metabolomics"/>
   <result pre="Bonnet S. Archer S.L. Allalunis-Turner J. Haromy A. Beaulieu C." exact="Thompson" post="R. Lee C.T. Lopaschuk G.D. Puttagunta L. Bonnet S."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4385942/results/search/funders/results.xml">
   <result pre="J M 1 2 3 * [1], Department of Biochemistry," exact="West Virginia University" post="Health Sciences Center USA [2], Program in Cancer Cell"/>
   <result pre="Health Sciences Center USA [2], Program in Cancer Cell Biology," exact="West Virginia University" post="USA [3], USA [4], Department of Medicine, West Virginia"/>
   <result pre="West Virginia University USA [3], USA [4], Department of Medicine," exact="West Virginia University" post="USA [5], Department of Medicine and Dan L Duncan"/>
   <result pre="Medicine and Dan L Duncan Cancer Center, Division of Biostatistics," exact="Baylor College of Medicine" post="USA * Department of Biochemistry, West Virginia University Health"/>
   <result pre="Biostatistics, Baylor College of Medicine USA * Department of Biochemistry," exact="West Virginia University" post="Health Sciences Center, 1 Medical Center Drive , PO"/>
   <result pre="F12 50 : 50. All were supplemented with 10% (v/v) FBS (Hyclone," exact="GE Healthcare" post="Life Sciences, Logan, UT, USA), penicillin and streptomycin. Lapatinib"/>
   <result pre="Cancer Center (MBRCC). Flow cytometry experiments were performed in the" exact="West Virginia University" post="Flow Cytometry Core Facility, which is supported by NIH"/>
   <result pre="experiments were performed in the West Virginia University Flow Cytometry" exact="Core" post="Facility, which is supported by NIH equipment grant RR020866"/>
   <result pre="grant RR020866 and the Institutional Development Award (IDeA) from the" exact="National Institute of General Medical Sciences" post="under grants P30GM103488 (CoBRE) and P20GM103434 (INBRE). Animal work"/>
   <result pre="(INBRE). Animal work and imaging experiments were performed in the" exact="West Virginia University" post="Microscope Imaging Facility and West Virginia University Animal Models"/>
   <result pre="performed in the West Virginia University Microscope Imaging Facility and" exact="West Virginia University" post="Animal Models and Imaging Facility, which was supported by"/>
   <result pre="and S10 RR026378. Work performed at the Statistics and Bioinformatics" exact="Core" post="Resources of the Dan L Duncan Cancer, Baylor College"/>
   <result pre="and Bioinformatics Core Resources of the Dan L Duncan Cancer," exact="Baylor College of Medicine," post="was supported by NCI grant P30 CA125123. We thank"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4389676/results/search/funders/results.xml">
   <result pre="to anti-HER treatment. In Additional file 1 we list the" exact="Food and Drug Administration" post="(FDA) approved/Clinical Laboratory Improvement Amendments certified diagnostic tests available"/>
   <result pre="the benefit from certain types of chemotherapy [ 110]. Recently," exact="Genomic Health" post="started reporting estrogen receptor (ER), progesterone receptor (PR), and"/>
   <result pre="1: A table listing laboratory diagnostic tests cleared by the" exact="Food and Drug Administration" post="or offered by central laboratories under Clinical Laboratory Improvement"/>
   <result pre="domain EGFR Epidermal growth factor receptor ER Estrogen receptor FDA" exact="Food and Drug Administration" post="FFPE Formalin-fixed, paraffin-embedded FISH Fluorescence in situ hybridization FLIM"/>
   <result pre="support from the Tumor Biomarkers Research Program funded by the" exact="Banco Bilbao Vizcaya Argentaria" post="(BBVA) Foundation. References References 1. Holbro T Beerli RR"/>
   <result pre="Immunohistochem Mol Morphol 2012 20 531 542 22495358 32. Portier" exact="BP" post="Wang Z Downs-Kelly E Rowe JJ Patil D Lanigan"/>
   <result pre="12389040 34. Gustavson MD Bourke-Martin B Reilly D Cregger M" exact="Williams" post="C Mayotte J et al. Standardization of HER2 immunohistochemistry"/>
   <result pre="Tovar C Rosinski J Filipovic Z Higgins B Kolinsky K" exact="Hilton" post="H et al. From the Cover: Small-molecule MDM2 antagonists"/>
   <result pre="application to protein-protein interactions using global analysis J R Soc" exact="Interface" post="2008 6 S93 S105 53. Kelleher MT Fruhwirth G"/>
   <result pre="kinase Calpha: a novel intersection in cell adhesion and motility" exact="EMBO" post="J 2003 22 5390 5402 14532112 56. Legg JW"/>
   <result pre="trafficking PKC-integrin complexes involved in the control of cell motility" exact="EMBO" post="J 2001 20 2723 2741 11387207 58. Ng T"/>
   <result pre="interaction studies. In: Brown TG, Cogswell CJ, Wilson T, editors." exact="SPIE" post="Proceedings. Volume 8949. Three-Dimensional and Multidimensional Microscopy: Image Acquisition"/>
   <result pre="Perez E Butler S Dueck A Baehner F Cherbavaz D" exact="Thompson" post="E et al. The relationship between quantitative HER2 gene"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4391602/results/search/funders/results.xml">
   <result pre="testing results. This has formed the basis of the expert" exact="American Society of Clinical Oncology" post="(ASCO) and the College of American Pathologists (CAP) panel"/>
   <result pre="2000 and May 2005 from the following study sites: Sarah" exact="Cannon" post="Research Institute (Nashville, TN, USA)/Tennessee Oncology, PLLC, (Nashville, TN,"/>
   <result pre="of each patient’s HERmark result. The HERmark™ Breast Cancer Assay" exact="Total" post="HER2 protein expression (H2T) was quantified using the HERmark"/>
   <result pre="Local HER2 FISH Local clinical HER2 status Negative Equivocal Positive" exact="Total" post="IHC Negative Equivocal Positive Total IHC Non-amplified Amplified Total"/>
   <result pre="HER2 status Negative Equivocal Positive Total IHC Negative Equivocal Positive" exact="Total" post="IHC Non-amplified Amplified Total FISH Negative Equivocal Positive Total"/>
   <result pre="Positive Total IHC Negative Equivocal Positive Total IHC Non-amplified Amplified" exact="Total" post="FISH Negative Equivocal Positive Total HER2 N % N"/>
   <result pre="Positive Total IHC Non-amplified Amplified Total FISH Negative Equivocal Positive" exact="Total" post="HER2 N % N % N % N %"/>
   <result pre="25 37% 10 15% 0 0% 58 85% 68 35%" exact="Total" post="88 46% 30 16% 73 38% 191 100% 107"/>
   <result pre="Oncol 2013 31 3997 4013 10.1200/JCO.2013.50.9984 24101045 9. Perez EA" exact="Roche" post="PC Jenkins RB Reynolds CA Halling KC Ingle JN"/>
   <result pre="Mayo Clin Proc 2002 77 148 54 10.1016/S0025-6196(11)62329-X 11838648 10." exact="Roche" post="PC Suman VJ Jenkins RB Davidson NE Martino S"/>
   <result pre="Engl J Med 2008 358 1409 11 10.1056/NEJMc0801440 18367751 22." exact="Sears" post="AK Perez SA Clifton GT Benavides LC Gates JD"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4396883/results/search/funders/results.xml">
   <result pre="the ethics committees of the hospitals. RNA-seq for transcriptome analysis" exact="Total" post="RNA was extracted using TRIzol (Life Technologies). All RNA"/>
   <result pre="RNA samples showed RNA integrity numbers &amp;gt;7 (Agilent 2100 bioanalyzer)." exact="Total" post="RNA quality and concentration was measured using an RNA"/>
   <result pre="to detect the cytoplasmic domain of HER2 were purchased from" exact="Merck" post="and Abcam, and the antibody used to detect the"/>
   <result pre="MTS assay according to the manufacturer’s instructions (Promega). Immunoblot analysis" exact="Total" post="cellular extracts from the cell lines were prepared in"/>
   <result pre="YC, JZ, JW, XY, XZ and QJ are employees of" exact="AstraZeneca" post="during this study. No other conflicts of interests to"/>
   <result pre="review, revision of the manuscript. This work was sponsored by" exact="AstraZeneca" post="References References 1. Parkin DM Bray F Ferlay J"/>
   <result pre="of tumorigenic HER2 C-terminal fragments by alternative initiation of translation" exact="EMBO" post="J 2006 25 3234 44 10.1038/sj.emboj.7601191 16794579 26. Mitra"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4403678/results/search/funders/results.xml">
   <result pre="Methods 140 subjects were enrolled from a single institution under" exact="Weill Cornell Medical College" post="IRB protocol #0804009734. Patients were eligible if they had"/>
   <result pre="study was approved by the Institutional Review Board (IRB) of" exact="Weill Cornell Medical College" post="under IRB protocol # 0804009734. Eligibility criteria included either"/>
   <result pre="controls are matched by age, race, and history of hypertension" exact="Total" post="Controls Cases Number of patients 140 111 29 Age"/>
   <result pre="by the following grant: Clinical and Translational Science Center at" exact="Weill Cornell Medical College" post="(UL1-TR000457-06). This work was partially supported by a research"/>
   <result pre="This work was partially supported by a research grant from" exact="Genentech" post="and support was provided by the Anne Moore Breast"/>
   <result pre="from Genentech and support was provided by the Anne Moore" exact="Breast Cancer Research Foundation." post="References References 1. Giacomini KM Brett CM Altman RB"/>
   <result pre="Genentech and support was provided by the Anne Moore Breast" exact="Cancer Research Foundation." post="References References 1. Giacomini KM Brett CM Altman RB"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4404037/results/search/funders/results.xml">
   <result pre="from 30% to 15% between 1985 and 2010, prompted the" exact="Society of Surgical Oncology" post="(SSO) and the American Society for Therapeutic Radiation Oncology"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4405013/results/search/funders/results.xml">
   <result pre="has been identified as a group 1 carcinogen by the" exact="World Health Organization" post="International Agency for Research on Cancer (WHO/IARC, 69372 Lyon"/>
   <result pre="[ 39]. Based on data from this REGARD trial, the" exact="Food and Drug Administration" post="(FDA) in United States approved ramucirumab as second-line therapy"/>
   <result pre="by variation in the tyrosine phosphorylation sites Proceedings of the" exact="National Academy of Sciences" post="of the United States of America 2002 99 22"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4406526/results/search/funders/results.xml">
   <result pre="2011 20 Supplement 3(0) S20 7 10.1016/S0960-9776(11)70289-2 22015288 40. collab:" exact="GlaxoSmithKline" post="ALTTO Trial–Trial Overview 2012 2013 10 19 http://alttotrials.com/hcp.php 41."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4407294/results/search/funders/results.xml">
   <result pre="[ 7]. One of the first commercially available and US" exact="Food and Drug Administration" post="(FDA)-approved signatures was the 70-gene MammaPrint assay, which stratifies"/>
   <result pre="has been incorporated into current National Comprehensive Cancer Network and" exact="American Society of Clinical Oncology" post="guidelines, since it demonstrated a role as a predictive"/>
   <result pre="low, medium, or high Guidelines FDA-approved National Comprehensive Cancer Network," exact="American Society of Clinical Oncology" post="FDA-cleared Clinical applications Accurate and reproducible representation of BC"/>
   <result pre="ER, estrogen receptor; FAC, fluorouracil, doxorubicin, and cyclophosphamide; FDA, US" exact="Food and Drug Administration;" post="OS, overall survival; PAM50, Prediction Analysis of Microarray; PCR,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4411474/results/search/funders/results.xml">
   <result pre="Iranian Journal of Cancer Prevention 2008-2398 2008-2401 Cancer Research Center," exact="Shahid Beheshti University of Medical Sciences" post="pmcid: 4411474 IJCP-08-125 : Case Report Appearance of Acute"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4413633/results/search/funders/results.xml">
   <result pre="histology was determined in accordance with the criteria of the" exact="World Health Organization." post="Pathologic staging was performed in accordance with the current"/>
   <result pre="TXNIP and p27 expression by Western blot analysis. Western blotting" exact="Total" post="protein was extracted using RIPA buffer supplemented with protease"/>
   <result pre="repeated at least three times. RNA isolation and quantitative RT-PCR" exact="Total" post="RNA was extracted from cultured cells using TRIzol Reagent"/>
   <result pre="0.001. Grant Supports This project was supported by grants from" exact="National Natural Science Foundation of China" post="(81272252), and a Foundation for Clinical Medicine Science and"/>
   <result pre="IC50 Clinical cancer research : an official journal of the" exact="American Association for Cancer Research" post="2007 13 12 3724 3730 17575238 16 Schafer ZT"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4423419/results/search/funders/results.xml">
   <result pre="after chemotherapy Competing interests PEG has received speaker’s honoraria from" exact="GlaxoSmithKline" post="and Pfizer and is supported by the Avon Foundation"/>
   <result pre="Competing interests PEG has received speaker’s honoraria from GlaxoSmithKline and" exact="Pfizer" post="and is supported by the Avon Foundation (New York,"/>
   <result pre="Foundation (New York, NY, USA). ER is an employee of" exact="GlaxoSmithKline" post="and owns stocks and shares of GlaxoSmithKline. All remaining"/>
   <result pre="DMF were members of the steering committee. Acknowledgements The sponsor," exact="GlaxoSmithKline" post="provided funding for the study, contributed to the study"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4424224/results/search/funders/results.xml">
   <result pre="dynamic PET scans lasting 90 min were performed on a" exact="Siemens" post="HiRez 6 PET-CT scanner (Siemens, Munich, Germany) after intravenous"/>
   <result pre="A Saleem, GE Searle and M Huiban were employed by" exact="GlaxoSmithKline" post="at the start of the study and then joined"/>
   <result pre="Imanova Ltd during the study (Imanova Ltd received payment from" exact="GlaxoSmithKline" post="for conducting the study imaging, scanning and providing consultation)."/>
   <result pre="are also employed by GlaxoSmithKline. T Kaneko was employed by" exact="GlaxoSmithKline" post="at the time of final analysis. A Saleem, M"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4427936/results/search/funders/results.xml">
   <result pre="searching of reference lists plus a forward citation search using" exact="Google" post="Scholar. Only reviews published in peer-reviewed journals were included"/>
   <result pre="than 50 % or more than 10 % from baseline," exact="National Cancer Institute" post="Common Toxicity Criteria Chronic heart failure grade 3 or"/>
   <result pre="• taxane treatment showed significant reduction in death and recurrence" exact="Lord" post="et al. 2008 [ 26] P: metastatic breast cancer"/>
   <result pre="by a Seeding Grant from the Faculty of Health Sciences," exact="Flinders University" post="and an IHBI MCR grant from the Queensland University"/>
   <result pre="Sciences, Flinders University and an IHBI MCR grant from the" exact="Queensland University of Technology." post="References References 1. Stratigos A Forsea A Van Der"/>
   <result pre="with meta-analysis Breast 2012 21 343 9 10.1016/j.breast.2012.02.011 22425607 26." exact="Lord" post="S, Ghersi D, Gattellari M, Wortley S, Wilcken N,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4436450/results/search/funders/results.xml">
   <result pre="Epidermal growth factor receptor EpCAM: Epithelial cell adhesion molecule FDA:" exact="Food and Drug Administration" post="HNC: Head and neck carcinoma ILD: Interstitial lung disease"/>
   <result pre="bevacizumab in cancer patients: a meta-analysis The Journal of the" exact="American Medical Association" post="2008 300 19 2277 2285 10.1001/jama.2008.656 24 Choueiri T."/>
   <result pre="9 7 26 Okines A. F. C. Langley R. E." exact="Thompson" post="L. C. et al. Bevacizumab with peri-operative epirubicin, cisplatin"/>
   <result pre="in 411 patients (pts) with melanoma (MEL) Proceedings of the" exact="American Society of Clinical Oncology" post="Meeting (ASCO '14) 2014 (Abstract LBA9000) 68 Hurwitz H."/>
   <result pre="metastatic carcinoma treated with chemotherapy and bevacizumab Journal of the" exact="National Cancer Institute" post="2007 99 1232 1239 17686822 76 Pierga J.-Y. Petit"/>
   <result pre="of pidilizumab in patients with metastatic melanoma Proceedings of the" exact="American Society of Clinical Oncology" post="Meeting (ASCO '14) 2014 abstract no. 9001 93 Creelan"/>
   <result pre="dyspnea, wheeze-bronchospasm, stridor, reduced PEF, and hypoxemia),   (b) reduced" exact="BP" post="or associated symptoms of end-organ dysfunction (e.g., hypotonia [collapse],"/>
   <result pre="dyspnea, wheeze-bronchospasm, stridor, reduced PEF, and hypoxemia),   (c) reduced" exact="BP" post="or associated symptoms (e.g., hypotonia [collapse], syncope, and incontinence),"/>
   <result pre="gastrointestinal symptoms (e.g., crampy abdominal pain, vomiting);   (3) reduced" exact="BP" post="after exposure to known allergen for that patient (minutes"/>
   <result pre="to several hours):   (a) infants and children: low systolic" exact="BP" post="(age specific) or &amp;gt;30% decrease in systolic BP *"/>
   <result pre="low systolic BP (age specific) or &amp;gt;30% decrease in systolic" exact="BP" post="*   (b) adults: systolic BP of &amp;lt;90 mmHg or"/>
   <result pre="&amp;gt;30% decrease in systolic BP *   (b) adults: systolic" exact="BP" post="of &amp;lt;90 mmHg or &amp;gt;30% decrease from that person's baseline"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4439018/results/search/funders/results.xml">
   <result pre="Zhang Jun Li Ke * [], Department of Public Health," exact="Shantou University" post="Medical College, No.22 Xinling Road, Shantou, Guangdong 515041, China"/>
   <result pre="Road, Shantou, Guangdong 515041, China Gao Jian-Xin Academic Editor []," exact="Shanghai Jiao Tong University" post="School of Medicine, CHINA Competing Interests: The authors have"/>
   <result pre="China Gao Jian-Xin Academic Editor [], Shanghai Jiao Tong University" exact="School of Medicine," post="CHINA Competing Interests: The authors have declared that no"/>
   <result pre="fatigue, and gastrointestinal disorders (diarrhea, nausea, vomiting) according to the" exact="National Cancer Institute" post="(NCI) Common Toxicity Criteria version 2 or Common Terminology"/>
   <result pre="study . Journal of clinical oncology: official journal of the" exact="American Society of Clinical Oncology" post=". 2011; 29( 3): 264– 271. 21149659 9 Baselga"/>
   <result pre="breast cancer . Annals of oncology: official journal of the" exact="European Society for Medical Oncology" post="/ ESMO . 2014; 25( 3): 592– 598. 24401928"/>
   <result pre="cancer . Journal of clinical oncology: official journal of the" exact="American Society of Clinical Oncology" post=". 2013; 31( 16): 1947– 1953. 23509322 15 Untch"/>
   <result pre="cancer . Journal of clinical oncology: official journal of the" exact="American Society of Clinical Oncology" post=". 2013; 31( 9): 1157– 1163. 23382472 18 Gianni"/>
   <result pre="cancer . Journal of clinical oncology: official journal of the" exact="American Society of Clinical Oncology" post=". 2013; 31( 14): 1719– 1725. 23569311 20 Miller"/>
   <result pre="cancer . Journal of clinical oncology: official journal of the" exact="American Society of Clinical Oncology" post=". 2014; 32( 14): 1437– 1444. 24733796 21 Cortes"/>
   <result pre="breast cancer . Annals of oncology: official journal of the" exact="European Society for Medical Oncology" post="/ ESMO . 2013; 24( 10): 2630– 2635. doi:"/>
   <result pre="trial . Journal of clinical oncology: official journal of the" exact="American Society of Clinical Oncology" post=". 2013; 31( 36): 4504– 4511. 24248687 23 Robidoux"/>
   <result pre="targeted therapies in advanced breast cancer . Journal of the" exact="National Cancer Institute." post="2008; 100( 24): 1780– 1791. doi: 10.1093/jnci/djn414 19066278 25"/>
   <result pre="cancer: a meta-analysis. Annals of oncology: official journal of the" exact="European Society for Medical Oncology" post="/ ESMO . 2011; 22( 6): 1308– 1317. doi:"/>
   <result pre="1st ed United Kingdom: Wiley-Backwell; 2011. 45 Higgins JP ," exact="Thompson" post="SG , Deeks JJ , Altman DG . Measuring"/>
   <result pre="19. 16445299 47 Spiegelhalter DJ , Best NG , Carlin" exact="BP" post=", van der Linde A . Bayesian measures of"/>
   <result pre="trial data . Annals of oncology: official journal of the" exact="European Society for Medical Oncology" post="/ ESMO . 2001; 12 Suppl 1: S57– 62."/>
   <result pre="group . Journal of clinical oncology: official journal of the" exact="American Society of Clinical Oncology" post=". 2005; 23( 19): 4265– 4274. 15911866 54 Gasparini"/>
   <result pre="study . Journal of clinical oncology: official journal of the" exact="American Society of Clinical Oncology" post=". 2009; 27( 12): 1999– 2006. 19289619 56 Kaufman"/>
   <result pre="study . Journal of clinical oncology: official journal of the" exact="American Society of Clinical Oncology" post=". 2009; 27( 33): 5529– 5537. 19786670 57 Huober"/>
   <result pre="cancer . Journal of clinical oncology: official journal of the" exact="American Society of Clinical Oncology" post=". 2009; 27( 33): 5538– 5546. 19786658 63 Di"/>
   <result pre="cancer . Journal of clinical oncology: official journal of the" exact="American Society of Clinical Oncology" post=". 2008; 26( 34): 5544– 5552. doi: 10.1200/JCO.2008.16.2578 18955454"/>
   <result pre="breast cancer. Journal of clinical oncology: official journal of the" exact="American Society of Clinical Oncology" post=". 2011; 29( 34): 4491– 4497. 22042958 66 Slamon"/>
   <result pre="advanced or metastatic breast cancer: systematic review and meta-analysis ." exact="Core" post="evidence. 2013; 8: 69– 78. doi: 10.2147/CE.S50474 24115917 72"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4439944/results/search/funders/results.xml">
   <result pre="Lett 1999 140 27 35 10403538 53 Lonning PE Haynes" exact="BP" post="Straume AH Dunbier A Helle H Knappskog S Dowsett"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4440424/results/search/funders/results.xml">
   <result pre="Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3" exact="EMBO" post="J 1995 14 17 4267 4275 7556068 15 Zhang"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4444439/results/search/funders/results.xml">
   <result pre="treatment with multikinase inhibitors, in particular tyrosine kinase inhibitors. The" exact="Food and Drug Administration" post="(FDA) ordered the inclusion of additional labels – so-called"/>
   <result pre="up with patients’ death were observed. For this reason the" exact="Food and Drug Administration" post="(FDA) ordered the inclusion of additional, so-called &quot;black box"/>
   <result pre="24 Shepherd F Rodrigues Pereira J Ciuleanu T et al." exact="National Cancer Institute" post="of Canada Clinical Trials Group. Erlotinib in previously treated"/>
   <result pre="with advanced pancreatic cancer: a phase III trial of the" exact="National Cancer Institute" post="of Canada Clinical Trials Group J Clin Oncol 2007"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4445592/results/search/funders/results.xml">
   <result pre="cancer is the most common malignancy in women worldwide. The" exact="American Cancer Society" post="estimates that 235,000 Americans would be diagnosed with invasive"/>
   <result pre="CLEOPATRA trial led to the initial approval by the US" exact="Food and Drug Administration" post="(FDA) for pertuzumab on June 8, 2012, for use"/>
   <result pre="Disclosure J Cortés acts as a consultant for Roche, and" exact="Celgene" post="and has received honoraria from Roche, Celgene, Eisai, and"/>
   <result pre="Interim safety results (N=704) from PERUSE Presented at: The 50th" exact="American Society of Clinical Oncology" post="Annual Meeting May 30–June 3, 2014 Chicago, IL Poster"/>
   <result pre="35 Giordano S Temin S Kirshner J et al. collab:" exact="American Society of Clinical Oncology" post="Systemic therapy for patients with advanced human epidermal growth"/>
   <result pre="with advanced human epidermal growth factor receptor 2-positive breast cancer:" exact="American Society of Clinical Oncology" post="Clinical Practice Guideline J Clin Oncol 2014 32 19"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4447178/results/search/funders/results.xml">
   <result pre="USA; January 15–17) is the world-class conference co-sponsored by the" exact="American Society of Clinical Oncology," post="the American Society for Radiation Oncology, the American Gastroenterological"/>
   <result pre="conference co-sponsored by the American Society of Clinical Oncology, the" exact="American Society for Radiation Oncology," post="the American Gastroenterological Association Institute, and the Society of"/>
   <result pre="of Clinical Oncology, the American Society for Radiation Oncology, the" exact="American Gastroenterological Association" post="Institute, and the Society of Surgical Oncology, in which"/>
   <result pre="for Radiation Oncology, the American Gastroenterological Association Institute, and the" exact="Society of Surgical Oncology," post="in which the most innovative research results in digestive"/>
   <result pre="antibody against PD-1, has recently received approval from the US" exact="Food and Drug Administration" post="for the treatment of advanced melanoma after the failure"/>
   <result pre="be used to run next-generation trials with targeted agents. The" exact="European Organisation for Research and Treatment of Cancer" post="(EORTC) Screening Patients for Efficient Clinical Trial Access in"/>
   <result pre="Oncol 2011 29 13 1715 1721 21444866 19 Okines AF" exact="Thompson" post="LC Cunningham D et al. Effect of HER2 on"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4453607/results/search/funders/results.xml">
   <result pre="Park S Y 1 7 * [1], Department of Pathology," exact="Seoul National University" post="Bundang Hospital Korea [2], Department of Pathology, Asan Medical"/>
   <result pre="Bundang Hospital Korea [2], Department of Pathology, Asan Medical Center," exact="University of Ulsan" post="College of Medicine Korea [3], Department of Medical Oncology,"/>
   <result pre="Ulsan College of Medicine Korea [3], Department of Medical Oncology," exact="Seoul National University" post="Bundang Hospital Korea [4], Department of Medical Oncology, Seoul"/>
   <result pre="National University Bundang Hospital Korea [4], Department of Medical Oncology," exact="Seoul National University" post="College of Medicine Korea [5], Department of Surgery, Seoul"/>
   <result pre="Medical Oncology, Seoul National University College of Medicine Korea [5]," exact="Department of Surgery," post="Seoul National University Bundang Hospital Korea [6], Department of"/>
   <result pre="National University College of Medicine Korea [5], Department of Surgery," exact="Seoul National University" post="Bundang Hospital Korea [6], Department of Surgery, Seoul National"/>
   <result pre="Department of Surgery, Seoul National University Bundang Hospital Korea [6]," exact="Department of Surgery," post="Seoul National University College of Medicine Korea [7], Department"/>
   <result pre="Seoul National University Bundang Hospital Korea [6], Department of Surgery," exact="Seoul National University" post="College of Medicine Korea [7], Department of Pathology, Seoul"/>
   <result pre="National University College of Medicine Korea [7], Department of Pathology," exact="Seoul National University" post="College of Medicine Korea [8], Department of Medical Oncology,"/>
   <result pre="Medicine Korea [8], Department of Medical Oncology, Asan Medical Center," exact="University of Ulsan" post="College of Medicine Korea [9], Department of Surgery, Asan"/>
   <result pre="Medical Center, University of Ulsan College of Medicine Korea [9]," exact="Department of Surgery," post="Asan Medical Center, University of Ulsan College of Medicine"/>
   <result pre="of Medicine Korea [9], Department of Surgery, Asan Medical Center," exact="University of Ulsan" post="College of Medicine Korea *;E-mail: sypmd@snu.ac.kr 10 These authors"/>
   <result pre="2014-10-10 112 1 103 111 rev-recd: 2014-08-23 accepted: 2014-10-02 (C)" exact="Cancer Research UK," post="2015 From twelve months after its original publication, this"/>
   <result pre="primary breast cancers, which comprised 105 cases operated on at" exact="Seoul National University" post="Bundang Hospital (SNUBH) between 2003 and 2009, and 137"/>
   <result pre="cases of HER2-positive metastatic breast cancer treated with trastuzumab at" exact="Seoul National University" post="Bundang Hospital, Seoul National University Hospital and Asan Medical"/>
   <result pre="cancer treated with trastuzumab at Seoul National University Bundang Hospital," exact="Seoul National University" post="Hospital and Asan Medical Center from 2001 to 2011"/>
   <result pre="This study was approved by the institutional review boards of" exact="Seoul National University" post="Bundang Hospital, Asan Medical Center and Seoul National University"/>
   <result pre="of Seoul National University Bundang Hospital, Asan Medical Center and" exact="Seoul National University" post="Hospital; the requirement for informed consent was waived. Tissue"/>
   <result pre="was supported by the Basic Science Research Program through the" exact="National Research Foundation" post="of Korea (NRF) funded by the Ministry of Education,"/>
   <result pre="the National Research Foundation of Korea (NRF) funded by the" exact="Ministry of Education," post="Science and Technology (Grant No. NRF-2012R1A1B4000557) and by Seoul"/>
   <result pre="of Education, Science and Technology (Grant No. NRF-2012R1A1B4000557) and by" exact="Seoul National University" post="Bundang Hospital Research Fund (Grant No. 11-2012-007). Supplementary Information"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4456592/results/search/funders/results.xml">
   <result pre="manuscript. Acknowledgements This work was supported by grants from the" exact="Breast Cancer Research Foundation," post="the National Institutes of Health (R01CA089481, R01CA149425, U01CA168925, R43CA171417),"/>
   <result pre="Acknowledgements This work was supported by grants from the Breast" exact="Cancer Research Foundation," post="the National Institutes of Health (R01CA089481, R01CA149425, U01CA168925, R43CA171417),"/>
   <result pre="supported by grants from the Breast Cancer Research Foundation, the" exact="National Institutes of Health" post="(R01CA089481, R01CA149425, U01CA168925, R43CA171417), R01 HL 118018 (B. Ky);"/>
   <result pre="(J. Tchou), and the 2013 Exceptional Project Award from the" exact="Breast Cancer Alliance" post="(J. Tchou). References References Barok M Tanner M Koninki"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4457853/results/search/funders/results.xml">
   <result pre="Research Group, Budapest, Hungary [3], Protein Structure and Bioinformatics Group," exact="International Centre for Genetic Engineering and Biotechnology," post="Trieste, Italy [4], 2nd Department of Pediatrics, Semmelweis University,"/>
   <result pre="Sturdivant RX . Applied logistic regression: Wiley com; 2013. 34" exact="National Institutes of Health" post="(NIH)—Learn About Clinical Studies. Available: https://clinicaltrials.gov/ct2/about-studies/learn#WhatIs. Accessed 4 July"/>
   <result pre="solid tumors. European Organization for Research and Treatment of Cancer," exact="National Cancer Institute" post="of the United States, National Cancer Institute of Canada"/>
   <result pre="Treatment of Cancer, National Cancer Institute of the United States," exact="National Cancer Institute" post="of Canada . J Natl Cancer Inst. 2000; 92("/>
   <result pre="46 Pesquita C , Faria D , Falcao AO ," exact="Lord" post="P , Couto FM . Semantic similarity in biomedical"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4464713/results/search/funders/results.xml">
   <result pre="Kamprad foundation for Cancer Research. References References 1. Esserman LJ" exact="Thompson" post="IM Jr Reid B Overdiagnosis and overtreatment in cancer:"/>
   <result pre="J Clin Oncol 2012 30 1268 73 10.1200/JCO.2010.34.0141 22393101 34." exact="Williams" post="KE, Barnes NL, Cramer A, Johnson R, Cheema K,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4465168/results/search/funders/results.xml">
   <result pre="Cancer Network currently list the taxanes solvent-based paclitaxel (sb-paclitaxel, Taxol;" exact="Bristol-Myers Squibb" post="Co., Princeton, NJ, USA), docetaxel (Taxotere; sanofi-aventis US LLC,"/>
   <result pre="(Taxotere; sanofi-aventis US LLC, Bridgewater, NJ, USA), and nab-paclitaxel (Abraxane;" exact="Celgene" post="Corporation, Summit, NJ, USA) as agents recommended for the"/>
   <result pre="the castor oil derivative Cremophor EL (recently renamed Kolliphor EL;" exact="BASF" post="Corporation, Florham Park, NJ, USA) and dehydrated ethanol, while"/>
   <result pre="carried out using PubMed and abstract search engines from the" exact="American Society of Clinical Oncology" post="and the San Antonio Breast Cancer Symposium. Search terms"/>
   <result pre="future MBC trials will test the combination since the US" exact="Food and Drug Administration" post="approval of bevacizumab for MBC has been withdrawn ["/>
   <result pre="weeks sb-paclitaxel Solvent-based paclitaxel Competing interests MM has participated in" exact="Celgene" post="advisory boards and received honoraria for his involvement. Acknowledgements"/>
   <result pre="author received editorial support from MediTech Media, Ltd, funded by" exact="Celgene" post="Corporation. The author was fully responsible for the content"/>
   <result pre="Accessed 26 Feb 2015. 2. Abraxane (package insert). Summit, NJ:" exact="Celgene" post="Corporation; 2014. 3. Taxol (package insert). Princeton, NJ: Bristol-Myers"/>
   <result pre="NJ: Celgene Corporation; 2014. 3. Taxol (package insert). Princeton, NJ:" exact="Bristol-Myers Squibb" post="Co; 2011. 4. Taxotere (package insert). Bridgewater, NJ: sanofi-aventis"/>
   <result pre="breast cancer [abstract 2703] 2012 Chicago, IL Poster presentation at" exact="American Association for Cancer Research" post="44. McArthur HL Rugo H Nulsen B Hawks L"/>
   <result pre="Cancer Res Treat 2011 130 825 31 10.1007/s10549-011-1678-9 46. US" exact="Food and Drug Administration." post="FDA Commissioner removes breast cancer indication from Avastin label"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4467394/results/search/funders/results.xml">
   <result pre="an antibody-drug conjugate) and lapatinib (TKI) were approved by the" exact="U.S. Food and Drug Administration" post="and the European Medicines Agency and are now used"/>
   <result pre="antibody-drug conjugate) and lapatinib (TKI) were approved by the U.S." exact="Food and Drug Administration" post="and the European Medicines Agency and are now used"/>
   <result pre="21]. Furthermore, a phase III study reported in the 2012" exact="American Society of Clinical Oncology" post="Annual Meeting found that, metastatic HER2-positive breast cancer patients"/>
   <result pre="and ADCC which could be induced by pertuzumab [ 41]." exact="Total" post="cell counting and apoptotic assays showed that SK250LR cell"/>
   <result pre="lines SK-BR-3 and BT-474 were obtained from cell services at" exact="Cancer Research UK" post="(Lincoln's Inn Fields laboratory), which has a stringent quality"/>
   <result pre="scramble siRNA. siNRG1-9 (5′-UUUCAAACCCCUCGAGAUA-3′) and siNRG1-11 (5′-GGGGAGUGCUUCAUGGUGA-3′) were designed by" exact="Thermo Scientific" post="and synthesised by Life Technologies. siRNA was diluted in"/>
   <result pre="All protocols were carried out with appropriate ethical approval under" exact="Home Office" post="regulations and the project license of Dr. Ji-Liang Li"/>
   <result pre="obtained from Novus Biologicals. HER4 antibody (1:200) was obtained from" exact="Thermo Scientific." post="Scoring of IHC staining was performed independently by two"/>
   <result pre="Wing-yin Leung was supported by Clarendon fund, University of Oxford," exact="Croucher Foundation" post="and Tin Ka Ping Foundation. Other UK funders include"/>
   <result pre="Foundation and Tin Ka Ping Foundation. Other UK funders include" exact="Cancer Research UK," post="Oxford Biomedical Research Centre, Oxford Experimental Cancer Medicine Centre,"/>
   <result pre="kinase inhibitors T-DM1 Trastuzumab emtansine pCR pathological complete response FDA" exact="Food and Drug Administration" post="TKD tyrosine kinase domain Akt Protein Kinase B (PKB)"/>
   <result pre="breast cancer Annals of oncology : official journal of the" exact="European Society for Medical Oncology" post="/ ESMO 2013 24 273 282 22910839 7 Johnson"/>
   <result pre="cancer Clinical cancer research : an official journal of the" exact="American Association for Cancer Research" post="2006 12 4436s 4440s 16857824 8 Agus DB Akita"/>
   <result pre="study Journal of clinical oncology : official journal of the" exact="American Society of Clinical Oncology" post="2012 30 1989 1995 22493419 19 Robidoux A Tang"/>
   <result pre="to prevent its onset in breast cancer Proceedings of the" exact="National Academy of Sciences" post="of the United States of America 2006 103 7795"/>
   <result pre="for inhibition of the HER2 tyrosine kinase Proceedings of the" exact="National Academy of Sciences" post="of the United States of America 2011 108 5021"/>
   <result pre="I Liu L Zhao S Liu Z Moseley MA 3rd" exact="Thompson" post="JW Chen FL Koch KM Spector NL Resistance to"/>
   <result pre="metastatic breast cancer cells to the brain Journal of the" exact="National Cancer Institute" post="2008 100 1092 1103 18664652 48 Rimawi MF Wiechmann"/>
   <result pre="xenografts Clinical cancer research : an official journal of the" exact="American Association for Cancer Research" post="2011 17 1351 1361 21138857 49 Arpino G Gutierrez"/>
   <result pre="breast cancer xenografts with multiagent HER-targeted therapy Journal of the" exact="National Cancer Institute" post="2007 99 694 705 17470737 50 Friess T Scheuer"/>
   <result pre="monotherapy Clinical cancer research : an official journal of the" exact="American Association for Cancer Research" post="2005 11 5300 5309 16033849"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4467661/results/search/funders/results.xml">
   <result pre="modification of EKB-569 (pelitinib), an irreversible EGFR inhibitor developed by" exact="Wyeth" post="Pharmaceuticals. 11 The chemical name is 2-butenamide, N-[4- [[3-chloro-4-(2-pyridinylmethoxy)"/>
   <result pre="target HER2 signaling. The first treatment approved by the US" exact="Food and Drug Administration" post="was the monoclonal antibody trastuzumab (Herceptin ®), which targets"/>
   <result pre="of ABCG2 substrate drugs within cells. 53 At the 2014" exact="American Society of Clinical Oncology" post="annual meeting, the preliminary data from a clinical trial"/>
   <result pre="its criteria have not always been consistent. Initially, the US" exact="Food and Drug Administration" post="guidelines for HER2 testing recommended that if ≥10% of"/>
   <result pre="of all ErbB receptors, is a mediator of lateral signaling" exact="EMBO" post="J 1997 16 7 1647 1655 9130710 11 Wissner"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4467984/results/search/funders/results.xml">
   <result pre="[7], Translational Research Department, Institut Curie, 75005, Paris, France [8]," exact="Novartis" post="Oncology Translational Research, Cambridge, MA, 02139, United States of"/>
   <result pre="Translational Research, Cambridge, MA, 02139, United States of America [9]," exact="Novartis" post="Pharma AG, Postfach, CH-4002, Basel, Switzerland [10], Department of"/>
   <result pre="de Barcelona, Campus de la UAB, 08193, Bellaterra, Spain [11]," exact="Institució Catalana de Recerca i Estudis Avançats" post="(ICREA), 08010, Barcelona, Spain Sapino Anna Academic Editor [],"/>
   <result pre="to anti-HER2 therapies. Funding This work has been supported by" exact="Novartis" post="Pharma within the Consorcio de Investigación Biomédica y Oncológica"/>
   <result pre="Consorcio de Investigación Biomédica y Oncológica Translacional Framework Programme, the" exact="Breast Cancer Research Foundation" post="(BCRF), Spanish Association Against Cancer (Asociación Española Contra el"/>
   <result pre="de Investigación Biomédica y Oncológica Translacional Framework Programme, the Breast" exact="Cancer Research Foundation" post="(BCRF), Spanish Association Against Cancer (Asociación Española Contra el"/>
   <result pre="Association Against Cancer (Asociación Española Contra el Cáncer, AECC) and" exact="Instituto de Salud Carlos III" post="(Intrasalud PI12/02536) to JA and the Network of Cooperative"/>
   <result pre="supported by a Juan de la Cierva postdoctoral fellow from" exact="Ministerio de Economía y Competitividad" post="(JCI-2011-10960). JD, MB, RS, and RM are employed by"/>
   <result pre="Competitividad (JCI-2011-10960). JD, MB, RS, and RM are employed by" exact="Novartis" post="and received funding in the form of salaries. The"/>
   <result pre="the Response to Trastuzumab and Chemotherapy. JNCI Journal of the" exact="National Cancer Institute" post="106: dju291 doi: 10.1093/jnci/dju291/-/DC1 25253614 13 Marangoni E ,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4469402/results/search/funders/results.xml">
   <result pre="of Clinical Oncology/College of American Pathologists clinical practice guideline update." exact="American Society of Clinical Oncology;" post="College of American Pathologists J Clin Oncol 2013 31"/>
   <result pre="18 21 5992 6000 10.1158/1078-0432.CCR-12-1318 22977193 19. Kanagal-Shamanna R Portier" exact="BP" post="Singh RR Routbort MJ Aldape KD Handal BA et"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4470009/results/search/funders/results.xml">
   <result pre="biopsy specimens from 15 patients (collected from the Pathology Department," exact="Cairo University" post="labs archives; 2011–2012) diagnosed as invasive breast cancer (ductal,"/>
   <result pre="data includes: Score membrane: 0,1,2,3, computed as follows: 3 +:" exact="Total" post="length of intensively stained membrane/total length of detected membranes"/>
   <result pre="of intensively stained membrane/total length of detected membranes &amp;gt;0.50 2:" exact="Total" post="length of stained membrane/total length of detected membranes &amp;gt;0.10"/>
   <result pre="of stained membrane/total length of detected membranes &amp;gt;0.10 1 +:" exact="Total" post="length of stained membrane/total length of detected membranes &amp;gt;002"/>
   <result pre="identifier (LSI) HER-2/neu DNA probe is a 190 Kb Spectrum" exact="Orange" post="directly-labeled, fluorescent DNA probe specific for the HER-2/neu gene"/>
   <result pre="19164073 13 Gustavson MD Bourke-Martin B Reilly D Cregger M" exact="Williams" post="C Mayotte J et al. Standardization of HER2 immunohistochemistry"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4471111/results/search/funders/results.xml">
   <result pre="of Heraklion, Heraklion, Crete, Greece [2], Laboratory of Tumor Biology," exact="School of Medicine," post="University of Crete, Heraklion, Crete, Greece Liu Xiaoan Academic"/>
   <result pre="Crete, Greece [2], Laboratory of Tumor Biology, School of Medicine," exact="University of Crete," post="Heraklion, Crete, Greece Liu Xiaoan Academic Editor [], The"/>
   <result pre="Liu Xiaoan Academic Editor [], The First Affiliated Hospital with" exact="Nanjing Medical University," post="CHINA Competing Interests: This work was partly supported by"/>
   <result pre="research grant from the Hellenic Society of Medical Oncology (HESMO)," exact="GlaxoSmithKline" post="(GSK), and the Cretan Association for Biomedical Research (CABR)."/>
   <result pre="and honorarium for participation in advisory boards from GSK, Amgen," exact="Novartis" post="and Sanofi. All other authors have declared that no"/>
   <result pre="research grant from the Hellenic Society of Medical Oncology (HESMO)," exact="GlaxoSmithKline" post="(GSK), and the Cretan Association for Biomedical Research (CABR)."/>
   <result pre="time to nadir counts was 1 month (range, 1–5 months)." exact="Total" post="CTC and HER2-positive CTC counts during treatment in all"/>
   <result pre="at the time of the analysis (purple). 10.1371/journal.pone.0123683.t002 Table 2" exact="Total" post="CTCs and HER2-positive CTC counts during lapatinib treatment and"/>
   <result pre="Post-5th Post-6th Post-7th Post-8th Best response(cycles on Tx) CTC counts" exact="Total" post="HER2 Total HER2 Total HER2 Total HER2 Total HER2"/>
   <result pre="Post-7th Post-8th Best response(cycles on Tx) CTC counts Total HER2" exact="Total" post="HER2 Total HER2 Total HER2 Total HER2 Total HER2"/>
   <result pre="Best response(cycles on Tx) CTC counts Total HER2 Total HER2" exact="Total" post="HER2 Total HER2 Total HER2 Total HER2 Total HER2"/>
   <result pre="on Tx) CTC counts Total HER2 Total HER2 Total HER2" exact="Total" post="HER2 Total HER2 Total HER2 Total HER2 Total HER2"/>
   <result pre="CTC counts Total HER2 Total HER2 Total HER2 Total HER2" exact="Total" post="HER2 Total HER2 Total HER2 Total HER2 Total HER2"/>
   <result pre="Total HER2 Total HER2 Total HER2 Total HER2 Total HER2" exact="Total" post="HER2 Total HER2 Total HER2 Total HER2 1 133"/>
   <result pre="Total HER2 Total HER2 Total HER2 Total HER2 Total HER2" exact="Total" post="HER2 Total HER2 Total HER2 1 133 125 551"/>
   <result pre="Total HER2 Total HER2 Total HER2 Total HER2 Total HER2" exact="Total" post="HER2 Total HER2 1 133 125 551 542 2"/>
   <result pre="Total HER2 Total HER2 Total HER2 Total HER2 Total HER2" exact="Total" post="HER2 1 133 125 551 542 2 2 46"/>
   <result pre="solid tumors. European Organization for Research and Treatment of Cancer," exact="National Cancer Institute" post="of the United States, National Cancer Institute of Canada"/>
   <result pre="Treatment of Cancer, National Cancer Institute of the United States," exact="National Cancer Institute" post="of Canada . J Natl Cancer Inst 92: 205–"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4471791/results/search/funders/results.xml">
   <result pre="[3], North (China) Translational Medicine Research and Cooperation Center, Heilongjiang" exact="Academy of Medical Sciences" post="Harbin, China Correspondence Da Pang, Department of breast surgery,"/>
   <result pre="Hospital; North (China) Translational Medicine Research and Cooperation Center, Heilongjiang" exact="Academy of Medical Sciences," post="Harbin 150081, China., Tel: +86-451-86298866; Fax: +86-451-86298866;, E-mail: pangdasir1@sina.com"/>
   <result pre="72 months (range, 3–82 months). RNA preparation and reverse transcription" exact="Total" post="RNA was extracted according to the protocol of TRIzol"/>
   <result pre="for 15 min at 4°C and the supernatant was obtained." exact="Total" post="proteins were quantified using the Pierce BCA Protein Assay"/>
   <result pre="prognostic indicator. This study was supported by grants from the" exact="National Natural Science Foundation of China" post="(81172498/H1622, 81101997/H1622) and Heilongjiang Special Funds for outstanding youth"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4472207/results/search/funders/results.xml">
   <result pre="11 [1], Bladder Cancer Center, Lank Center for Genitourinary Oncology," exact="Dana-Farber Cancer Institute" post="Boston, Massachusetts [2], Department of Medical Oncology, University Hospital"/>
   <result pre="Mar–IMIM Barcelona, Spain [3], Department of Biostatistics and Computational Biology," exact="Dana-Farber Cancer Institute" post="Boston, Massachusetts [4], University of Athens and Hellenic Co-operative"/>
   <result pre="Greece [5], Center for Molecular Oncologic Pathology, Department of Pathology," exact="Brigham and Women's Hospital" post="Boston, Massachusetts [6], Department of Pathology, Brigham and Women's"/>
   <result pre="Brigham and Women's Hospital Boston, Massachusetts [6], Department of Pathology," exact="Brigham and Women's Hospital" post="Boston, Massachusetts [7], The Johns Hopkins University School of"/>
   <result pre="of Pathology, Brigham and Women's Hospital Boston, Massachusetts [7], The" exact="Johns Hopkins University" post="School of Medicine Baltimore, Maryland [8], Hospital de Mar"/>
   <result pre="and Women's Hospital Boston, Massachusetts [7], The Johns Hopkins University" exact="School of Medicine" post="Baltimore, Maryland [8], Hospital de Mar Research Institute–IMIM Barcelona,"/>
   <result pre="Cancer Center New York City, New York Correspondence Joaquim Bellmunt," exact="Dana-Farber Cancer Institute," post="450 Brookline Avenue, Dana 1230, Boston, MA 02215. Tel:"/>
   <result pre="the different institutions, de-identified and approved for use by the" exact="Dana-Farber Cancer Institute" post="IRB. Tissue preparation Slides from FFPE tissue blocks were"/>
   <result pre="a log base 2 ratio greater than 0.9. mRNA analysis" exact="Total" post="RNA was extracted from tumor specimens following manufacturer's protocols"/>
   <result pre="factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II" exact="National Cancer Institute" post="trial J. Clin. Oncol 2007 25 2218 2224 17538166"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4476721/results/search/funders/results.xml">
   <result pre="Sankyo Co., Ltd., Tokyo, Japan de Groot Anne Editor []," exact="University of Rhode Island," post="UNITED STATES Competing Interests: All authors are employed by"/>
   <result pre="doi: 10.1200/JCO.2009.23.3734 19786658 3 Moy B , Rappold E ," exact="Williams" post="L , Kelly T , Nicolodi L , Maltzman"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4477383/results/search/funders/results.xml">
   <result pre="3 Mehta Minesh P. 4 [1], Departments of Radiation Oncology," exact="Louisiana State University" post="School of Medicine, Shreveport, Louisiana 71130, USA [2], Willis-Knighton"/>
   <result pre="P. 4 [1], Departments of Radiation Oncology, Louisiana State University" exact="School of Medicine," post="Shreveport, Louisiana 71130, USA [2], Willis-Knighton Health System, Shreveport,"/>
   <result pre="University, Akron, Ohio 44304, USA [4], Department of Radiation Oncology," exact="University of Maryland" post="School of Medicine, Baltimore, Maryland 21201, USA Address for"/>
   <result pre="44304, USA [4], Department of Radiation Oncology, University of Maryland" exact="School of Medicine," post="Baltimore, Maryland 21201, USA Address for correspondence: Prof. Minesh"/>
   <result pre="for correspondence: Prof. Minesh P. Mehta, Department of Radiation Oncology," exact="University of Maryland," post="22 Greene Street, Baltimore, Maryland 21201, USA. E-mail: mmehta@umm.edu"/>
   <result pre="epidermal growth factor receptor 2-positive breast cancer and brain metastases:" exact="American Society of Clinical Oncology" post="clinical practice guideline J Clin Oncol 2014 32 2100"/>
   <result pre="6 Chicago, Illinois Poster presentation at 2014 Annual Meeting of" exact="American Society of Clinical Oncology" post="(ASCO) 15 Barnholtz-Sloan JS Yu C Sloan AE Vengoechea"/>
   <result pre="Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An" exact="American Society for Radiation Oncology" post="evidence-based guideline Pract Radiat Oncol 2012 2 210 25"/>
   <result pre="Atlanta, Georgia Oral Presentation at 2013 Annual Meeting of the" exact="American Society for Radiation Oncology" post="(ASTRO) 25 Radiation Therapy Oncology Group.(2013) Avoidance of the"/>
   <result pre="lung cancer (NSCLC). Oral Presentation at 2014 Annual Meeting of" exact="American Society of Clinical Oncology" post="(ASCO), Chicago, Illinois J Clin Oncol 2014 32 5s"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4479882/results/search/funders/results.xml">
   <result pre="anti-HER2 therapies. Funding This work was supported by the Spanish" exact="Instituto de Salud Carlos III" post="(ISCIII) (FIS PI11/00692, TP) and the Spanish Ministerio de"/>
   <result pre="Salud Carlos III (ISCIII) (FIS PI11/00692, TP) and the Spanish" exact="Ministerio de Ciencia e Innovación" post="(MICCIN CIT-090000-2009-10, TP and SAF-2011-22893, EG-S), La Marató de"/>
   <result pre="de TV3 Foundation (TP, EG-S), La Caixa Foundation (RB) and" exact="Pfizer" post="S.L. (TP). The University of Girona awarded AB and"/>
   <result pre="developed by exposing SK cells continuously to trastuzumab (Herceptin, Hoffmann-La" exact="Roche" post="Pharma), starting with 1μM concentration for three months of"/>
   <result pre="(Girona, Spain), for kindly supplying trastuzumab. Temsirolimus was yielded by" exact="Pfizer" post="(New York, NY, EUA), Lapatinib was provided by GlaxoSmithKline"/>
   <result pre="by Pfizer (New York, NY, EUA), Lapatinib was provided by" exact="GlaxoSmithKline" post="(Middlesex, UK) and Pertuzumab was provided by Genentech (San"/>
   <result pre="provided by GlaxoSmithKline (Middlesex, UK) and Pertuzumab was provided by" exact="Genentech" post="(San Francisco, CA, USA). We are also grateful to"/>
   <result pre="of PDX models and Dr. A. Welm (Huntsman Cancer Institute," exact="University of Utah," post="Salt Lake City, Utah, USA) for providing samples from"/>
   <result pre="The ErbB signaling network: receptor heterodimerization in development and cancer." exact="EMBO" post="J. 2000; 19( 13): 3159– 67. doi: 10.1093/emboj/19.13.3159 ;"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4484424/results/search/funders/results.xml">
   <result pre="of NT control cells (NT) is arbitrarily reported to 1." exact="FOX" post="= 5-FU (1 μM) + oxaliplatin (1 μM), FIRI"/>
   <result pre="5% CO 2 and cultured as the parental cells. Western-blotting" exact="Total" post="cellular extracts and western blotting were performed as previously"/>
   <result pre="at 20 nM. Quantitative reverse transcription polymerase chain reaction qRT-PCR" exact="Total" post="RNA from PC cells was prepared using the NucleoSpin"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4488128/results/search/funders/results.xml">
   <result pre="design After approval by the Institutional Review Board of the" exact="University of Pennsylvania," post="87 patients with HER2 pos IBC were enrolled in"/>
   <result pre="in the Clinical Immunology laboratory at the Hospital of the" exact="University of Pennsylvania." post="In addition, HER2-specific IL-4 and IL-10 production (surrogates for"/>
   <result pre="h incubation, IFN-γ (1000 U/mL) was added; the following day," exact="National Institutes of Health" post="(NIH) reference standard lipopolysaccharide (LPS) was added (10 ng/mL)"/>
   <result pre="NIH-designated General Clinical Research Center at the Hospital of the" exact="University of Pennsylvania." post="Injections comprised 10–20 × 10 6 HER2-pulsed DC1s suspended"/>
   <result pre="in HER2 pos BC [ 7, 8]; in fact, the" exact="Food and Drug Administration" post="(FDA) supports pCR as a trial endpoint for drug"/>
   <result pre="suppressor cells MHC major histocompatability complex NK natural killer NIH" exact="National Institutes of Health" post="OR odds ratio PBMC peripheral blood mononuclear cells PBS"/>
   <result pre="approved the final manuscript. Acknowledgements The study was supported by" exact="National Institutes of Health" post="R01 CA096997, Pennies in Action® ( www.penniesinaction.org), and University"/>
   <result pre="of Health R01 CA096997, Pennies in Action® ( www.penniesinaction.org), and" exact="University of Pennsylvania" post="Abramson Cancer Center Breast Translational Center of Excellence Grant."/>
   <result pre="Center, and the Leukapheresis Unit at the Hospital of the" exact="University of Pennsylvania." post="References References 1. Meric F Hung MC Hortobagyi GN"/>
   <result pre="16. Szabo SJ Sullivan BM Stemmann C Satoskar AR Sleckman" exact="BP" post="Glimcher LH Distinct effects of T-bet in TH1 lineage"/>
   <result pre="Approval. 2014. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm305501.pdf. Accessed 12 March 2015. 21. Perez EA" exact="Thompson" post="EA Ballman KV Anderson SK Asmann YW Kalari KR"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4491676/results/search/funders/results.xml">
   <result pre="Acknowledgments This work was supported by grants received from the" exact="Irish Cancer Society," post="Grant CRS11KIE (to Maeve Kiely) and funds from Science"/>
   <result pre="Cancer Society, Grant CRS11KIE (to Maeve Kiely) and funds from" exact="Science Foundation Ireland" post="(13/CDA/2228) and the Mid-Western Cancer Foundation (to Patrick A."/>
   <result pre="activity is controlled by the early gene IEX-1 and ERK" exact="EMBO" post="J. 2006 25 727 738 10.1038/sj.emboj.7600980 16456541 60. Silverstein"/>
   <result pre="SRC through different mechanisms: Activation in vivo and in vitro" exact="EMBO" post="J. 1997 16 2384 2396 10.1093/emboj/16.9.2384 9171352 71. Kuo"/>
   <result pre="and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis" exact="EMBO" post="Mol. Med. 2013 5 105 121 23180565 101. Baldacchino"/>
   <result pre="subunit, B56γ, mediates DNA damage-induced dephosphorylation of p53 at Thr55" exact="EMBO" post="J. 2007 26 402 411 10.1038/sj.emboj.7601519 17245430 121. Nobumori"/>
   <result pre="I. Liu L. Zhao S. Liu Z. Moseley M.A. III" exact="Thompson" post="J.W. Chen F.L. Koch K.M. et al. Resistance to"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4494590/results/search/funders/results.xml">
   <result pre="interests exist. References References 1 SEER Cancer Statistics Review, 1975-2006" exact="National Cancer Institute" post="Horner MJ Ries LAG Krapcho M et al. 2009"/>
   <result pre="Ross DT Johnsen H Akslen LA Fluge O Pergamenschikov A" exact="Williams" post="C Zhu SX Lønning PE Børresen-Dale AL Brown PO"/>
   <result pre="Press MF Spears PA Vance GH Viale G Hayes DF;" exact="American Society of Clinical Oncology;" post="College of American Pathologists 3997 4013 31 2013 24101045"/>
   <result pre="breast cancer stem-like cells by activating Notch signalling in brain" exact="EMBO" post="Mol Med Xing F Kobayashi A Okuda H Watabe"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4494975/results/search/funders/results.xml">
   <result pre="65 UI/mL 3 (50%) 13 (48%)  Missing 11 Abbreviations: WHO," exact="World Health Organization" post="* Enrolled patient although not meeting the inclusion criterion"/>
   <result pre="two treatment cycles. Adverse events were graded according to the" exact="National Cancer Institute" post="Common Terminology Criteria for Adverse Events (CTCAE), version 3.0."/>
   <result pre="work was supported by the program &quot;Investissement d'avenir&quot; grant agreement:" exact="Labex" post="MabImprove, ANR-10-LABX-53-01. CONFLICTS OF INTEREST Marc Ychou and David"/>
   <result pre="Comprehensive Cancer Centers). Study drugs were provided by F. Hoffmann-La" exact="Roche" post="Ltd (trastuzumab) and Merck Serono (cetuximab); Merck Serono also"/>
   <result pre="drugs were provided by F. Hoffmann-La Roche Ltd (trastuzumab) and" exact="Merck" post="Serono (cetuximab); Merck Serono also provided additional funding. Data"/>
   <result pre="by F. Hoffmann-La Roche Ltd (trastuzumab) and Merck Serono (cetuximab);" exact="Merck" post="Serono also provided additional funding. Data collection, analysis and"/>
   <result pre="were performed by the study sponsor. References REFERENCES 1 collab:" exact="National Cancer Institute" post="Cancer of the Pancreas - SEER Stat Fact Sheets"/>
   <result pre="with advanced pancreatic cancer: a phase III trial of the" exact="National Cancer Institute" post="of Canada Clinical Trials Group J Clin Oncol 2007"/>
   <result pre="solid tumors. European Organization for Research and Treatment of Cancer," exact="National Cancer Institute" post="of the United States, National Cancer Institute of Canada"/>
   <result pre="Treatment of Cancer, National Cancer Institute of the United States," exact="National Cancer Institute" post="of Canada J Natl Cancer Inst 2000 92 205"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4495150/results/search/funders/results.xml">
   <result pre="a retrospective study approved by the Institutional Review Board of" exact="Sun Yat-sen University." post="A total of 243 female patients with HER2 positive"/>
   <result pre="with HER2 positive metastatic breast cancer, who received treatment at" exact="Sun Yat-sen University" post="Cancer Center during the period January 2002 to January"/>
   <result pre="of 243 patients with HER2-positive metastatic breast cancer Clinical characteristic" exact="Total" post="( n = 243) Age at metastasis, mean ±"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4496366/results/search/funders/results.xml">
   <result pre="by the Institutional Animal Care and Use Committee of the" exact="University of Florida." post="Tumors were initiated by the injection of 2 ×"/>
   <result pre="the mammary fat pads of female NSG mice (005557, The" exact="Jackson Laboratory," post="Bar Harbor, ME) in sterile saline. Mice with palpable"/>
   <result pre="cut and stained with hematoxylin and eosin (H&amp;amp;E) by the" exact="University of Florida" post="Molecular Pathology Core ( http://molecular.pathology.ufl.edu/). Analysis of DDA chemical"/>
   <result pre="and eosin (H&amp;amp;E) by the University of Florida Molecular Pathology" exact="Core" post="( http://molecular.pathology.ufl.edu/). Analysis of DDA chemical reactivity by mass"/>
   <result pre="FIGURES LINK This research was supported in part by a" exact="Florida Department of Health" post="Bankhead-Coley grant 4BF03 to B.K.L. R.B.F. is grateful to"/>
   <result pre="LINK This research was supported in part by a Florida" exact="Department of Health" post="Bankhead-Coley grant 4BF03 to B.K.L. R.B.F. is grateful to"/>
   <result pre="Bankhead-Coley grant 4BF03 to B.K.L. R.B.F. is grateful to the" exact="University of Florida" post="for a Graduate School Fellowship. The authors thank Dr."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4501549/results/search/funders/results.xml">
   <result pre="1 3 Chang King-Jen 1 Chao Wei-Ting 3 * [1]," exact="Department of Surgery," post="Cheng-Ching General Hospital, Chungkang Branch, Taichung, Taiwan [2], Department"/>
   <result pre="Hospital, Chungkang Branch, Taichung, Taiwan [3], Department of Life Science," exact="Tunghai University," post="Taichung, Taiwan Tan Ming Editor [], University of South"/>
   <result pre="several effective trials, in 2001, trastuzumab was approved by the" exact="Food and Drug Administration" post="(FDA) in the USA for patients with advanced breast"/>
   <result pre="Wang LH in Institute of Molecular and Genomic Medicine of" exact="National Health Research Institutes," post="Miaoli, Taiwan. Cells were grown in Dulbecco's modified Eagle's"/>
   <result pre="LH in Institute of Molecular and Genomic Medicine of National" exact="Health Research" post="Institutes, Miaoli, Taiwan. Cells were grown in Dulbecco's modified"/>
   <result pre="cells/ml and incubated alone or in 10 μg/ml trastuzumab (Herceptin," exact="Roche" post="Ltd., Basel, Swiss), 1 μg/ml T-DM1 (Kadcyla, Roche Ltd.,"/>
   <result pre="trastuzumab (Herceptin, Roche Ltd., Basel, Swiss), 1 μg/ml T-DM1 (Kadcyla," exact="Roche" post="Ltd., Basel, Swiss), or 1μg/ml paclitaxel (Phyxol, Sinphar Ltd.,"/>
   <result pre="are grateful for a donation from the Tunghai &amp;amp; Cheng-Ching" exact="Cancer Research Foundation." post="Thank Dr. Lin Yiching and Mr. Su Kuo-Chiang for"/>
   <result pre="5. Epub 1995/02/28. ; PubMed Central PMCID: PMC42523. 7877987 25" exact="Williams" post="TM , Lisanti MP . Caveolin-1 in oncogenic transformation,"/>
   <result pre="binding site for SH2 domains of phospholipase C gamma ." exact="EMBO" post="J. 1992; 11( 2): 559– 67. Epub 1992/02/01. ;"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4501645/results/search/funders/results.xml">
   <result pre="0.5% TX-100 and supplemented with protease and phosphatase inhibitors (Sigma)." exact="Total" post="and phospho-EGFR, ErbB2 (HER2) and ErbB3 (HER3) were measured"/>
   <result pre="also worthy of further evaluation. Acknowledgements AZD5363 was discovered by" exact="AstraZeneca" post="subsequent to a collaboration with Astex Therapeutics (and its"/>
   <result pre="a collaboration with Astex Therapeutics (and its collaboration with the" exact="Institute of Cancer Research" post="and Cancer Research Technology Limited). References References 1 Altomare"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4504492/results/search/funders/results.xml">
   <result pre="5 Bayani Nora 2 Itani Sleiman 6 Esch Amanda 1" exact="Thompson" post="Wallace 1 Griffith Obi L. 2 Wang Nicholas J."/>
   <result pre="Life Sciences Division, Berkeley, California, United States of America [3]," exact="University of California" post="San Francisco, Division of Heme/Onc, San Francisco, California, United"/>
   <result pre="Netherlands Cancer Institute, Division of Biochemistry, Amsterdam, The Netherlands [5]," exact="University of Warwick," post="Centre for Complexity Science, Coventry, United Kingdom [6], University"/>
   <result pre="of Warwick, Centre for Complexity Science, Coventry, United Kingdom [6]," exact="University of California," post="Berkeley, Department of Electrical Engineering and Computer Sciences, Berkeley,"/>
   <result pre="Texas, United States of America Wong Kwong-Kwok Editor [], The" exact="University of Texas MD Anderson Cancer Center," post="UNITED STATES Competing Interests: The authors have declared that"/>
   <result pre="+/PIK3CA wt cells. Funding This work was supported by the" exact="National Institutes of Health," post="National Cancer Institute grants U54 CA 112970, the U24"/>
   <result pre="This work was supported by the National Institutes of Health," exact="National Cancer Institute" post="grants U54 CA 112970, the U24 CA 126477, the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4506360/results/search/funders/results.xml">
   <result pre="of the clinical trials required for regulatory approval by the" exact="U.S. Food and Drug Administration" post="(FDA) emphasize the need for alternative strategies. Relatively little"/>
   <result pre="the clinical trials required for regulatory approval by the U.S." exact="Food and Drug Administration" post="(FDA) emphasize the need for alternative strategies. Relatively little"/>
   <result pre="Investigational Cancer Therapeutics (Phase I Clinical Trials Program) at The" exact="University of Texas MD Anderson Cancer Center" post="and the challenges facing the broader application of this"/>
   <result pre="efforts be more easily funded through federal sources such as" exact="National Cancer Institute" post="and other agencies [ 29]. CONCLUSIONS Our experience has"/>
   <result pre="HDAC inhibitor vorinostat in heavily pretreated refractory Hodgkin lymphoma patients" exact="American Society of Clinical Oncology" post="Annual Meeting Chicago, IL (abstract #8508) 2014 6 Moroney"/>
   <result pre="Early-phase Cancer Clinical Trials: Are the Goals Therapeutic or Scientific?" exact="American Society of Clinical Oncology," post="Educational Book 2011 23 Younes A Bartlett NL Leonard"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4506361/results/search/funders/results.xml">
   <result pre="Foundation Medicine, Inc. TG has received non-salary research support from" exact="Bristol-Myers Squibb" post="and Bayer Oncology. UD, HA, and FAB have nothing"/>
   <result pre="TG has received non-salary research support from Bristol-Myers Squibb and" exact="Bayer" post="Oncology. UD, HA, and FAB have nothing to declare."/>
   <result pre="Biotechnol 2013 11 31 11 1023 31 24142049 3 collab:" exact="American Cancer Society" post="Cancer Facts &amp;amp; Figures 2015 Atlanta American Cancer Society"/>
   <result pre="collab: American Cancer Society Cancer Facts &amp;amp; Figures 2015 Atlanta" exact="American Cancer Society" post="2015 4 Stathopoulos GP Survival of untreated advanced colorectal"/>
   <result pre="6 23630214 6 Kufe DW Holland JF Frei E collab:" exact="American Cancer Society" post="Cancer medicine 6 6 Hamilton, Ont.; Lewiston, NY BC"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4511219/results/search/funders/results.xml">
   <result pre="8 Panel Members † [1], International Breast Cancer Study Group" exact="University of Sydney" post="Sydney Australia [2], Department of Medical Oncology Dana-Farber Cancer"/>
   <result pre="University of Sydney Sydney Australia [2], Department of Medical Oncology" exact="Dana-Farber Cancer Institute" post="Harvard Medical School Boston USA [3], International Breast Cancer"/>
   <result pre="Sydney Australia [2], Department of Medical Oncology Dana-Farber Cancer Institute" exact="Harvard Medical School" post="Boston USA [3], International Breast Cancer Study Group, Program"/>
   <result pre="Study Group Statistical Center, Department of Biostatistics and Computational Biology" exact="Dana-Farber Cancer Institute" post="Harvard Medical School Boston USA [5], Department of Surgery"/>
   <result pre="Center, Department of Biostatistics and Computational Biology Dana-Farber Cancer Institute" exact="Harvard Medical School" post="Boston USA [5], Department of Surgery and Comprehensive Cancer"/>
   <result pre="Biology Dana-Farber Cancer Institute Harvard Medical School Boston USA [5]," exact="Department of Surgery" post="and Comprehensive Cancer Center Medical University of Vienna Vienna"/>
   <result pre="early breast cancer St Gallen Consensus Funding CA75362 United States" exact="National Cancer Institute" post="SPP150019 introduction The fourteenth St Gallen International Breast Cancer"/>
   <result pre="conference attendees; by Grant No. CA75362 from the United States" exact="National Cancer Institute" post="(IBCSG Statistical Center, M. Regan, PI) and by Susan"/>
   <result pre="irradiation in early breast cancer . In Proceedings of the" exact="American Society of Clinical Oncology" post="J Clin Oncol 2011; 29( Suppl): abstr LBA 1003."/>
   <result pre="3091– 3099. 23918944 68 Hartmann LC , Degnim AC ," exact="Santen" post="RJ et al. Atypical hyperplasia of the breast—risk assessment"/>
   <result pre="Avenue, New York, USA Jonas Bergh, Radiumhemmet &amp;amp; Karolinska Oncology," exact="Karolinska Institutet" post="and University Hospital, 171 76, Stockholm, Sweden Hervé Bonnefoi,"/>
   <result pre="171 76, Stockholm, Sweden Hervé Bonnefoi, Institut Bergonié Cancer Center," exact="Université de Bordeaux," post="Bordeaux, France Harold Burstein, Department of Medical Oncology/Solid Tumor"/>
   <result pre="Bordeaux, France Harold Burstein, Department of Medical Oncology/Solid Tumor Oncology," exact="Dana-Farber Cancer Institute," post="450 Brookline Avenue, Boston, MA 02215, USA Fatima Cardoso,"/>
   <result pre="Switzerland Alan S. Coates, International Breast Cancer Study Group and" exact="University of Sydney," post="Sydney, 40 Cook Road, Centennial Park NSW 2021, Australia"/>
   <result pre="Oncology, Via Ripamonti 435, 20141 Milan, Italy Nancy E. Davidson," exact="University of Pittsburgh" post="Cancer Institute and UPMC Cancer Center, 5150 Centre Avenue,"/>
   <result pre="Italy Richard D. Gelber, Department of Biostatistics and Computational Biology," exact="Dana-Farber Cancer Institute," post="450 Brookline Avenue, Boston, MA 02215, USA Michael Gnant,"/>
   <result pre="Boston, MA 02215, USA Michael Gnant, Medical University of Vienna," exact="Department of Surgery" post="and Comprehensive Cancer Center, Währinger Gürtel 18-20, 1090 Wien,"/>
   <result pre="Lunenfeld Research Institute, Mount Sinai Hospital and Princess Margaret Hospital," exact="University of Toronto," post="1284-600 University Avenue, Toronto, ON M5G 1X4, Canada Nadia"/>
   <result pre="15, 81377 München, Germany Daniel F. Hayes, Breast Oncology Program," exact="University of Michigan" post="Comprehensive Cancer Center, 1500 East Medical Center Drive, Ann"/>
   <result pre="43, 89073 Ulm, Germany Clifford A. Hudis, Breast Medicine Service," exact="Memorial Sloan-Kettering Cancer Center," post="Memorial Hospital, 1275 York Avenue, and Weill Cornell Medical"/>
   <result pre="Memorial Sloan-Kettering Cancer Center, Memorial Hospital, 1275 York Avenue, and" exact="Weill Cornell Medical College," post="1300 York Avenue, New York, NY 10065, USA James"/>
   <result pre="NY 10065, USA James N. Ingle, Division of Medical Oncology," exact="Mayo Clinic," post="200 First Street S.W., Rochester, MN 55905, USA Jacek"/>
   <result pre="Academy, Sahlgrenska University Hospital, 413 45 Göteborg, Sweden Monica Morrow," exact="Memorial Sloan-Kettering Cancer Center," post="Evelyn Lauder Breast Center, 300 East 66 Street, New"/>
   <result pre="Via Ripamonti 435, 20141 Milan, Italy C. Kent Osborne, Director," exact="Dan L. Duncan Cancer Center, Baylor College of Medicine," post="450A, One Baylor Plaza, Houston, TX 77030, USA Ann"/>
   <result pre="Italy C. Kent Osborne, Director, Dan L. Duncan Cancer Center," exact="Baylor College of Medicine," post="450A, One Baylor Plaza, Houston, TX 77030, USA Ann"/>
   <result pre="One Baylor Plaza, Houston, TX 77030, USA Ann H. Partridge," exact="Dana-Farber Cancer Institute," post="450 Brookline Avenue, Boston, MA, 02215, USA Lorena de"/>
   <result pre="Bordet, Rue Héger-Bordet 1, 1000 Brussels, Belgium Kathleen I. Pritchard," exact="University of Toronto," post="Sunnybrook Odette Cancer Centre, Ontario Clinical Oncology Group (OCOG),"/>
   <result pre="Bayview Avenue, Toronto, ON M4N 1H6, Canada Emiel J.T. Rutgers," exact="Department of Surgery," post="Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121,"/>
   <result pre="68 Leningradskaya Street, Pesochny-2, 197758 St Petersburg, Russia Zhi-Ming Shao," exact="Fudan University," post="Cancer Hospital, 270 Dong-An Road, Shanghai, China Ian Smith,"/>
   <result pre="Shanghai, China Ian Smith, Breast Unit, Royal Marsden Hospital and" exact="Institute of Cancer Research," post="Fulham Road, London, SW3 6JJ, UK Beat Thürlimann, Breast"/>
   <result pre="9007 St Gallen, Switzerland Masakazu Toi, Department of Breast Surgery," exact="Kyoto University" post="Hospital, 54 Shogoin-Kawahara cho, Sakyo-ku, Kyoto 606-8507, Japan Andrew"/>
   <result pre="cho, Sakyo-ku, Kyoto 606-8507, Japan Andrew Tutt, Breast Oncology Unit," exact="King's Health Partners" post="AHSC, Guy's Hospital, 3rd Floor, Bermondsey Wing, and Institute"/>
   <result pre="Health Partners AHSC, Guy's Hospital, 3rd Floor, Bermondsey Wing, and" exact="Institute of Cancer Research" post="London, UK Giuseppe Viale, Department of Pathology, European Institute"/>
   <result pre="Department of Oncology, McMaster University and Juravinski Cancer Centre at" exact="Hamilton Health Sciences," post="699 Concession Street, Hamilton, ON, L8V 5C2, Canada Eric"/>
   <result pre="ON, L8V 5C2, Canada Eric P. Winer, Breast Oncology Center," exact="Dana-Farber Cancer Institute," post="450 Brookline Avenue, Boston, MA, 02115, USA (Chairman) Binghe"/>
   <result pre="USA (Chairman) Binghe Xu, Department of Medical Oncology, Cancer Hospital," exact="Chinese Academy of Medical Sciences" post="and Peking Union Medical College, 17 Panjiayuan Nanli, Choayang"/>
   <result pre="(Chairman) Binghe Xu, Department of Medical Oncology, Cancer Hospital, Chinese" exact="Academy of Medical Sciences" post="and Peking Union Medical College, 17 Panjiayuan Nanli, Choayang"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4519046/results/search/funders/results.xml">
   <result pre="Oregon, United States of America Languino Lucia R. Editor []," exact="Thomas Jefferson University," post="UNITED STATES Competing Interests: The authors have declared that"/>
   <result pre="Provided funding: EAN. ¤ Current address: Department of Neurological Surgery," exact="University of California" post="San Francisco, San Francisco, California, United States of America"/>
   <result pre="the normal brain. Funding This work was supported by the" exact="National Institutes of Health" post="National Cancer Institute grant CA137488; National Institute of Neurological"/>
   <result pre="This work was supported by the National Institutes of Health" exact="National Cancer Institute" post="grant CA137488; National Institute of Neurological Diseases and Stroke"/>
   <result pre="Review grant; a Department of Defense grant W81XWH; and the" exact="Walter S. and Lucienne Driskill Foundation," post="all to Edward A. Neuwelt. Immunofluorescence was performed at"/>
   <result pre="100μm thick coronal slices were sectioned using a vibratome (HM650V," exact="Thermo Scientific," post="Waltham MA). Immunohistochemistry was performed on every sixth section"/>
   <result pre="section by staining for human mitochondrial antigen (Abcam, Cambridge MA)." exact="Total" post="tumor area was manually outlined on scans of all"/>
   <result pre="t-test for comparison of individual groups. Analyses were performed with" exact="Microsoft" post="Excel and Graphpad Prism software. Results Breast cancer cell"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4524128/results/search/funders/results.xml">
   <result pre="correction of anemia. According to the guidelines published by the" exact="American Association of Blood Banks," post="transfusion is recommended for hospitalized patients without cardiovascular disease"/>
   <result pre="was evaluated within 30 days of initiating RT using the" exact="National Cancer Institute" post="Common Toxicity Criteria, version 4.0. Biologically effective dose (BED)"/>
   <result pre="3 regimens). Table 1 Patient characteristics Characteristics Radiotherapy Chemoradiotherapy b" exact="Total" post="( n = 10) % ( n) ( n = 5) % ("/>
   <result pre="21 10.1016/S0140-6736(11)61873-4 22226517 5. Cunningham D Allum WH Stenning SP" exact="Thompson" post="JN Van de Velde CJ Nicolson M Scarffe JH"/>
   <result pre="van Lanschot JJ Steyerberg EW van Berge Henegouwen MI Wijnhoven" exact="BP" post="Richel DJ Nieuwenhuijzen GA Hospers GA Bonenkamp JJ Cuesta"/>
   <result pre="157 49 58 10.7326/0003-4819-157-1-201206190-00429 22751760 8. No author listed. A" exact="Medical Research Council" post="(MRC) randomised trial of palliative radiotherapy with two fractions"/>
   <result pre="with inoperable non-small-cell lung cancer (NSCLC) and poor performance status." exact="Medical Research Council" post="Lung Cancer Working Party. Br J Cancer. 1992;65:934–41 9."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4524286/results/search/funders/results.xml">
   <result pre="of the manuscript. Acknowledgement The authors wish to thank the" exact="Science Foundation Ireland," post="Strategic Research Cluster award 08/SRC/B1410 for funding this work."/>
   <result pre="2013 4 10.1038/cddis.2013.60 23470539 24. Vander Heiden MG Cantley LC" exact="Thompson" post="CB Understanding the Warburg effect: the metabolic requirements of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4525792/results/search/funders/results.xml">
   <result pre="no specific monitoring recommendations for chemotherapy-related cardiotoxicity. 48, 49 The" exact="American Society of Clinical Oncology" post="report the potential for cardiac toxicity with anthracyclines, platinum-based"/>
   <result pre="resuming therapy with anthracyclines and trastuzumab are outlined by the" exact="Food and Drug Administration" post="agency. 52, 53 Following treatment, in the absence of"/>
   <result pre="and approved of the final manuscript. References REFERENCES 1 collab:" exact="American Cancer Society" post="Cancer Facts and Figures 2015 Atlanta American Cancer Society"/>
   <result pre="collab: American Cancer Society Cancer Facts and Figures 2015 Atlanta" exact="American Cancer Society" post="2015 2 Gaetano S Epidemiology of cardiovascular disease in"/>
   <result pre="chamber quantification by echocardiography in adults: an update from the" exact="American Society of Echocardiography" post="and the European Association of Cardiovascular Imaging J Am"/>
   <result pre="12952829 50 Hensley ML Hagerty KL Kewalramani T et al." exact="American Society of Clinical Oncology" post="2008 clinical practice guideline update: use of chemotherapy and"/>
   <result pre="patients during and after cancer therapy: a report from the" exact="American Society of Echocardiography" post="and the European Association of Cardiovascular Imaging Eur Heart"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4529453/results/search/funders/results.xml">
   <result pre="targeted therapies. Presently, four HER2-targeted therapies are approved by the" exact="Food and Drug Administration" post="(FDA) for treatment of HER2-positive breast cancer: Trastuzumab ®,"/>
   <result pre="HER2 testing has been standardized for breast carcinoma, and the" exact="American Society of Clinical Oncology" post="(ASCO) recommends that HER2 status should be determined for"/>
   <result pre="confirmed in further studies. This study was partially supported by" exact="Roche" post="Tissue Diagnostics France (2 avenue du Vercors, 38240 Meylan)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4533098/results/search/funders/results.xml">
   <result pre="peptide synthesis). The synthesized peptides were purified by using a" exact="Hitachi" post="HPLC system (L-7100, Japan) on a TSK gel ODS-100V"/>
   <result pre="Beijing Natural Science Foundation Beijing Natural Science Foundation (5142021) and" exact="National Natural Science Foundation of China" post="(No. 31270875, 31470049). We express our gratitude to Dr."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4534500/results/search/funders/results.xml">
   <result pre="and 0.72 per 100,000, respectively, based on data from the" exact="National Center for Health Statistics" post="[ 8]. The incidence of IHCC worldwide is increasing,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4535951/results/search/funders/results.xml">
   <result pre="2 * [1], Department of Internal Medicine, Division of Hematology/Oncology," exact="University of California" post="Davis, Sacramento, CA, 95817, United States of America [2],"/>
   <result pre="CA, 95817, United States of America [2], Department of Urology," exact="University of California" post="Davis, Sacramento, CA, 95817, United States of America [3],"/>
   <result pre="States of America [4], Department of Biochemistry and Molecular Medicine," exact="University of California" post="Davis, Sacramento, CA, 95817, United States of America [5],"/>
   <result pre="States of America [5], Department of Pathology and Laboratory Medicine," exact="University of California" post="Davis, Sacramento, CA, 95817, United States of America [6],"/>
   <result pre="Davis, Sacramento, CA, 95817, United States of America [6], The" exact="Jackson Laboratory," post="Sacramento, CA, 95838, United States of America [7], University"/>
   <result pre="Jackson Laboratory, Sacramento, CA, 95838, United States of America [7]," exact="University of Southern California," post="Los Angeles, CA, 90089, United States of America Kumar-Sinha"/>
   <result pre="CA, 90089, United States of America Kumar-Sinha Chandan Editor []," exact="University of Michigan," post="UNITED STATES Competing Interests: The authors have declared that"/>
   <result pre="chemotherapy. There is no targeted therapy approved by the US" exact="Food and Drug Administration" post="(FDA) even though recurrent genetic aberrations have been identified."/>
   <result pre="information and cancer specimens from patients was approved by the" exact="University of California" post="Davis Institutional Review Board (Protocol No. 218204). All participants"/>
   <result pre="information was collected. The animal protocol was approved by the" exact="Jackson Laboratory" post="(JAX) Institutional Animal Care and Use Committee (IACUC, Protocol"/>
   <result pre="least 85–90% of cells were cancer cells before specimen collection." exact="Total" post="cellular RNA was isolated from either fresh-frozen xenograft tumor"/>
   <result pre="the miRNeasy FFPE Kit (Qiagen), according to the manufacturer’s protocols." exact="Total" post="RNA was eluted from the columns in nuclease-free water"/>
   <result pre="side panel as BLCA Driver (IntOGen), TCGA Significantly Mutated, or" exact="BGI" post="Significantly Mutated. Somatic mutations were found in 51 different"/>
   <result pre="BLCA Driver and Significantly Mutated Genes—Identified by TCGA, IntOGen, and" exact="BGI" post="Analyses. (XLSX) LINK Click here for additional data file."/>
   <result pre=", Bromage A , Tymms M , Sooraj D ," exact="Williams" post="ED , et al. ( 2012) Xenome—a tool for"/>
   <result pre="25: 1105– 1111. doi: 10.1093/bioinformatics/btp120 19289445 21 Trapnell C ," exact="Williams" post="BA , Pertea G , Mortazavi A , Kwan"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4538762/results/search/funders/results.xml">
   <result pre="stage IIA, stage IIB, and stage IIIA breast cancers. (Reference:" exact="National Cancer Institute;" post="http://www.cancer.gov/dictionary?cdrid=446564 ) ††Advanced breast cancer: Breast cancer that has"/>
   <result pre="authors read and approved the final manuscript. References References 1." exact="American Cancer Society." post="Global Cancer Facts &amp;amp; Figures. 2011; Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027766.pdf."/>
   <result pre="&amp;amp; Figures. 2011; Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027766.pdf. Accessed 12/20, 2012. 2." exact="World Health Organization." post="Breast cancer: prevention and control. 2013; Available at: http://www.who.int/cancer/detection/breastcancer/en/index1.html."/>
   <result pre="and control. 2013; Available at: http://www.who.int/cancer/detection/breastcancer/en/index1.html. Accessed 7/25, 2013. 3." exact="World Health Organization." post="National cancer control programmes. 2013; Available at: http://www.who.int/cancer/nccp/en/. Accessed"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4538915/results/search/funders/results.xml">
   <result pre="development. In 1994, Cremophor-EL-paclitaxel was approved by the United States" exact="Food and Drug Administration" post="(FDA) for treatment of metastatic breast cancer in patients"/>
   <result pre="Estrogen receptor FASG French Adjuvant Study Group FDA United States" exact="Food and Drug Administration" post="FEC50 5-Fluorouracil, epirubicin, and cyclophosphamide HER2 Human epidermal growth"/>
   <result pre="of Medicine/Montefiore Medical Center. Associate Director for Clinical Research at" exact="Albert Einstein Cancer Center." post="References References 1. Jemal A Center MM DeSantis C"/>
   <result pre="Altekruse SF, et al. (eds). SEER Cancer Statistics Review, 1975–2011," exact="National Cancer Institute." post="Bethesda, MD. Based on November 2013 SEER data submission,"/>
   <result pre="Hicks DG Dowsett M McShane LM Allison KH et al." exact="American Society of Clinical Oncology;" post="College of American Pathologists. Recommendations for human epidermal growth"/>
   <result pre="Mennel R Norton L Ravdin P Taube S et al." exact="American Society of Clinical Oncology." post="American Society of Clinical Oncology 2007 update of recommendations"/>
   <result pre="P Taube S et al. American Society of Clinical Oncology." exact="American Society of Clinical Oncology" post="2007 update of recommendations for the use of tumor"/>
   <result pre="N Engl J Med 2010 363 2200 10 21121833 92." exact="Roche" post="H Fumoleau P Spielmann M Canon JL Delozier T"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4541732/results/search/funders/results.xml">
   <result pre="were subjected to SDS-PAGE electrophoresis and transferred to nitrocellulose membrane." exact="Total" post="proteins were detected by immunoblotting (IB) with ( I):"/>
   <result pre="of tumorigenic HER2 C-terminal fragments by alternative initiation of translation" exact="EMBO" post="J. 2006 25 3234 3244 10.1038/sj.emboj.7601191 16794579 12. Kaiser"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4542411/results/search/funders/results.xml">
   <result pre="Correspondence: Mauricio J Reginato, Department of Biochemistry and Molecular Biology," exact="Drexel University" post="College of Medicine, 245 N 15th Street, Philadelphia, PA,"/>
   <result pre="target genes. A few agents currently approved by the US" exact="Food and Drug Administration" post="have demonstrated disruption of the HIF-1/p300 interaction complex. Chetomin"/>
   <result pre="on this review. MJR is supported by grants from the" exact="National Institutes of Health" post="(RO1CA155413). Disclosure The authors declare no conflicts of interest"/>
   <result pre="18 4 349 358 16158227 54 Erler JT Cawthorne CJ" exact="Williams" post="KJ et al. Hypoxia-mediated down-regulation of Bid and Bax"/>
   <result pre="solid tumours BMC Cancer 2012 12 1 496 23098625 98" exact="Williams" post="KJ Albertella MR Fitzpatrick B et al. In vivo"/>
   <result pre="2005 315 3 971 979 102 Glück AA Aebersold DM" exact="Zimmer" post="Y Medová M Interplay between receptor tyrosine kinases and"/>
   <result pre="Sun et al, 96 McKeage et al 97 DNA AQ4NE09" exact="Williams" post="et al 98 Angiogenesis VEGF-A Bevacizumab, ranibizumab Ellis and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4546491/results/search/funders/results.xml">
   <result pre="METHODS Patients and tissues This study was approved by the" exact="Wayne State University" post="School of Medicine Institutional Review Board and written informed"/>
   <result pre="tissues This study was approved by the Wayne State University" exact="School of Medicine" post="Institutional Review Board and written informed consent was obtained"/>
   <result pre="Cancer Gene Census (a cancer atlas project supported by the" exact="Wellcome Trust" post="Sanger Institute, London, UK), and work by Lawrence et"/>
   <result pre="two separate areas of invasive cancer were scored following the" exact="American Society of Clinical Oncology" post="(ASCO) and the College of American Pathologists (CAP) guidelines"/>
   <result pre="by the Karmanos Cancer Institute (ABF and SM). The Genomics" exact="Core" post="and the Biobanking and Correlative Sciences Core are supported"/>
   <result pre="SM). The Genomics Core and the Biobanking and Correlative Sciences" exact="Core" post="are supported by NIH Center grant P30 CA022453 to"/>
   <result pre="Center grant P30 CA022453 to the Karmanos Cancer Institute at" exact="Wayne State University." post="Editorial note This paper has been accepted based in"/>
   <result pre="(iressa) Clinical cancer research : an official journal of the" exact="American Association for Cancer Research" post="2002 8 3496 3502 12429640 8 Gluck S Castrellon"/>
   <result pre="Dieras V Paul D Lossignol D Christodoulou C Stemmler HJ" exact="Roche" post="H Liu MC Greil R Ciruelos E Loibl S"/>
   <result pre="cancer Clinical cancer research : an official journal of the" exact="American Association for Cancer Research" post="2009 15 1452 1459 19228746 11 Narayana A Mathew"/>
   <result pre="trastuzumab Journal of clinical oncology : official journal of the" exact="American Society of Clinical Oncology" post="2013 31 4445 4452 24127447 36 Kaplan MA Ertugrul"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4548203/results/search/funders/results.xml">
   <result pre="Popel Aleksander S. 1 [], 1 Department of Biomedical Engineering," exact="School of Medicine," post="Johns Hopkins University Baltimore, MD, USA [], 2 Division"/>
   <result pre="1 [], 1 Department of Biomedical Engineering, School of Medicine," exact="Johns Hopkins University" post="Baltimore, MD, USA [], 2 Division of Cardiovascular Medicine,"/>
   <result pre="Department of Medicine and Robert M. Berne Cardiovascular Research Center," exact="University of Virginia" post="School of Medicine Charlottesville, VA, USA Edited by: Daniel"/>
   <result pre="and Robert M. Berne Cardiovascular Research Center, University of Virginia" exact="School of Medicine" post="Charlottesville, VA, USA Edited by: Daniel Moura, University of"/>
   <result pre="of Porto, Portugal *Correspondence: Liang-Hui Chu, Department of Biomedical Engineering," exact="School of Medicine," post="Johns Hopkins University, 720 Rutland Avenue, 613 Traylor Bldg.,"/>
   <result pre="*Correspondence: Liang-Hui Chu, Department of Biomedical Engineering, School of Medicine," exact="Johns Hopkins University," post="720 Rutland Avenue, 613 Traylor Bldg., Baltimore, MD 21205,"/>
   <result pre="acid synthesis and synthesis of the cell wall component Tuberculosis" exact="Williams" post="et al., 2011 Balsalazide PTGS2 7 Converted in the"/>
   <result pre="personalized medicine. Clin. Pharmacol. Ther. 92, 414– 417. 10.1038/clpt.2012.96 22992668" exact="Williams" post="C. Panaccione R. Ghosh S. Rioux K. ( 2011)."/>
   <result pre="Heart disease and stroke statistics–2010 update: a report from the" exact="American Heart Association" post=". Circulation 121, e46– e215. 10.1161/CIRCULATIONAHA.109.192667 20019324 Yan S."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4550185/results/search/funders/results.xml">
   <result pre="in median OS between the two treatments. 87 The US" exact="Food and Drug Administration" post="(FDA) subsequently approved the high-dose fulvestrant schedule as second-line"/>
   <result pre="support in the writing of this article was funded by" exact="Novartis" post="Pharmaceuticals Corporation. ACADEMIC EDITOR: William C. S. Cho, Editor"/>
   <result pre="comments to the academic editor. FUNDING: Funding was provided by" exact="Novartis" post="Pharmaceuticals Corporation. The author confirms that Novartis had no"/>
   <result pre="was provided by Novartis Pharmaceuticals Corporation. The author confirms that" exact="Novartis" post="had no influence over the study design, content of"/>
   <result pre="journal. COMPETING INTERESTS: David Riseberg is a member of the" exact="Novartis" post="Speakers Bureau. Paper subject to independent expert blind peer"/>
   <result pre="J Clin 2013 63 1 11 30 23335087 2 collab:" exact="American Cancer Society" post="American Cancer Society Breast Cancer Facts and Figures 2013–2014"/>
   <result pre="63 1 11 30 23335087 2 collab: American Cancer Society" exact="American Cancer Society" post="Breast Cancer Facts and Figures 2013–2014 Atlanta GA American"/>
   <result pre="Cancer Society Breast Cancer Facts and Figures 2013–2014 Atlanta GA" exact="American Cancer Society" post="2013 3 Audisio RA Breast cancer in the elderly:"/>
   <result pre="J Cancer 2011 47 suppl 3 S286 9 21943986 4" exact="Williams" post="GR Jones E Muss HB Challenges in the treatment"/>
   <result pre="2013 2013 893104 23365573 44 Arimidex (anastrozole tablets) Wilmington, DE" exact="AstraZeneca" post="Pharmaceuticals LP 2004 45 collab: Afinitor (everolimus tablets for"/>
   <result pre="Afinitor Disperz (everolimus tablets for oral suspension) East Hanover, NJ" exact="Novartis" post="Pharmaceuticals Corporation 2014 46 Aromasin (exemestane tablets) New York,"/>
   <result pre="and Upjohn Company 2004 47 Faslodex (fulvestrant) injection Wilmington, DE" exact="AstraZeneca" post="Pharmaceuticals LP 11 2012 48 Femara (letrozole tablets) 2.5"/>
   <result pre="48 Femara (letrozole tablets) 2.5 mg tablets East Hanover, NJ" exact="Novartis" post="Pharmaceuticals Corporation 2006 49 Nolvadex (tamoxifen citrate tablet) Wilmington,"/>
   <result pre="Pharmaceuticals Corporation 2006 49 Nolvadex (tamoxifen citrate tablet) Wilmington, DE" exact="AstraZeneca" post="Pharmaceuticals LP 2007 50 Jolly T Williams GR Jones"/>
   <result pre="tablet) Wilmington, DE AstraZeneca Pharmaceuticals LP 2007 50 Jolly T" exact="Williams" post="GR Jones E Muss HB Treatment of metastatic breast"/>
   <result pre="91 16985247 62 Tykerb (lapatinib) tablets Research Triangle Park NC" exact="GlaxoSmithKline" post="2012 63 Johnston S Pippen J Jr Pivot X"/>
   <result pre="for locally recurrent or metastatic breast cancer Presented at the" exact="American Society of Clinical Oncology" post="Annual Meeting June 1-June 5, 2012 Chicago, IL, USA"/>
   <result pre="trial Breast 2013 22 2 130 7 23453899 101 collab:" exact="Novartis" post="Pharmaceuticals Open-label, phase II, study of everolimus plus letrozole"/>
   <result pre="9, 2015]. Available at: http://clinicaltrials.gov/show/NCT01698918 [NLM Identifier: NCT01698918. 102 collab:" exact="University of Maryland" post="collab: Novartis Pharmaceuticals collab: GlaxoSmithKline GCC 0901 – study"/>
   <result pre="http://clinicaltrials.gov/show/NCT01698918 [NLM Identifier: NCT01698918. 102 collab: University of Maryland collab:" exact="Novartis" post="Pharmaceuticals collab: GlaxoSmithKline GCC 0901 – study of how"/>
   <result pre="NCT01698918. 102 collab: University of Maryland collab: Novartis Pharmaceuticals collab:" exact="GlaxoSmithKline" post="GCC 0901 – study of how well letrozole works"/>
   <result pre="Available at: http://clinicaltrials.gov/show/NCT01499160 [NLM Identifier: NCT01499160] 103 collab: PrECOG, LLC;" exact="Novartis" post="Study of fulvestrant +/− everolimus in post-menopausal, hormone-receptor +"/>
   <result pre="at: http://clinicaltrials.gov/show/NCT01797120 [NLM Identifier: NCT01797120] 104 collab: Suleiman Massarweh collab:" exact="Novartis" post="Study of combined fulvestrant and everolimus in advanced/metastatic breast"/>
   <result pre="Clin Oncol 2013 10 3 143 53 23400000 109 collab:" exact="Novartis" post="Pharmaceuticals Corp Phase III study of BKM120/placebo with fulvestrant"/>
   <result pre="9, 2015]. Available at: http://clinicaltrials.gov/show/NCT01610284 [NLM Identifier: NCT01610284] 110 collab:" exact="Novartis" post="Pharmaceuticals A Phase III study of BKM120 with fulvestrant"/>
   <result pre="9, 2015]. Available at: http://clinicaltrials.gov/show/NCT01633060 [NLM Identifier: NCT01633060] 111 collab:" exact="Vanderbilt-Ingram Cancer Center" post="PhIb BKM120 or BEZ235+endocrine treatment in post-menopausal patients with"/>
   <result pre="San Antonio, TX, USA Abstract OT2-01 118 collab: Washington University" exact="School of Medicine" post="PD 0332991 and anastrozole for stage 2 or 3"/>
   <result pre="[NLM Identifier: NCT01723774] 119 collab: Spanish Breast Cancer Research Group" exact="Pfizer" post="Phase III study of palbociclib (PD-0332991) in combination with"/>
   <result pre="9, 2015]. Available at: http://clinicaltrials.gov/show/NCT02028507 [NLM Identifier: NCT02028507] 120 collab:" exact="Pfizer" post="Study Of Letrozole With Or Without Palbociclib (PD-0332991) For"/>
   <result pre="9, 2015]. Available at: http://clinicaltrials.gov/show/NCT01709370 [NLM Identifier: NCT01709370] 122 collab:" exact="Pfizer" post="A study of palbociclib (PD-0332991) + letrozole vs letrozole"/>
   <result pre="9, 2015]. Available at: http://clinicaltrials.gov/show/NCT01740427 [NLM Identifier: NCT01740427] 123 collab:" exact="Novartis" post="Pharmaceuticals Study of LEE011, BYL719 and letrozole in advanced"/>
   <result pre="9, 2015]. Available at: http://clinicaltrials.gov/show/NCT01872260 [NLM Identifier: NCT01872260] 124 collab:" exact="Novartis" post="Pharmaceuticals Study of efficacy and safety of LEE011 in"/>
   <result pre="9, 2015]. Available at: http://clinicaltrials.gov/show/NCT01958021 [NLM Identifier: NCT01958021] 125 collab:" exact="Novartis" post="Pharmaceuticals Phase Ib/II trial of LEE011 with everolimus (RAD001)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4552740/results/search/funders/results.xml">
   <result pre="Pathology, Hannover Medical School, Hannover, Germany Ho Yuan-Soon Editor []," exact="Taipei Medical University," post="TAIWAN Competing Interests: The authors have declared that no"/>
   <result pre="Belgium under the Authorisation No.: 1285, issued by The Belgian" exact="Ministry of Health." post="The institutional animal care and use committee: Ethic Committee"/>
   <result pre="mixture containing siRNA dilution and the transfection reagent DharmaFect3 (Dharmacon," exact="Thermo Scientific," post="Etten-Leur, the Netherlands) was added to the wells. Final"/>
   <result pre="biological targeted therapy of malignant diseases. We are thankful to" exact="GlaxoSmithKline" post="for providing lapatinib. The excellent assistance of Elisa Schipper"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4553016/results/search/funders/results.xml">
   <result pre="products that are validated, approved and regulated by the US" exact="Food and Drug Administration" post="(FDA). Other IVD tests are created by the pathology"/>
   <result pre="FP staining reactions than 3+ or 0/1+ cores, respectively. ASCO," exact="American Society of Clinical Oncology;" post="CAP, College of American Pathologists; IHC, immunohistochemistry; NordiQC; Nordic"/>
   <result pre="Approved IVD Laboratory-developed IVD Difference Direct cost/patient 364 1394 1030" exact="Total" post="direct costs a 14 447 666 55 377 720"/>
   <result pre="930 054 Cost of lost productivity/patient b 83 190 107" exact="Total" post="cost of lost productivity c 3 301 263 7"/>
   <result pre="Approved IVD Laboratory-developed IVD Difference Direct cost/patient 176 1228 1052" exact="Total" post="direct costs a 859 446 5 992 471 5"/>
   <result pre="133 025 Cost of lost productivity/patient b 52 120 68" exact="Total" post="cost of lost productivity c 255 594 586 221"/>
   <result pre="in situ hybridisation FN False negative FP False positive FDA" exact="Food and Drug Administration" post="HER2 Human epidermal growth factor receptor 2 IHC Immunohistochemistry"/>
   <result pre="and EW are employed by Ventana. JG is employed by" exact="Roche" post="Professional Diagnostics. VT and U-PR are employed by and"/>
   <result pre="and U-PR are employed by and own stock options in" exact="Roche" post="Diagnostics. Authors’ contributions MV, SN and RR provided the"/>
   <result pre="are employed by Ventana Medical Systems. JG is employed by" exact="Roche" post="Professional Diagnostics. VT and U-PR are employed by F."/>
   <result pre="Professional Diagnostics. VT and U-PR are employed by F. Hoffmann-La" exact="Roche" post="Diagnostics Division. Acknowledgements Medical writing/editing assistance for this manuscript"/>
   <result pre="of Miller Medical Communications Ltd (UK), with funding provided by" exact="Roche" post="Diagnostics. The economic model was developed by Analytica LA-SER"/>
   <result pre="cost-effectiveness analysis CMAJ 2007 176 1429 1434 10.1503/cmaj.061011 17485695 20." exact="American Cancer Society." post="Breast Cancer Facts &amp;amp; Figures 2013-2014. 2013. [Cited 25"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4558113/results/search/funders/results.xml">
   <result pre="generously provided by Dr. David Carling (MRC Clinical Sciences Centre," exact="Imperial College, London," post="UK). E. Coli DH5α was made competent via CaCl2"/>
   <result pre="previously described methods [ 47]. NOD-SCID mice (SKCCC Animal Resources" exact="Core" post="Facility) were then inoculated subcutaneously with 5×10 6 cells"/>
   <result pre="vitro kinase assay. FUNDING This work was supported by the" exact="National Cancer Institute" post="(T32 CA67751) and the Safeway Breast Cancer Foundation. CONFLICTS"/>
   <result pre="cancer 2009 9 307 19723334 18 Hadad SM Fleming S" exact="Thompson" post="AM Targeting AMPK: a new therapeutic opportunity in breast"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4558136/results/search/funders/results.xml">
   <result pre="study. CONFLICTS OF INTEREST This work was supported by the" exact="Deutsche Forschungsgemeinschaft" post="(KFO 179-2) and the BMBF consortium MetastaSys (0316173A). Roche"/>
   <result pre="Deutsche Forschungsgemeinschaft (KFO 179-2) and the BMBF consortium MetastaSys (0316173A)." exact="Roche" post="Diagnostics provided detection kits for the immunohistochemical staining. References"/>
   <result pre="Parkin DM Whelan SC Ferlay J Teppo L Thomas DB" exact="World Health Organization" post="Cancer Incidence in Five Continents Lyon The World Health"/>
   <result pre="World Health Organization Cancer Incidence in Five Continents Lyon The" exact="World Health Organization" post="and The International Agency for Research on Cancer 2002"/>
   <result pre="Smith DB Shepherd S Maraveyas A Ferry DR Meade AM" exact="Thompson" post="L Griffiths GO et al. Different strategies of sequential"/>
   <result pre="Ercan D Rogers A Roncalli M Takeda M Fujisaka Y" exact="Philips" post="J Shimizu T et al. Activation of ERBB2 signaling"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4558503/results/search/funders/results.xml">
   <result pre="L 1 * [1], Department of Biochemistry and Molecular Genetics," exact="University of Illinois at Chicago," post="Chicago, IL, USA * Department of Biochemistry and Molecular"/>
   <result pre="of Illinois College of Medicine , M/C 669, 900 South" exact="Ashland" post="Avenue, Chicago 60607, IL, USA. Tel: +312 996 7964;"/>
   <result pre="Tyr-342 (P-Y342) antibody was purchased from Millipore (Bedford, MA, USA)." exact="Total" post="STAT3 and phospho-STAT3 PY705, phospho-FAK P-Y576/577, and phospho-BCAR1 P-Y165"/>
   <result pre="USA). Sheep anti-mouse and donkey anti-rabbit antibodies were purchased from" exact="GE Healthcare" post="Biosciences (Pittsburgh, PA, USA). Statistics For Figure 1a, survival"/>
   <result pre="thank Dr. Hui Xie in the UIC Design and Analysis" exact="Core" post="for assistance with statistics, and Ms. Priya Mathur for"/>
   <result pre="the number of P-STAT3-positive cells was not observed. ( c)" exact="Total" post="PTK6 is ubiquitously expressed in ERBB2 mammary gland tumors"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4558517/results/search/funders/results.xml">
   <result pre="gift of Dr. Angel R deLera (Departamento de Química Orgánica," exact="Universidade de Vigo," post="Pontevedra, Spain). 3-MA (no. S2767)/BafA (B1793) and chloroquine (no."/>
   <result pre="X-100, supplemented with proteinase inhibitor cocktail (complete; Roche, Basel, Switzerland)." exact="Total" post="protein (25–80  μg) was separated on a 12% SDS-polyacrylamide"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4567019/results/search/funders/results.xml">
   <result pre="3 Yoshida Kazuhiro 1 [1], Department of Surgical Oncology, Graduate" exact="School of Medicine," post="Gifu University Gifu, Japan [2], Department of Breast and"/>
   <result pre="Gifu, Japan [2], Department of Breast and Molecular Oncology, Graduate" exact="School of Medicine," post="Gifu University Gifu, Japan [3], Molecular Pharmacology, Department of"/>
   <result pre="Correspondence Manabu Futamura,, Department of Breast and Molecular Oncology, Graduate" exact="School of Medicine," post="Address: Gifu University, Yanagido 1-1, Gifu 501-1194, Japan., Tel:"/>
   <result pre="cultured according to the manufacturer's guidelines. Reverse transcription-polymerase chain reaction" exact="Total" post="RNA was isolated from subconfluent cells using ISOGEN reagent"/>
   <result pre="reverse transcription-polymerase chain reaction (RT-PCR) analysis as previously described 22." exact="Total" post="RNA (5 μg) was reverse-transcribed with SuperScript II reverse"/>
   <result pre="v-akt murine thymoma viral oncogene homolog (Akt) inhibitor MK-2206 from" exact="Merck" post="Oncology (Whitehouse Station, NJ). Cell proliferation assay Cell proliferation"/>
   <result pre="All statistical analyses were performed with EZR (Saitama Medical Center," exact="Jichi Medical University," post="Omiya, Japan) 24. Student's t-test was used to compare"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4570757/results/search/funders/results.xml">
   <result pre="(WMA) Declaration of Helsinki. Ethical approval was waived by the" exact="University of California" post="Los Angeles Office of the Human Research Protection Program"/>
   <result pre="the Director of Neuro-Oncology in the Department of Neurology at" exact="Northwestern University" post="EG is a Clinical Professor with UCLA’s David Geffen"/>
   <result pre="University EG is a Clinical Professor with UCLA’s David Geffen" exact="School of Medicine" post="NL 2 (BS Microbiology/Immunology/Molecular Genetics 2014) is a research"/>
   <result pre="&amp;amp; Oncology as well as Clinical Researcher at the UCLA’s" exact="Jonsson Comprehensive Cancer Center" post="Acknowledgements We thank Roxanna Khosravi (Houghton Mifflin), Dr. Catherine"/>
   <result pre="breast cancer. Journal of clinical oncology: official journal of the" exact="American Society of Clinical Oncology." post="2002;20(3):719-26. 6. Cobleigh MA, Vogel CL, Tripathy D, Robert"/>
   <result pre="metastatic disease. Journal of clinical oncology: official journal of the" exact="American Society of Clinical Oncology." post="1999;17(9):2639-48. 7. Romond EH, Perez EA, Bryant J, Suman"/>
   <result pre="breast cancer. Journal of clinical oncology: official journal of the" exact="American Society of Clinical Oncology." post="2006;24(18):2786-92. 10. Baselga J Bradbury I Eidtmann H et"/>
   <result pre="breast cancer. Journal of clinical oncology: official journal of the" exact="American Society of Clinical Oncology." post="2012;30(14):1594-600. 25. Peoples GE, Gurney JM, Hueman MT, Woll"/>
   <result pre="cancer patients. Journal of clinical oncology: official journal of the" exact="American Society of Clinical Oncology." post="2005;23(30):7536-45. 26. Mittendorf EA, Holmes JP, Ponniah S, Peoples"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4574060/results/search/funders/results.xml">
   <result pre="1 2 Yerushalmi Rinat 3 4 [1], Chief Physician’s Office," exact="Clalit Health Services" post="Headquarters, Tel-Aviv, Israel [2], The Bruce and Ruth Rappaport"/>
   <result pre="patients, treated with either lapatinib or TBP. Patients and Methods" exact="Clalit Health Services" post="(CHS) is the largest healthcare provider organization in Israel,"/>
   <result pre="data was extracted from the existing computerized data bases of" exact="Clalit Health Services," post="the IRB waved the need for the patients to"/>
   <result pre="with advanced human epidermal growth factor receptor 2–positive breast cancer:" exact="American Society of Clinical Oncology" post="Clinical Practice Guideline . J Clin Oncol. 2014; 32:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4578850/results/search/funders/results.xml">
   <result pre="absence of DCIS (Fig. 2). As a result, the US" exact="Food and Drug Administration" post="(FDA) have advocated use of either ypT0 ypN0 or"/>
   <result pre="Sataloff Tumour: T-A includes pCR and minimal residual disease  T-A." exact="Total" post="or near total therapeutic effect T-A versus other categories"/>
   <result pre="Lancet Oncol 2014 15 640 7 10.1016/S1470-2045(14)70080-4 24657003 11. US" exact="Department of Health" post="and Human Services, Food and Drug Administration Center for"/>
   <result pre="10.1016/S1470-2045(14)70080-4 24657003 11. US Department of Health and Human Services," exact="Food and Drug Administration" post="Center for Drug Evaluation and Research (CDER). Guidance for"/>
   <result pre="Breast 2003 12 320 7 10.1016/S0960-9776(03)00106-1 14659147 26. Chevallier B" exact="Roche" post="H Olivier JP Chollet P Hurteloup P Inflammatory breast"/>
   <result pre="new genome-driven integrated classification of breast cancer and its implications" exact="EMBO" post="J 2013 32 617 28 10.1038/emboj.2013.19 23395906 32. Goldie"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4586465/results/search/funders/results.xml">
   <result pre="an FDA-approved, NCI-funded phase 1 clinical trial (NCT01376505) at the" exact="Ohio State University" post="James Cancer Hospital and the Comprehensive Cancer Center. We"/>
   <result pre="mass spectroscopy at the CCIC (Campus Chemical Instrumentation Center, The" exact="Ohio State University," post="Columbus, OH, USA). All fractions were analyzed on analytical"/>
   <result pre="were purchased from The James Cancer Hospital pharmacy of The" exact="Ohio State University" post="Wexner Medical Center (Columbus, OH, USA), and AG825 was"/>
   <result pre="protein assay. All experiments were performed in accordance with the" exact="U.S. Public Health Service" post="Policy on Humane Care and Use of Laboratory Animals"/>
   <result pre="Care and Use of Laboratory Animals and approved by the" exact="Ohio State University" post="Institutional Animals Care and Use Committee and detailed in"/>
   <result pre="Danvers, MA, USA) supplemented with protease and phosphatase inhibitors (Sigma-Aldrich)." exact="Total" post="protein extracts were run on SDS-PAGE and blotted onto"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4586793/results/search/funders/results.xml">
   <result pre="D816VKit Is Resistant 1 Supported by a grant from the" exact="National Health and Medical Research Council" post="of Australia (NHMRC). MF is recipient of an Australian"/>
   <result pre="1 Supported by a grant from the National Health and" exact="Medical Research Council" post="of Australia (NHMRC). MF is recipient of an Australian"/>
   <result pre="43 60 66 10.1016/j.oraloncology.2006.01.005 16807070 75. Gorringe K.L. Jacobs S." exact="Thompson" post="E.R. Sridhar A. Qiu W. Choong D.Y. Campbell I.G."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4588449/results/search/funders/results.xml">
   <result pre="Kyung Hae 1 [1], Department of Oncology, Asan Medical Center," exact="University of Ulsan" post="College of Medicine Korea * ( sbkim3@amc.seoul.kr) epub: 2015-09-09"/>
   <result pre="of Helsinki and Good Clinical Practice, approved by the Korea" exact="Food and Drug Administration" post="and by the Institutional Review Board of the Asan"/>
   <result pre="Co., Ltd. (Seoul, Korea) and supported by grants from the" exact="Ministry of Knowledge Economy" post="(grant no. R0000339). References Bargmann, CI, Hung, MC and"/>
   <result pre="the study. Table 1 Subject characteristics Cohort 1 2 3" exact="Total" post="Number of subjects 3 3 3 9 Mean age"/>
   <result pre="vaccination Cohort Class of agent, n (%) 1 2 3" exact="Total" post="Before study entry  Chemotherapy   Antimetabolites a 2 (66.7) 0"/>
   <result pre="1 Table 4 Clinical tumor response Cohort 1 2 3" exact="Total" post="Response rate, n (%) 0 (0.0) 0 (0.0) 1"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4589126/results/search/funders/results.xml">
   <result pre="inhibitor, is the first anti-angiogenic agent approved by the US" exact="Food and Drug Administration" post="for use in the treatment of advanced gastric cancers."/>
   <result pre="has shown that the anti-HER-2 monoclonal antibody, trastuzumab (Herceptin; Hoffman-La" exact="Roche" post="Ltd., Basel, Switzerland), has a modest survival benefit in"/>
   <result pre="cancer including epidermal growth factor receptor (EGFR) inhibitors, cetuximab (Erbitux;" exact="Merck" post="Serono, Darmstadt, Germany) 24 and panitumumab (Vectibix; Amgen Inc.,"/>
   <result pre="cetuximab (Erbitux; Merck Serono, Darmstadt, Germany) 24 and panitumumab (Vectibix;" exact="Amgen" post="Inc., Thousand Oaks, CA, USA), 25 and the mTOR"/>
   <result pre="Oaks, CA, USA), 25 and the mTOR inhibitor, everolimus (Afinitor;" exact="Novartis" post="International AG, Basel, Switzerland), 26 none of which demonstrated"/>
   <result pre="27 Phase III trials investigating trastuzumab emtansine (Kadcyla TDM-1; Hoffman-La" exact="Roche" post="Ltd) in the GATSBY trial and pertuzumab (Perjeta; Hoffman-La"/>
   <result pre="Roche Ltd) in the GATSBY trial and pertuzumab (Perjeta; Hoffman-La" exact="Roche" post="Ltd) in the JACOB trial are ongoing. 28 Trials"/>
   <result pre="hours, and then q14d) with or without onartuzumab (MetMab; Hoffman-La" exact="Roche" post="Ltd) did not improve PFS. 29 A Phase III"/>
   <result pre="Two studies that examined the role of bevacizumab (Avastin; Hoffman-La" exact="Roche" post="Ltd) directed against the vascular endothelial growth factor (VEGF)"/>
   <result pre="cisplatin chemotherapy with (n=387) or without (n=387) bevacizumab (Avastin; Hoffman-La" exact="Roche" post="Ltd). This study showed a better response rate (46%"/>
   <result pre="clinical trials. Angiogenic receptor tyrosine kinases (sunitinib, sorafenib) Sunitinib (Sutent;" exact="Pfizer" post="Inc., New York, NY, USA) and sorafenib (Nexavar; Bayer"/>
   <result pre="(Sutent; Pfizer Inc., New York, NY, USA) and sorafenib (Nexavar;" exact="Bayer" post="AG, Leverkusen, Germany) are small molecule, multi-targeted, tyrosine kinase"/>
   <result pre="full manuscript is keenly awaited. Anti-VEGFR-2 antibody (ramucirumab) Ramucirumab (Cyramza™;" exact="Eli Lilly and Company," post="India-napolis, IN, USA, IMC-1121B, LY30009806) is a novel, fully"/>
   <result pre="Based on the results of the REGARD study, the US" exact="Food and Drug Administration" post="approved ramucirumab, in April 2014, as monotherapy, in patients"/>
   <result pre="with graphic design. Disclosure MMKC has received travel support from" exact="Merck" post="Sharp and Dohme. KMS was a member of the"/>
   <result pre="received compensation for Advisory Boards conducted by Lilly, Amgen, Hoffman-La" exact="Roche" post="Ltd, and Bayer; research support from Amgen, Hoffman-La Roche"/>
   <result pre="Hoffman-La Roche Ltd, and Bayer; research support from Amgen, Hoffman-La" exact="Roche" post="Ltd, and Bayer; and travel support from Roche and"/>
   <result pre="Amgen, Hoffman-La Roche Ltd, and Bayer; and travel support from" exact="Roche" post="and Bayer. JRZ was also a member of the"/>
   <result pre="15S abstr 4004–256S 62 Ramucirumab in combination with paclitaxel US" exact="Food and Drug Administration;" post="US Department of Health and Human Service Available from:"/>
   <result pre="in combination with paclitaxel US Food and Drug Administration; US" exact="Department of Health" post="and Human Service Available from: http://www.fda.gov/Drugs/InformationOnDrugs/Approved-Drugs/ucm42.htm 1930 Accessed January"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4589954/results/search/funders/results.xml">
   <result pre="953-0118 perez.edith@mayo.edu Baehner Frederick L. RBaehner@genomichealth.com Butler Steven M. smbutler@genomichealth.com" exact="Thompson" post="E. Aubrey thompson.aubrey@mayo.edu Dueck Amylou C. Dueck.Amylou@mayo.edu Jamshidian Farid"/>
   <result pre="are based on the central laboratory tests originally done at" exact="Mayo Clinic" post="after local laboratory testing being positive for HER2. HER2"/>
   <result pre="free of genomic DNA by a β-actin-specific TaqMan® PCR assay." exact="Total" post="purified RNA content was quantified by Ribogreen® (Life Technologies,"/>
   <result pre="and FISH assessments as part of the parent N9831 study." exact="Mayo Clinic" post="IRB was the ethical body that approved our study."/>
   <result pre="are reported. The Onco type DX assay was performed by" exact="Genomic Health," post="while blinded to the N9831 study data, and statistical"/>
   <result pre="and statistical analyses were conducted jointly by the Alliance and" exact="Genomic Health," post="Inc. This study was approved by the North American"/>
   <result pre="clinically eligible, and 1032 formalin FPE tumors were processed by" exact="Genomic Health," post="Inc., of which 901 (87.3 %) had successful Onco"/>
   <result pre="Concordance a Positive concordance and negative concordance Negative Equivocal Positive" exact="Total" post="n (%) n (%) n (%) n (%) Central"/>
   <result pre="(Ref = IHC) 3+ 39 (4.3) 53 (5.9) 664 (73.9) 756 (84.2)" exact="Total" post="130 (14.5) 85 (9.5) 683 (76.1) 898 HER2 status"/>
   <result pre="by RT-PCR 84.4 % Pos. concordance = 83.8 % Negative Equivocal Positive" exact="Total" post="n (%) n (%) n (%) n (%) Neg."/>
   <result pre="(Ref = FISH) ≥2 64 (7.2) 65 (7.4) 667 (75.5) 796 (90.0)" exact="Total" post="126 (14.3) 82 (9.3) 676 (76.5) 884 Central HER2"/>
   <result pre="FISH ratio 85.8 % Pos. concordance = 88.9 % (Ref = FISH) &amp;lt;2 ≥2" exact="Total" post="n (%) n (%) n (%) Central HER2 IHC"/>
   <result pre="(8.6) 99 (11.2) 3+ 37 (4.2) 706 (80.0) 743 (84.2)" exact="Total" post="88 (10.0) 794 (90.0) 882 Positive concordance = (number of results"/>
   <result pre="B. Cherbavaz, Carl Yoshizawa and Steven Shak are employees of" exact="Genomic Health," post="Inc. All other authors declare that they have no"/>
   <result pre="behalf of the North Central Cancer Treatment Group N9831 and" exact="Genomic Health" post="trial teams. Supported by the National Institutes of Health"/>
   <result pre="Group N9831 and Genomic Health trial teams. Supported by the" exact="National Institutes of Health" post="grants number U10-CA180821, U10-CA180882, and U10-CA025224 and RO1-CA129949; the"/>
   <result pre="Health grants number U10-CA180821, U10-CA180882, and U10-CA025224 and RO1-CA129949; the" exact="Breast Cancer Research Foundation;" post="and Genentech (35-03). Presented in part at the 49th"/>
   <result pre="grants number U10-CA180821, U10-CA180882, and U10-CA025224 and RO1-CA129949; the Breast" exact="Cancer Research Foundation;" post="and Genentech (35-03). Presented in part at the 49th"/>
   <result pre="and U10-CA025224 and RO1-CA129949; the Breast Cancer Research Foundation; and" exact="Genentech" post="(35-03). Presented in part at the 49th Annual Meeting"/>
   <result pre="Presented in part at the 49th Annual Meeting of the" exact="American Society of Clinical Oncology," post="June 1–5, 2013, Chicago, IL, USA. References References 1."/>
   <result pre="Oncol. 2011 29 4491 7 10.1200/JCO.2011.36.7045 22042958 31. Perez EA" exact="Roche" post="PC Jenkins RB Reynolds CA Halling KC Ingle JN"/>
   <result pre="Mayo Clin Proc. 2002 77 148 54 10.1016/S0025-6196(11)62329-X 11838648 32." exact="Roche" post="PC Suman VJ Jenkins RB Davidson NE Martino S"/>
   <result pre="ed 1999 London Churchill Livingstone 42. Tavassoli FA Devilee P" exact="World Health Organization" post="Classification of Tumours. Pathology and Genetics of Tumours of"/>
   <result pre="Inst. 2013 105 1782 8 10.1093/jnci/djt321 24262440 51. Perez EA" exact="Thompson" post="EA Ballman KV Anderson SK Asmann YW Kalari KR"/>
   <result pre="analysis on a wide variety of archival fixed tissues 2007" exact="American Association for Cancer Research" post="Los Angeles 54. Vandesompele J, De Preter K, Pattyn"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4590321/results/search/funders/results.xml">
   <result pre="[1], [2], Correspondence: Alvaro Moreno-Aspitia, Department of Hematology and Oncology," exact="Mayo Clinic," post="4500 San Pablo Road, Jacksonville, FL 32224, USA, Tel"/>
   <result pre="prevent dimerization between HER2 and HER3 and is currently US" exact="Food and Drug Administration" post="(FDA) approved as a first-line therapy in combination with"/>
   <result pre="in HER2-positive MBC and in the neoadjuvant setting. Lapatinib (Tykerb;" exact="GlaxoSmithKline" post="plc, London, UK), another approved agent, is an oral"/>
   <result pre="finally at surgery. The initial analysis presented at the 2011" exact="American Society of Clinical Oncology" post="(ASCO) annual meeting included the 49 patients in whom"/>
   <result pre="reported in three patients. No cardiac deaths were reported. The" exact="Mayo Clinic" post="Cancer Research Consortium 0639 (RC0639) trial, a randomized, phase"/>
   <result pre="adaptive novel agents to treat breast cancer Bethesda, MD US" exact="National Institutes of Health" post="2009 Available from: http://www.ClinicalTrials.gov/show/NCT01042379 Accessed May 1, 2015 49"/>
   <result pre="in patients with HER2-positive primary breast cancer Bethesda, MD US" exact="National Institutes of Health" post="2011 Available from: http://www.ClinicalTrials.gov/show/NCT01358877 Accessed May 1, 2015 67"/>
   <result pre="Neoadjuvant breast cancer treatment: Tryphaena trial overview Basel, Switzerland Hoffman-La" exact="Roche" post="Ltd 2015 Available from: http://www.perjeta.com/hcp/neoadjuvant/tryphaena;jsessionid=C9DC7FA332D52237F59F3D2D255C52B2.gxe501b-m2 Accessed May 1, 2015"/>
   <result pre="Lancet 2014 384 9938 164 172 24529560 74 collab: US" exact="Food and Drug Administration" post="[webpage on the Internet] Guidance for Industry: Pathological Complete"/>
   <result pre="Endpoint to Support Accelerated Approval 2014 White Oak, MD US" exact="Food and Drug Administration" post="2014 Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm305501.pdf Accessed May 1, 2015 75"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4591587/results/search/funders/results.xml">
   <result pre="the completeness and accuracy of the data and analyses. While" exact="Genentech" post="is sponsoring the study, the authors have primary responsibility"/>
   <result pre="an employee of Pharmaceutical Product Development, a company contracted by" exact="Genentech" post="as a methodology consultant. Authors’ contributions EK, MSB, and"/>
   <result pre="plc and paid for by Genentech, Inc. References References 1." exact="World Health Organization." post="GLOBOCAN 2012: estimated cancer incidence, mortality, and prevalence worldwide"/>
   <result pre="with advanced human epidermal growth factor receptor 2-positive breast cancer:" exact="American Society of Clinical Oncology" post="clinical practice guideline J Clin Oncol 2014 32 2078"/>
   <result pre="group JAMA 2000 283 2008 12 10.1001/jama.283.15.2008 10789670 23. US" exact="Food and Drug Administration." post="Guidance for industry clinical trial endpoints for the approval"/>
   <result pre="2 2 11 10.1186/2046-4053-2-10 23302739 28. Hayden JA Cote P" exact="Bombardier" post="C Evaluation of the quality of prognosis studies in"/>
   <result pre="risk factors of chronic diseases: pilot study of new checklists." exact="Agency for Healthcare Research and Quality," post="Rockville, MD, 2011. http://www.ncbi.nlm.nih.gov/books/NBK53272/pdf/TOC.pdf. Accessed 25 Mar 2015. 38."/>
   <result pre="Trials 1986 7 177 88 10.1016/0197-2456(86)90046-2 3802833 42. Higgins JP" exact="Thompson" post="SG Deeks JJ Altman DG Measuring inconsistency in meta-analyses"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4593385/results/search/funders/results.xml">
   <result pre="mutation inhibitor, dabrafenib, has been approved by the United States" exact="Food and Drug Administration" post="(FDA) based on its clinical benefits of better PFS"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4600684/results/search/funders/results.xml">
   <result pre="to: Haralabos P. Kalofonos. Division of Oncology, Department of Medicine," exact="University of Patras" post="Medical School, Rion, Patras 26504, Greece. Tel: +30-2610-999-535, Fax:"/>
   <result pre="35]. In add-ition, the American College of Cardiology and the" exact="American Heart Association" post="have reported that breast operations are low-risk and that"/>
   <result pre="clearance of the axilla is usually recommended. However, in an" exact="American College of Surgeons" post="Oncology Group trial (Z0011), patients with positive sentinel lymph"/>
   <result pre="the complications of a delayed surgery [ 8]. In the" exact="European Organisation for Research and Treatment of Cancer" post="(EORTC) AMAROS trial (310 of 1,425 sentinel lymph node-positive"/>
   <result pre="be used after 5 years of tamoxifen [ 104]. The" exact="American Society of Clinical Oncology" post="guidelines also recommend the incorporation of AIs as up-front"/>
   <result pre="RF Caudle AS Bedrosian I et al. Impact of the" exact="American College of Surgeons" post="Oncology Group Z0011 criteria applied to a contemporary patient"/>
   <result pre="Radiat Oncol 2012 22 295 303 22985812 59 Kunkler IH" exact="Williams" post="LW Jack W Canney P Prescott RJ Dixon MJ"/>
   <result pre="M Lyden M Five-year outcome of patients classified using the" exact="American Society for Radiation Oncology" post="consensus statement guidelines for the application of accelerated partial"/>
   <result pre="analysis J Clin Oncol 2008 26 5227 5232 18838712 98" exact="Santen" post="RJ Clinical review: effect of endocrine therapies on bone"/>
   <result pre="12090977 104 Senkus E Kyriakides S Penault-Llorca F Poortmans P" exact="Thompson" post="A Zackrisson S et al. Primary breast cancer: ESMO"/>
   <result pre="Seidenfeld J Anderson H Buchholz TA Davidson NE et al." exact="American Society of Clinical Oncology" post="clinical practice guideline: update on adjuvant endocrine therapy for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4602505/results/search/funders/results.xml">
   <result pre="Sergio Gonzalez [], Correspondence: Vincenzo Arena, Istituto di Anatomia Patologica," exact="Università Cattolica del Sacro Cuore," post="L.go F.Vito, 1 00168 Rome, Italy (e-mail: vincenzo.arena@rm.unicatt.it). collection:"/>
   <result pre="(RCs) of the survey were the Pathology Laboratories of the" exact="National Cancer Institute" post="Regina Elena (MM) and of the Catholic University Sacred"/>
   <result pre="Test kit (Dako), 3 the monoclonal antibody (MAb) 4B5 (Ventana," exact="Roche" post="Diagnostics, Milan, Italy), and 1 used the MAb CB11"/>
   <result pre="Italy) equipped with a software able to capture images (Eureka" exact="Interface" post="System, Menarini, Florence, Italy). HER2 was defined amplified by"/>
   <result pre="Statistical analyses were performed with the SAS software (version 9.2.;" exact="SAS Institute" post="Inc., Cary, NC). RESULTS Table 1 reports the IHC"/>
   <result pre="cocktail assay, ER = estrogen receptor, US FDA = US" exact="Food and Drug Administration," post="G = tumor grading, IHC = immunohistochemistry, k cs"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4609140/results/search/funders/results.xml">
   <result pre="Eli Lilly Japan (Kobe, Japan), five-fluorouracil (5FU) was purchased from" exact="Kyowa Hakko Kirin" post="Co. (Tokyo, Japan), and oxaliplatin (L-OHP) was purchased from"/>
   <result pre="Inc. (Tokyo, Japan), and trastuzumab emtansine (T-DM1) was provided by" exact="Genentech" post="Inc. (South San Francisco, CA, USA). Flow cytometric analysis"/>
   <result pre="&amp;lt;0.05 was considered statistically significant. Statistical analyses were performed using" exact="Microsoft" post="Office Excel 2007 (Microsoft Corporation, Redmond, WA, USA) with"/>
   <result pre="(Tokyo, Japan), and trastuzumab emtansine (T-DM1) was kindly provided by" exact="Genentech" post="Inc. (South San Francisco, CA, USA). This work was"/>
   <result pre="References 1. collab: Center for Cancer Control and Information Services" exact="National Cancer Center," post="Japan. Vital Statistics Japan (Ministry of Health, Labour and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4612451/results/search/funders/results.xml">
   <result pre="5 6 * [1], Department of Biochemistry &amp;amp; Molecular Biology;" exact="Dalhousie University" post="Canada [2], Centre de recherche du Centre hospitalier de"/>
   <result pre="Institut du cancer de Montréal Canada [3], Division de gynéco-oncologie;" exact="Université de Montréal" post="Canada [4], Département de médecine, Université de Montréal Canada"/>
   <result pre="de gynéco-oncologie; Université de Montréal Canada [4], Département de médecine," exact="Université de Montréal" post="Canada [5], Department of Pathology; Dalhousie University Canada [6],"/>
   <result pre="de médecine, Université de Montréal Canada [5], Department of Pathology;" exact="Dalhousie University" post="Canada [6], Beatrice Hunter Cancer Research Institute Canada *Correspondence"/>
   <result pre="Montréal Canada [5], Department of Pathology; Dalhousie University Canada [6]," exact="Beatrice Hunter Cancer Research Institute" post="Canada *Correspondence to: Graham Dellaire; Email: dellaire@dal.ca collection: 2015-4-4"/>
   <result pre="[5], Department of Pathology; Dalhousie University Canada [6], Beatrice Hunter" exact="Cancer Research Institute" post="Canada *Correspondence to: Graham Dellaire; Email: dellaire@dal.ca collection: 2015-4-4"/>
   <result pre="HER2 targeting shRNA lentiviral vector and cultured for 48 h." exact="Total" post="cell lysates were prepared and subjected to Western blot"/>
   <result pre="μM lapatinib (respectively) for 48 h to inhibit HER2 signaling." exact="Total" post="cell lysates were subjected to Western blot analysis for"/>
   <result pre="for tumor procurement. Funding This work was funded by a" exact="Canadian Breast Cancer Foundation" post="(CBCF)-Atlantic operating grant awarded to GD. GD is a"/>
   <result pre="awarded to GD. GD is a Senior Scientist of the" exact="Beatrice Hunter Cancer Research Institute" post="(BHCRI), and DPC was supported by a CIBC Graduate"/>
   <result pre="GD. GD is a Senior Scientist of the Beatrice Hunter" exact="Cancer Research Institute" post="(BHCRI), and DPC was supported by a CIBC Graduate"/>
   <result pre="from the BHCRI with funds provided by CBCF-Atlantic, and The" exact="Canadian Cancer Society," post="Nova Scotia Division as part of The Terry Fox"/>
   <result pre="Canadian Cancer Society, Nova Scotia Division as part of The" exact="Terry Fox Foundation" post="Strategic Health Research Training (STIHR) Program in Cancer Research"/>
   <result pre="Scotia Division as part of The Terry Fox Foundation Strategic" exact="Health Research" post="Training (STIHR) Program in Cancer Research at the Canadian"/>
   <result pre="Health Research Training (STIHR) Program in Cancer Research at the" exact="Canadian Institutes of Health Research" post="(CIHR). DPC also was supported by funds to GD"/>
   <result pre="(STIHR) Program in Cancer Research at the Canadian Institutes of" exact="Health Research" post="(CIHR). DPC also was supported by funds to GD"/>
   <result pre="Pan Y , Wei Y , Cheng X , Zhou" exact="BP" post=", Tan M , Zhou X , Xia W"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4612553/results/search/funders/results.xml">
   <result pre="16 20 1 25 38 4 30 4 5 2" exact="Total" post="number 64 15 3 31 33 22 31 3"/>
   <result pre="0 0 3 0 1 1 12 13 10 5" exact="Total" post="number 64 6 0 4 13 3 2 3"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4619560/results/search/funders/results.xml">
   <result pre="European countries (France, Germany, The Netherlands, Belgium, and Sweden). Results" exact="Total" post="direct costs across the first 3 treatment lines were"/>
   <result pre="cost comparisons, with 2-sided p values. Analyses were performed using" exact="Microsoft" post="Excel. Table 1 Unit cost data by country in"/>
   <result pre="hormone therapy-based therapy options based on hormone therapy sensitivity a" exact="Total" post="Cohort Analysis Subgroup analysis Patient group description All patients"/>
   <result pre="line ( n = 107) HT-eligible c in 2nd line ( n = 248)" exact="Total" post="cost difference (over 3 lines of therapy) d HT"/>
   <result pre="NA NA €325 10.9 % €135 5.8 % (€0) (€0)" exact="Total" post="€231 51.6 % €2424 81.2 % €1894 81.0 %"/>
   <result pre="% €10 0.3 % €15 0.6 % (€0) (€0) (€0)" exact="Total" post="€216.3 48.4 % €561 18.8 % €443 19.0 %"/>
   <result pre="equally to this work. Competing interests Research was funded by" exact="Novartis" post="Pharmaceuticals Corporation. GJ: Consultant and research grant, Novartis Pharmaceuticals"/>
   <result pre="funded by Novartis Pharmaceuticals Corporation. GJ: Consultant and research grant," exact="Novartis" post="Pharmaceuticals Corporation. PN: No conflict of interest. NM: Consultant,"/>
   <result pre="Novartis Pharmaceuticals Corporation. PN: No conflict of interest. NM: Consultant," exact="Novartis" post="Pharmaceuticals Corporation. JZ: Employee, Novartis Pharmaceuticals Corporation. RD: Consultant,"/>
   <result pre="conflict of interest. NM: Consultant, Novartis Pharmaceuticals Corporation. JZ: Employee," exact="Novartis" post="Pharmaceuticals Corporation. RD: Consultant, Novartis Pharmaceuticals Corporation. GB: Employee,"/>
   <result pre="Novartis Pharmaceuticals Corporation. JZ: Employee, Novartis Pharmaceuticals Corporation. RD: Consultant," exact="Novartis" post="Pharmaceuticals Corporation. GB: Employee, Novartis Farma S.p.A. SS: Employee,"/>
   <result pre="Novartis Pharmaceuticals Corporation. RD: Consultant, Novartis Pharmaceuticals Corporation. GB: Employee," exact="Novartis" post="Farma S.p.A. SS: Employee, Novartis Pharmaceuticals Corporation. J-FR: Consultant,"/>
   <result pre="Novartis Pharmaceuticals Corporation. GB: Employee, Novartis Farma S.p.A. SS: Employee," exact="Novartis" post="Pharmaceuticals Corporation. J-FR: Consultant, Novartis Pharmaceuticals Corporation. FA: Advisory"/>
   <result pre="Novartis Farma S.p.A. SS: Employee, Novartis Pharmaceuticals Corporation. J-FR: Consultant," exact="Novartis" post="Pharmaceuticals Corporation. FA: Advisory board, speaker bureau, and research"/>
   <result pre="Corporation. FA: Advisory board, speaker bureau, and research grant from" exact="Novartis" post="Pharmaceuticals Corporation. Authors’ contributions GJ participated in study design,"/>
   <result pre="Acknowledgements Financial support for medical editorial assistance was provided by" exact="Novartis" post="Pharmaceuticals Corporation. We thank Duprane Pedaci Young, PhD, ProEd"/>
   <result pre="European Union 2012 Vienna Presented at: ESMO 2012 Congress 3." exact="European Society for Medical Oncology." post="ESMO 2012 press release: the true costs of cancer"/>
   <result pre="epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer:" exact="American Society of Clinical Oncology" post="Clinical Practice Guideline J Clin Oncol 2014 32 29"/>
   <result pre="York: Milliman, Inc.; 2010. http://us.milliman.com/uploadedFiles/insight/research/health-rr/cancer-patients-receiving-chemotherapy.pdf. Accessed 4 Aug 2015. 17." exact="European Central Bank." post="Statistical Data Warehouse. http://sdw.ecb.europa.eu/quickview.do?SERIES_KEY=ICP.M.U2.N.000000.4.ANR&amp;amp;start=01-01-2008&amp;amp;end=31-12-2012&amp;amp;submitOptions.x=0&amp;amp;submitOptions.y=0&amp;amp;trans=N. (2015). Accessed 4 Aug 2015."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4621756/results/search/funders/results.xml">
   <result pre="[1], [2], *Corresponding author: Leslie C Timpe, Department of Mathematics," exact="San Francisco State University," post="San Francisco, California 94132, USA, Tel: 415 3386078; lct@sfsu.edu"/>
   <result pre="spectrometry Statistical modeling Lasso regression Elastic net regression Introduction The" exact="U.S. Food and Drug Administration" post="has approved roughly two dozen drugs for breast cancer"/>
   <result pre="Statistical modeling Lasso regression Elastic net regression Introduction The U.S." exact="Food and Drug Administration" post="has approved roughly two dozen drugs for breast cancer"/>
   <result pre="Support for this work was provided by grants from the" exact="National Institutes of Health," post="R15CA164929 and P20 MD000544, and the National Science Foundation,"/>
   <result pre="National Institutes of Health, R15CA164929 and P20 MD000544, and the" exact="National Science Foundation," post="grant nos. CHEM-0619163 and CHE-1228656. References 1 Gonzalez de"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4624825/results/search/funders/results.xml">
   <result pre="to less than 50 %. According to recommendations by the" exact="American Society of Echocardiography" post="(ASE) and the European Association of CV Imaging (EACVI)"/>
   <result pre="after the baseline study showing a decrease in LVEF bThe" exact="American Society of Echocardiography" post="and the European Association of Cardiovascular Imaging recommend cardiology"/>
   <result pre="Screening and Monitoring Surveillance and monitoring consensus statements by the" exact="European Society for Medical Oncology" post="(ESMO) [ 5••] and imaging societies [ 21••, 59••]"/>
   <result pre="disclosures. The contents do not represent the views of the" exact="U.S. Department of Veterans Affairs" post="or the U.S. Government. References References References Papers of"/>
   <result pre="patients during and after cancer therapy: a report from the" exact="American Society of Echocardiography" post="and the European Association of Cardiovascular Imaging Eur Heart"/>
   <result pre="report from the European Association of Cardiovascular Imaging and the" exact="American Society of Echocardiography" post="Eur Heart J Cardiovasc Imaging 2013 14 721 40"/>
   <result pre="Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the" exact="American Association for Thoracic Surgery" post="and Society of Thoracic Surgeons Circulation 2008 2008 117"/>
   <result pre="in collaboration with the American Association for Thoracic Surgery and" exact="Society of Thoracic Surgeons" post="Circulation 2008 2008 117 61. McAnulty J Halperin B"/>
   <result pre="chronic conditions: a stepwise approach from the American Geriatrics Society:" exact="American Geriatrics Society" post="Expert Panel on the Care of Older Adults with"/>
   <result pre="2012;60:1957–68. Recommendations on approach to caring for older adults. 85." exact="Williams" post="SL Haskard KB DiMatteo MR The therapeutic effects of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4627342/results/search/funders/results.xml">
   <result pre="adverse effect hindering the clinical application of many drugs. The" exact="U.S. Food and Drug Administration" post="(FDA) had delayed many drugs approval and withdrawn approved"/>
   <result pre="effect hindering the clinical application of many drugs. The U.S." exact="Food and Drug Administration" post="(FDA) had delayed many drugs approval and withdrawn approved"/>
   <result pre="Most events were grade 1 or 2 according to the" exact="National Cancer Institute" post="Common Terminology Criteria for Adverse Events (CTCAE) version 3.0."/>
   <result pre="cohort of 39 patients Group ALT increased AST increased Hyperbilirubinaemia" exact="Total" post="Paclitaxel alone 1/21 (4.76%) 1/21 (4.76%) 0/21 (0.00%) 2/21"/>
   <result pre="October 2008) were retrieved from the database archive of the" exact="Sun Yat-sen University" post="(Guangzhou, China) for analysis. All patients were diagnosed with"/>
   <result pre="X-ray processor (Carestream Health, USA). Protein expression was quantified by" exact="Scion" post="Image software (Scion Co, USA). Cytotoxicity We collected the"/>
   <result pre="The work was approved by the ethics review committee at" exact="Sun Yat-sen University" post="(Guangzhou, China). Liver tissues of 50-100 mg were cut"/>
   <result pre="20 g, were obtained from the Center of Experimental Animals," exact="Sun Yat-sen University" post="(Guangzhou, China) and were randomized into six treatment groups:"/>
   <result pre="and Dr Rongzhen Luo) from the department of pathology of" exact="Sun Yat-sen University" post="Cancer Center. All animal care and experimental procedures were"/>
   <result pre="care and experiments of laboratory animals (Center of Experimental Animals," exact="Sun Yat-sen University," post="China). Pharmacokinetic study in NIH mice Male and female"/>
   <result pre="20-23 g were obtained from the Center of Experimental Animals," exact="Sun Yat-sen University" post="(Guangzhou, China) for the pharmacokinetic study. The mice were"/>
   <result pre="and Experiments of Laboratory Animals of Center of Experimental Animals," exact="Sun Yat-sen University." post="Reverse transcription-PCR Total cellular RNA was isolated by Trizol"/>
   <result pre="of Center of Experimental Animals, Sun Yat-sen University. Reverse transcription-PCR" exact="Total" post="cellular RNA was isolated by Trizol Reagent (Gibco BRL,"/>
   <result pre="National Natural Sciences Foundations (No. 81061160507 and 81072669) and Chinese" exact="Ministry of Education" post="Post doctor Foundation (No. 20100470959) and Excellent Dissertation Foundation"/>
   <result pre="gene product P-glycoprotein in normal human tissues Proceedings of the" exact="National Academy of Sciences" post="of the United States of America 1987 84 7735"/>
   <result pre="Hepatotoxicity Clinical cancer research : an official journal of the" exact="American Association for Cancer Research" post="2009 15 7616 7623 19996204 11 Wysowski DK Swartz"/>
   <result pre="15983284 12 Park BK Kitteringham NR Maggs JL Pirmohamed M" exact="Williams" post="DP The role of metabolic activation in drug-induced hepatotoxicity"/>
   <result pre="cancer Journal of clinical oncology : official journal of the" exact="American Society of Clinical Oncology" post="2009 27 5538 5546 19786658 16 Wang H Lapatinib"/>
   <result pre="therapy 2014 7 1367 1373 25114575 17 Moy ER B" exact="Williams" post="L Kelly T Nicolodi L Maltzman J. D. Goss"/>
   <result pre="lapatinib Journal of clinical oncology : official journal of the" exact="American Society of Clinical Oncology" post="2009 27 15s 1043 18 Loriot Y Perlemuter G"/>
   <result pre="Arbushites MC Guerrera SF Koehler M Oliva C Stein SH" exact="Williams" post="LS Dering J Finn RS Press MF Phase III,"/>
   <result pre="cancer Journal of clinical oncology : official journal of the" exact="American Society of Clinical Oncology" post="2008 26 5544 5552 18955454 23 Xu BH Jiang"/>
   <result pre="and irinotecan Annals of oncology : official journal of the" exact="European Society for Medical Oncology" post="/ ESMO 2007 18 2025 2029 17846021 29 Geyer"/>
   <result pre="during pregnancy Annals of oncology : official journal of the" exact="European Society for Medical Oncology" post="/ ESMO 2008 19 607 620 17921242 33 Borowski"/>
   <result pre="carcinomas Journal of clinical oncology : official journal of the" exact="American Society of Clinical Oncology" post="2005 23 5305 5313 15955900 37 Patel N Joseph"/>
   <result pre="gene expression data using real-time quantitative PCR and the 2(−Delta" exact="Delta" post="C(T)) Method Methods (San Diego, Calif) 2001 25 402"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4627999/results/search/funders/results.xml">
   <result pre="in accordance with the latest Ethical Guidelines for Medical and" exact="Health Research" post="Involving Human Subjects and the local regulations in Japan."/>
   <result pre="eribulin. Adverse events were recorded and graded according to the" exact="National Cancer Institute" post="Common Terminology Criteria for Adverse Events (version 3.0, Japanese"/>
   <result pre="contribution. Medical writing service was provided by Koki Yamashita, PhD." exact="Eisai" post="Co., Ltd. (Tokyo, Japan) provided financial support to CACTUS"/>
   <result pre="was conducted. Competing interests The author has received honoraria from" exact="Eisai" post="Co., ltd. References References Aogi K Iwata H Masuda"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4631578/results/search/funders/results.xml">
   <result pre="cancer progress to metastases of the central nervous system (CNS)." exact="Total" post="cerebral radiotherapy is considered as standard treatment for these"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4632920/results/search/funders/results.xml">
   <result pre="Thyroid and Breast Surgery, The Tenth People’s Hospital of Shanghai," exact="Tongji University" post="Shanghai, China [2], Department of Biochemistry and Molecular Biology,"/>
   <result pre="of Biochemistry and Molecular Biology, College of Basic Medical Sciences," exact="Second Military Medical University" post="Shanghai, China [3], Department of General Surgery, Shanghai Putuo"/>
   <result pre="Medicine Shanghai, China [4], Department of General Surgery, Changhai Hospital," exact="Second Military Medical University" post="Shanghai, China Correspondence, Zhe Li, Department of Thyroid and"/>
   <result pre="Thyroid and Breast Surgery, The Tenth People’s Hospital of Shanghai," exact="Tongji University," post="Shanghai 200072, China., Tel: +86 21 66301024, Fax: +86"/>
   <result pre="of Biochemistry and Molecular Biology, College of Basic Medical Sciences," exact="Second Military Medical University," post="Shanghai 200433, China., Tel: +86 21 81870970, Fax: +86"/>
   <result pre="second HER2 inhibitor to be approved by the United States" exact="Food and Drug Administration" post="after trastuzumab (Herceptin, Roche, San Francisco, CA, USA). Lapatinib"/>
   <result pre="results were repeated for three times. Studies with xenografts The" exact="Tongji University" post="Institutional Animal Care and Use Committee approved our animal"/>
   <result pre="clinical studies are warranted. This project was supported by the" exact="National Natural Science Foundation of China" post="(No.51003078), Shanghai Municipal Health Bureau research projects (No.2008133), and"/>
   <result pre="supported by the National Natural Science Foundation of China (No.51003078)," exact="Shanghai Municipal Health Bureau" post="research projects (No.2008133), and the Shanghai Municipal Science and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4637019/results/search/funders/results.xml">
   <result pre="past few years (2001 Heart and stroke statistical update. Dallas:" exact="American Heart Association," post="2000). Here we first give an updated overview of"/>
   <result pre="pazopanib and vandetanib have also been approved by the US" exact="Food and Drug Administration" post="[ 1, 66, 67]. All these drugs interfere with"/>
   <result pre="in preventing HF ( Table 1) [ 67]. The US" exact="National Cancer Institute" post="has recently published recommendations to maintain patients' blood pressure"/>
   <result pre="cardiotoxicity: basic mechanisms and potential cardioprotective therapies Journal of the" exact="American Heart Association" post="2014 3 2 10.1161/JAHA.113.000665 31 Salvatorelli E. Menna P."/>
   <result pre="provides insights into genomic programs of hibernation Proceedings of the" exact="National Academy of Sciences" post="of the United States of America 2008 105 1"/>
   <result pre="required for normal cardiac contraction and relaxation Proceedings of the" exact="National Academy of Sciences" post="2015 112 6 1880 1885 10.1073/pnas.1417949112 96 Force T."/>
   <result pre="vascular endothelial growth factor signaling pathway inhibitors Journal of the" exact="National Cancer Institute" post="2010 102 596 604 20351338 104 Carver J. R."/>
   <result pre="detection of trastuzumab and anthracycline mediated cardiomyopathy Journal of the" exact="American Society of Echocardiography" post="2009 22 4 418 424 10.1016/j.echo.2009.01.016 19269133 114 Hare"/>
   <result pre="the need for cardio-oncology and cardio-oncological prevention Journal of the" exact="National Cancer Institute" post="2010 102 1 14 25 10.1093/jnci/djp440 20007921 135 Oeffinger"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4648606/results/search/funders/results.xml">
   <result pre="Li; Janice Lu, Department of Breast Cancer, Beijing Shijitan Hospital," exact="Capital Medical University," post="10 Tieyi Road, Haidian District, Beijing 100038, People’s Republic"/>
   <result pre="Friendship Hospital, Shandong Cancer Hospital, the First Affiliated Hospital of" exact="Nanjing Medical University," post="and Jiangsu Cancer Hospital. Patients who met all the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4648969/results/search/funders/results.xml">
   <result pre="were recorded at every visit and graded according to the" exact="National Cancer Institute" post="Common Terminology Criteria of Adverse Events (NCI-CTCAE) version 3.0"/>
   <result pre="Table 3. Table 3 Treatment-related adverse events Adverse event Dose-level" exact="Total" post="1 2 3 7 5 No. of patients 3"/>
   <result pre="(1–49) 0 2 (25) 2 (25) 1 (12) 1 (12)" exact="Total" post="33 8 (0–49) 1 (3) 6 (18) 12 (36)"/>
   <result pre="trial J Clin Oncol 1997 15 2403 2413 9196156 19." exact="Food and Drug Administration." post="Gemzar (2006) http://www.cancer.gov/aboutcancer/treatment/drugs/fda-gemcitabine-hydrochloride. Accessed 1 April 2014 20. European"/>
   <result pre="solid tumors. European Organization for Research and Treatment of Cancer," exact="National Cancer Institute" post="of the United States, National Cancer Institute of Canada"/>
   <result pre="Treatment of Cancer, National Cancer Institute of the United States," exact="National Cancer Institute" post="of Canada J Natl Cancer Inst 2000 92 205"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4650737/results/search/funders/results.xml">
   <result pre="number of patients eventually relapses (SEER Cancer Statistics Review, 1975–2007," exact="National Cancer Institute." post="Bethesda, MD, http://seer.cancer.gov/csr/1975_2007/, based on November 2009 SEER data"/>
   <result pre="calculated according to the comparative method of 2- ΔΔCT. Microarray" exact="Total" post="RNA was extracted from BCSC #1 BCSCs and from"/>
   <result pre="7 days, according to Trizol protocol (Ambion by Life Technologies)." exact="Total" post="RNA was used for miRNA microarray analysis (G4470B, Agilent"/>
   <result pre="work was supported by grants from AIRC (2011-IG11450) and Italian" exact="Ministry of Health" post="(Ricerca Finalizzata 2009, RF-2009-1491608) to VDL and by Italian"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4650834/results/search/funders/results.xml">
   <result pre="were analyzed using descriptive statistics. Data analysis was performed using" exact="Microsoft" post="Excel 2010 (Microsoft Corporation, Redmond, WA, USA). Results Figure"/>
   <result pre="the final manuscript. Funding This work was financially supported by" exact="Roche" post="Farmacêutica Química, Lda (Portugal). References References 1. Slamon DJ"/>
   <result pre="HER-2/neu oncogene Science 1987 235 177 82 10.1126/science.3798106 3798106 11." exact="Food and Drug Administration." post="U.S. Department of Health and Human Services. Center for"/>
   <result pre="235 177 82 10.1126/science.3798106 3798106 11. Food and Drug Administration." exact="U.S. Department of Health and Human Services." post="Center for Drug Evaluation and Research and Center for"/>
   <result pre="177 82 10.1126/science.3798106 3798106 11. Food and Drug Administration. U.S." exact="Department of Health" post="and Human Services. Center for Drug Evaluation and Research"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4650980/results/search/funders/results.xml">
   <result pre="group of patients. Funding Jonathan Ezra Grim was supported by" exact="American Cancer Society" post="RSG-13-183-01. Janghee Woo was supported by 5T32CA009515-30 National Cancer"/>
   <result pre="American Cancer Society RSG-13-183-01. Janghee Woo was supported by 5T32CA009515-30" exact="National Cancer Institute," post="US NIH. Stacey A. Cohen was supported by Young"/>
   <result pre="A. Cohen was supported by Young Investigator Award from the" exact="Conquer Cancer Foundation" post="of the American Society for Clinical Oncology. Conflict of"/>
   <result pre=": 168 – 76. 24557418 98 Okines AF Langley RE" exact="Thompson" post="LC et al. Bevacizumab with peri-operative epirubicin, cisplatin and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4656949/results/search/funders/results.xml">
   <result pre="the Sectoral Operational Programme Human Resources Development financed from the" exact="European Social Fund" post="under the contract number POSDRU/159/1.5/S/137390. References 1 Beebe DC"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4657380/results/search/funders/results.xml">
   <result pre="brain metastases cause in patients with HER2-positive breast cancer, the" exact="American Society of Clinical Oncology" post="(ASCO) published in 2014 its first clinical practice guideline"/>
   <result pre="bevacizumab in metastatic breast cancer, which resulted in the US" exact="Food and Drug Administration" post="(FDA) withdrawal of the conditional approval of the drug."/>
   <result pre="approved the final manuscript. Acknowledgements We want to thank the" exact="University of Iowa" post="Libraries for the support for this publication. Competing interests"/>
   <result pre="82 5 2111 2117 10.1016/j.ijrobp.2011.02.027 21497451 15. Klos KJ O’Neill" exact="BP" post="Brain metastases Neurol 2004 10 1 31 46 10.1097/01.nrl.0000106922.83090.71"/>
   <result pre="with advanced human epidermal growth factor receptor 2-positive breast cancer:" exact="American Society of Clinical Oncology" post="clinical practice guideline J Clin Oncol Off J Am"/>
   <result pre="metastatic breast cancer (MBC): a phase II trial of the" exact="National Cancer Institute" post="of Canada—Clinical Trials Group (NCIC-CTG) Ann Oncol Off J"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4657385/results/search/funders/results.xml">
   <result pre="[], 4 UMR CNRS 7360, Laboratoire Interdisciplinaire des Environnements Continentaux," exact="Université de Lorraine" post="Metz, France Edited by: Julie Gavard, University of Nantes,"/>
   <result pre="activation. ErbB receptors cancer epithelial-mesenchymal transition migration cell signaling Funding" exact="Centre National de la Recherche Scientifique" post="10.13039/501100004794 Institut national de la santé et de la"/>
   <result pre="cell signaling Funding Centre National de la Recherche Scientifique 10.13039/501100004794" exact="Institut national de la santé et de la recherche médicale" post="10.13039/501100001677 Université de Lorraine 10.13039/100008990 fig-count: table-count: equation-count: ref-count:"/>
   <result pre="national de la santé et de la recherche médicale 10.13039/501100001677" exact="Université de Lorraine" post="10.13039/100008990 fig-count: table-count: equation-count: ref-count: page-count: word-count: Structure of"/>
   <result pre="in 2004 Colorectal, head, neck and pancreas cancers Panitumumab (Vectibix)" exact="Amgen" post="EGFR mAb directed against EGFR First approval by FDA"/>
   <result pre="in 2004 Non-small cell lung cancer, pancreatic cancer Gefitinib (Iressa)" exact="AstraZeneca" post="EGFR Inhibitor of EGFR signaling First approval by FDA"/>
   <result pre="in 2003 Non-small cell lung cancer, esophageal cancer Lapatinib (Tykerb/Tyverb)" exact="GlaxoSmithKline" post="EGFR/HER2 Inhibitor of EGFR/HER2 signaling First approval by FDA"/>
   <result pre="First approval by FDA in 2007 Metastatic breast cancer Dacomitinib" exact="Pfizer" post="EGFR/HER2/HER4 Pan-inhibitor of ErbB receptors signaling Phase III Non-small"/>
   <result pre="receptors signaling Phase III Non-small cell lung cancer Trastuzumab (Herceptin)" exact="Genentech" post="HER2 mAb directed against HER2 First approval by FDA"/>
   <result pre="cancer HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma Pertuzumab (Perjeta)" exact="Genentech" post="HER2 mAb directed against HER2 First approval by FDA"/>
   <result pre="other HER2-positive tumors Patritumab (U3-1287) Daiichi Sankyo Pharmaceutical Development and" exact="Amgen" post="HER3 mAb directed against HER3 Phase I–II Non-small cell"/>
   <result pre="molecule inhibitors under clinical trials or approved by the US" exact="Food and Drug Administration" post="(FDA) are reversible or irreversible inhibitors. They bind to"/>
   <result pre="fundings from the Université de Reims Champagne-Ardenne (URCA) and the" exact="Centre National de la Recherche Scientifique" post="(CNRS). References References Alaoui-Jamali M. A. Morand G. B."/>
   <result pre="2530 10.1038/srep02530 Bonnomet A. Syne L. Brysse A. Feyereisen E." exact="Thompson" post="E. W. Noel A. et al. ( 2012). A"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4659935/results/search/funders/results.xml">
   <result pre="2 † Caldas Carlos b 1 2 5 † [1]," exact="Cancer Research UK" post="Cambridge Institute, University of Cambridge UK [2], Department of"/>
   <result pre="1 2 5 † [1], Cancer Research UK Cambridge Institute," exact="University of Cambridge" post="UK [2], Department of Oncology, University of Cambridge UK"/>
   <result pre="Cambridge Institute, University of Cambridge UK [2], Department of Oncology," exact="University of Cambridge" post="UK [3], Center for Noninvasive Diagnostics, Translational Genomics Research"/>
   <result pre="Center for Noninvasive Diagnostics, Translational Genomics Research Institute USA [4]," exact="Mayo Clinic" post="Center for Individualized Medicine USA [5], Cambridge Breast Unit,"/>
   <result pre="Hospital, Cambridge University Hospital National Health Service Foundation Trust and" exact="National Institute for Health Research" post="Cambridge Biomedical Research Centre, and the Cambridge Experimental Cancer"/>
   <result pre="Hospital National Health Service Foundation Trust and National Institute for" exact="Health Research" post="Cambridge Biomedical Research Centre, and the Cambridge Experimental Cancer"/>
   <result pre="Centre, and the Cambridge Experimental Cancer Medicine Centre UK [6]," exact="Peter MacCallum Cancer Centre" post="Australia [7], Department of Histopathology, Addenbrooke's Hospital, Cambridge University"/>
   <result pre="lower back pain, loss of height, marked kyphosis and hepatomegaly." exact="Core" post="biopsies from the breast lump showed ductal carcinoma in"/>
   <result pre="reported as enriched in ctDNA previously LINK Supplementary Data 4" exact="Total" post="copy number at mutant loci inferred from whole exome"/>
   <result pre="NIHR Cambridge Biomedical Research Centre. We acknowledge the support of" exact="Cancer Research UK," post="the University of Cambridge, National Institute for Health Research"/>
   <result pre="Centre. We acknowledge the support of Cancer Research UK, the" exact="University of Cambridge," post="National Institute for Health Research Cambridge Biomedical Research Centre"/>
   <result pre="the support of Cancer Research UK, the University of Cambridge," exact="National Institute for Health Research" post="Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine"/>
   <result pre="Cancer Research UK, the University of Cambridge, National Institute for" exact="Health Research" post="Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine"/>
   <result pre="research leading to these results has received funding from the" exact="European Research Council" post="under the European Union's Seventh Framework Programme (FP/2007-2013)/ERC Grant"/>
   <result pre="funding from the European Research Council under the European Union's" exact="Seventh Framework Programme" post="(FP/2007-2013)/ERC Grant Agreement no 337905. Dr Dawson was supported"/>
   <result pre="Agreement no 337905. Dr Dawson was supported by an Australian" exact="National Breast Cancer Foundation" post="and Victorian Cancer Agency Early Career Fellowship. Dr Murtaza"/>
   <result pre="was supported by an Australian National Breast Cancer Foundation and" exact="Victorian Cancer Agency" post="Early Career Fellowship. Dr Murtaza was supported by Science"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4664841/results/search/funders/results.xml">
   <result pre="E. 4 Jeyapalan S. 5 * [1], Department of Neurology" exact="Harvard Medical School," post="Beth Israel Deaconess Medical Center Boston, MA USA [2],"/>
   <result pre="S. 5 * [1], Department of Neurology Harvard Medical School," exact="Beth Israel Deaconess Medical Center" post="Boston, MA USA [2], Department of Neuroradiology Harvard Medical"/>
   <result pre="Deaconess Medical Center Boston, MA USA [2], Department of Neuroradiology" exact="Harvard Medical School," post="Beth Israel Deaconess Medical Center Boston, MA USA [3],"/>
   <result pre="Boston, MA USA [2], Department of Neuroradiology Harvard Medical School," exact="Beth Israel Deaconess Medical Center" post="Boston, MA USA [3], Department of Radiation Oncology Harvard"/>
   <result pre="Medical Center Boston, MA USA [3], Department of Radiation Oncology" exact="Harvard Medical School," post="Beth Israel Deaconess Medical Center Boston, MA USA [4],"/>
   <result pre="MA USA [3], Department of Radiation Oncology Harvard Medical School," exact="Beth Israel Deaconess Medical Center" post="Boston, MA USA [4], Department of Neurosurgery Harvard Medical"/>
   <result pre="Deaconess Medical Center Boston, MA USA [4], Department of Neurosurgery" exact="Harvard Medical School," post="Beth Israel Deaconess Medical Center Boston, MA USA [5],"/>
   <result pre="Boston, MA USA [4], Department of Neurosurgery Harvard Medical School," exact="Beth Israel Deaconess Medical Center" post="Boston, MA USA [5], Department of Neurology, Tuft Medical"/>
   <result pre="Boston, MA USA [5], Department of Neurology, Tuft Medical School," exact="Tufts Medical Center," post="Boston, MA *Correspondence address. E-mail: sjeyapalan@tuftsmedicalcenter.org collection: 2015-4 epub:"/>
   <result pre="the main causes of death in women. According to the" exact="American Cancer Society," post="∼1.3 million women are diagnosed with breast cancer per"/>
   <result pre="gene suppression [ 6]. On 22 February 2008, the US" exact="Food and Drug Administration" post="approved bevacizumab (Avastin; Genentech) plus paclitaxel as first-line therapy"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4665969/results/search/funders/results.xml">
   <result pre="without increased cardiac toxicity. Therefore, in June, 2012, the US" exact="Food and Drug Administration" post="approved the use of pertuzumab in combination with trastuzumab"/>
   <result pre="events. Japanese patients were enrolled in this study. F. Hoffmann-La" exact="Roche" post="Ltd. (Basel, Switzerland) announced the first results of the"/>
   <result pre="cancer (MARIANNE) https://clinicaltrials.gov/ct2/show/NCT01120184 Accessed 4 2 2015 28 F. Hoffmann-La," exact="Roche" post="Ltd. Update on phase III MARIANNE study in people"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4666271/results/search/funders/results.xml">
   <result pre="anticancer treatment; uncontrolled infection; ≥Grade 2 peripheral neuropathy according to" exact="National Cancer Institute" post="Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0;"/>
   <result pre="9.1.3 Unix SAS ® system (a registered trademark of the" exact="SAS Institute," post="Inc., Cary, NC, USA) was used for analysis. Results"/>
   <result pre="n (%) Grade 1 Grade 2 Grade 3 Grade 4" exact="Total" post="Alopecia 6 (50) 6 (50) 0 0 12 (100)"/>
   <result pre="This study was fully funded and lapatinib was supplied by" exact="GlaxoSmithKline" post="K.K. Conflict of interest Kenichi Inoue, Katsumasa Kuroi, Satoru"/>
   <result pre="with advanced human epidermal growth factor receptor 2–positive breast cancer:" exact="American Society of Clinical Oncology" post="clinical practice guideline J Clin Oncol 2014 32 2078"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4669075/results/search/funders/results.xml">
   <result pre="mammary tumors in transgenic mice: implications for human breast cancer" exact="EMBO" post="J 1999 18 2149 2164 10205169 124 Castiglioni F"/>
   <result pre="Mol Cell 2003 11 495 505 12620236 129 Dey N" exact="Williams" post="C Leyland-Jones B De P A critical role for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4678619/results/search/funders/results.xml">
   <result pre="the Institutional Review Board and the Ethics Committee of the" exact="Osaka University" post="Hospital (approval #10302, approved on March 11, 2011). Competing"/>
   <result pre="23426424 34. Moxley KM Benbrook DM Queimado L Zuna RE" exact="Thompson" post="D McCumber M et al. The role of single"/>
   <result pre="83 1021 1032 10.1016/j.bcp.2011.12.016 22209898 38. Mirandola L Yu Y" exact="Cannon" post="MJ Jenkins MR Rahman RL Nguyen DD et al."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4679405/results/search/funders/results.xml">
   <result pre="M. 7 Diéras V. 8 [1], Department of Medical Oncology" exact="Dana-Farber Cancer Institute" post="Boston [2], Department of Medicine Duke University Medical Center"/>
   <result pre="Medical Oncology Dana-Farber Cancer Institute Boston [2], Department of Medicine" exact="Duke University" post="Medical Center Durham [3], Product Development, Oncology Genentech, Inc."/>
   <result pre="Correspondence to: Dr Ian E. Krop, Department of Medical Oncology," exact="Dana-Farber Cancer Institute," post="Harvard University School of Medicine, Breast Oncology Center, 450"/>
   <result pre="Ian E. Krop, Department of Medical Oncology, Dana-Farber Cancer Institute," exact="Harvard University" post="School of Medicine, Breast Oncology Center, 450 Brookline Avenue,"/>
   <result pre="Krop, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard University" exact="School of Medicine," post="Breast Oncology Center, 450 Brookline Avenue, Boston, MA 02215,"/>
   <result pre="work was supported by Genentech, Inc., a member of the" exact="Roche" post="Group. The protocol was designed in collaboration with the"/>
   <result pre="She has also served as a consultant (&amp;lt;$10 000) for" exact="GlaxoSmithKline" post="and Novartis. KB has served as a consultant for"/>
   <result pre="served as a consultant for F. Hoffmann-La Roche/Genentech, Inc., and" exact="GlaxoSmithKline" post="and has received grant support from GlaxoSmithKline. DM has"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4682234/results/search/funders/results.xml">
   <result pre="of Asian descent between May 2007 and March 2011 from" exact="Gunma University" post="Hospital. All patients had been identified as uterine corpus"/>
   <result pre="[ 33]. The histological grade classification was according to the" exact="World Health Organization" post="classification and FIGO [ 34]. This study was approved"/>
   <result pre="This study was approved by the Institutional Review Board of" exact="Gunma University" post="(Permit Number: 12–49) and conducted according to the ethical"/>
   <result pre="Number: 12–49) and conducted according to the ethical guidelines of" exact="Gunma University." post="Tissue specimens were handled according to the local ethics"/>
   <result pre="cancer cell lines and primary resected endometrioid adenocarcinoma tissue samples." exact="Total" post="cellular and tissue RNA were extracted using Isogen (WAKO,"/>
   <result pre="Use of the Laboratory Animals and were approved by the" exact="Gunma University" post="Animal Care and Use Committee (Permit Number: 13–042). Female"/>
   <result pre="adenocarcinoma, were obtained from patients who had undergone surgery at" exact="Gunma University" post="Hospital (Table 1). In our institution, 20.9 % of"/>
   <result pre="excellent technical assistance and the Departments of Diagnostic Pathology in" exact="Gunma University" post="Graduate School of Medicine for the in vivo technical"/>
   <result pre="and the Departments of Diagnostic Pathology in Gunma University Graduate" exact="School of Medicine" post="for the in vivo technical support. References References 1."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4687700/results/search/funders/results.xml">
   <result pre="University Nanjing China [2], Department of Medical Oncology Jinling Hospital" exact="School of Medicine" post="Southern Medical University Guangzhou China * Correspondence to: Prof."/>
   <result pre="breast cancer HER‐2 HER‐2 mutation variants cancer risk resistance Funding" exact="National Natural Science Foundation of China" post="81272252 81470357 Funding Foundation for Clinical Medicine Science and"/>
   <result pre="article. Acknowledgments This research was supported by grants from the" exact="National Natural Science Foundation of China" post="(no. 81272252 and 81470357), a Foundation for Clinical Medicine"/>
   <result pre="Med. 2006; 84: 671– 81. 16607561 18 Bekaii‐Saab T ," exact="Williams" post="N , Plass C , et al A novel"/>
   <result pre="all ErbB receptors, is a mediator of lateral signaling ." exact="EMBO" post="J. 1997; 16: 1647– 55. 9130710 85 Alimandi M"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4687715/results/search/funders/results.xml">
   <result pre="protein, where k is the first-order rate constant [ 26]." exact="Total" post="GSH level in supernatants were determined according to the"/>
   <result pre="remains for the future. References References 1 Donato R ," exact="Cannon" post="BR , Sorci G , Riuzzi F , Hsu"/>
   <result pre="CIRCIMAGING.112.973321 [pii] doi: 10.1161/CIRCIMAGING.112.973321 . 22744937 36 Wright NT ," exact="Cannon" post="BR , Zimmer DB , Weber DJ . S100A1:"/>
   <result pre="10.1161/CIRCIMAGING.112.973321 . 22744937 36 Wright NT , Cannon BR ," exact="Zimmer" post="DB , Weber DJ . S100A1: Structure, Function, and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4689767/results/search/funders/results.xml">
   <result pre="a biopsy to be taken of suspicious lesions [I, A]." exact="Core" post="biopsy: essential for diagnosis and to obtain prognostic information."/>
   <result pre="axillary dissection in patients with sentinel lymph node metastases: the" exact="American College of Surgeons" post="Oncology Group Z0011 randomized trial Ann Surg 2010 252"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4689775/results/search/funders/results.xml">
   <result pre="decisions on systemic therapy for women with metastatic breast cancer:" exact="American Society of Clinical Oncology" post="Clinical Practice Guideline. J Clin Oncol. 2015;JCO.2015.61.1459. 11. Clinical"/>
   <result pre="and colorectal cancer. Adopted on 17 May 1996 by the" exact="American Society of Clinical Oncology." post="J Clin Oncol. 1996;14(10):2843–77. 12. Eisenhauer EA, Therasse P,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4694793/results/search/funders/results.xml">
   <result pre="268 273 22184384 12 Cunningham D Allum WH Stenning SP" exact="Thompson" post="JN Van de Velde CJ Nicolson M Scarffe JH"/>
   <result pre="Norman AR collab: Upper Gastrointestinal Clinical Studies Group of the" exact="National Cancer Research Institute" post="of the United K Capecitabine and oxaliplatin for advanced"/>
   <result pre="AR collab: Upper Gastrointestinal Clinical Studies Group of the National" exact="Cancer Research Institute" post="of the United K Capecitabine and oxaliplatin for advanced"/>
   <result pre="Correa P Human Gastric Carcinogenesis: A Multistep and Multifactorial Process—First" exact="American Cancer Society" post="Award Lecture on Cancer Epidemiology and Prevention Cancer Res"/>
   <result pre="2014 110 5 1163 1168 24473399 91 collab: ClinicalTrials.gov, U.S" exact="National Institutes of Health" post="Available from: https://clinicaltrials.gov. Accessed December 2014 92 Satoh T"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4694855/results/search/funders/results.xml">
   <result pre="[ 7– 10] and no drugs are approved by the" exact="Food and Drug Administration" post="(FDA) specifically for salivary gland tumors. Importantly, several possible"/>
   <result pre="N-of-One, Inc., Lexington, MA. References REFERENCES 1 Barnes L collab:" exact="World Health Organization" post="and International Agency for Research on Cancer 2005 Pathology"/>
   <result pre="Cancer 2005 Pathology and genetics of head and neck tumours" exact="World Health Organization" post="2 Guzzo M Locati LD Prott FJ Gatta G"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4694868/results/search/funders/results.xml">
   <result pre="of six patient cohorts tested for patient survival analyses Cohort" exact="Total" post="# patients # of ER+ patients # of ER+"/>
   <result pre="SUPPORT Financial support: This study was partially supported by the" exact="National Institutes of Health" post="(NIH) grant R01 CA44735, National Cancer Institute of the"/>
   <result pre="by the National Institutes of Health (NIH) grant R01 CA44735," exact="National Cancer Institute" post="of the NIH (P30CA33572), and the California Breast Cancer"/>
   <result pre="CA44735, National Cancer Institute of the NIH (P30CA33572), and the" exact="California Breast Cancer Research Program" post="(CBCRP) Dissertation Award 15GB-0027. Research reported in this publication"/>
   <result pre="the Bioinformatics core and Interactive Genomics core supported by the" exact="National Cancer Institute" post="of the NIH under award number P30CA33572. CONFLICTS OF"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4695049/results/search/funders/results.xml">
   <result pre="1 μM Lapatinib (gift from Dr. Anne Hamburger at the" exact="University of Maryland," post="Baltimore). For TAZ siRNA knockdown experiments, TAZ siRNA was"/>
   <result pre="(Cell Signaling, D24E4, #8418), FLAG antibody (Dr. Chen-Yong Lin at" exact="Georgetown University," post="Washington DC), RUNX2 (Cell Signaling, D1L7F, #12556), HER2 (Santa"/>
   <result pre="gift from Dr. Hancai Dan (Department of Pathology) at the" exact="University of Maryland," post="Baltimore. NIH3T3 cells were transfected with NFκB.Luciferase (100 ng)"/>
   <result pre="for her kind gift of lapatinib, Dr. Chen-Yong Lin at" exact="Georgetown University" post="for a gift of anti-FLAG antibody, and Dr. Hancai"/>
   <result pre="State of Maryland, and the Gudelsky Foundation Funds from the" exact="University of Maryland" post="Greenebaum Cancer Center (AP) supported this project. CONFLICTS OF"/>
   <result pre="McDonald L Ferrari N Terry A Bell M Mohammed ZM" exact="Orange" post="C Jenkins A Muller WJ Gusterson BA Neil JC"/>
   <result pre="231 244 22717556 31 Lee JM Dedhar S Kalluri R" exact="Thompson" post="EW The epithelial-mesenchymal transition: new insights in signaling, development,"/>
   <result pre="Sci 2001 114 111 118 11112695 44 Symowicz J Adley" exact="BP" post="Gleason KJ Johnson JJ Ghosh S Fishman DA Hudson"/>
   <result pre="NO Baniwal SK Luo J Coetzee S Khalid O Berman" exact="BP" post="Tripathy D Ellis MJ Frenkel B Opposing effects of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4696215/results/search/funders/results.xml">
   <result pre="of paclitaxel [ 8]. nab-Paclitaxel was approved by the US" exact="Food and Drug Administration" post="in January 2005 for the treatment of breast cancer"/>
   <result pre="n = 211) Third or later line ( n = 281) All ( N = 664)" exact="Total" post="n c n % Total n c n %"/>
   <result pre="( n = 281) All ( N = 664) Total n c n %" exact="Total" post="n c n % Total n c n %"/>
   <result pre="Total n c n % Total n c n %" exact="Total" post="n c n % Total n c n %"/>
   <result pre="Total n c n % Total n c n %" exact="Total" post="n c n % Neutropenia 165 33 20.0 190"/>
   <result pre="initiators by line of therapy and treatment regimen a,b Variable" exact="Total" post="no. OS TNTD Events Median, mo 95 % CI"/>
   <result pre="initiators by line of therapy and treatment schedule a,b Variable" exact="Total" post="No. OS TNTD Events Median, mo 95 % CI"/>
   <result pre="the treatment of breast cancer was revoked by the US" exact="Food and Drug Administration" post="[ 28]. The effect of this was reflected in"/>
   <result pre="analysis tend to bias toward underreporting in comparison with prospective" exact="National Cancer Institute" post="Common Terminology Criteria for Adverse Events documentation. Although claims"/>
   <result pre="authors received editorial support from MediTech Media, Ltd, funded by" exact="Celgene" post="Corporation. The authors are fully responsible for the content"/>
   <result pre="Immunol 2011 156 3 320 4 10.1159/000324454 21720178 5. collab:" exact="Bristol-Myers Squibb" post="Co Taxol® (paclitaxel) [prescribing information] 2011 Princeton, NJ USA:"/>
   <result pre="Squibb Co Taxol® (paclitaxel) [prescribing information] 2011 Princeton, NJ USA:" exact="Bristol-Myers Squibb" post="Co 6. collab: sanofi-aventis US LLC Taxotere® (docetaxel) [prescribing"/>
   <result pre="Clin Pharmacol 2014 54 10 1097 107 10.1002/jcph.304 24719309 9." exact="Celgene" post="Corporation. Abraxane® (paclitaxel protein-bound particles for injectable suspension) [prescribing"/>
   <result pre="(paclitaxel protein-bound particles for injectable suspension) [prescribing information]. Summit, NJ:" exact="Celgene" post="Corporation; 2013. 10. Gradishar WJ Tjulandin S Davidson N"/>
   <result pre="for triple-negative metastatic breast cancer. Chicago, IL: Poster presented at:" exact="American Society of Clinical Oncology" post="Annual Meeting; 2014. [TPS1146]."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4700735/results/search/funders/results.xml">
   <result pre="therapy Gastric cancer Monoclonal antibody Tyrosine kinase inhibitor Funding the" exact="National Natural Science Foundation of China" post="81460377 Yang Zhen the National Science and Technology Major"/>
   <result pre="Drug Innovation and Development&quot; of China 2011ZX09302-007-03 Lu Nonghua the" exact="Natural Science Foundation of Jiangxi Province," post="China 20142BAB215036 20151BAB205041 Yang Zhen the Science and Technology"/>
   <result pre="EGF epidermal growth factor, EGFR epidermal growth factor receptor, FDA" exact="Food and Drug Administration," post="MMP matrix metalloproteinase, VEGF vascular endothelial growth factor, PDGF"/>
   <result pre="number of molecular targeted drugs have been approved by the" exact="Food and Drug Administration" post="(FDA) for clinical use (Fig. 1). A comprehensive understanding"/>
   <result pre="EGFR epidermal growth factor receptor EMA European Medicines Agency FDA" exact="Food and Drug Administration" post="FGFR fibroblast growth factor receptor FISH fluorescence in situ"/>
   <result pre="This work was supported in part by grants from the" exact="National Natural Science Foundation of China" post="(81460377), the Natural Science Foundation of Jiangxi Province, China"/>
   <result pre="from the National Natural Science Foundation of China (81460377), the" exact="Natural Science Foundation of Jiangxi Province," post="China (20142BAB215036 and 20151BAB205041), the Science and Technology Foundation"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4703392/results/search/funders/results.xml">
   <result pre="(Houston, TX), and canertinib (CI-1033, PD-183805) was kindly provided by" exact="Pfizer" post="(Groton, CT), respectively. All kinase blockers were dissolved in"/>
   <result pre="STAT5 inhibitor II (IQDMA) were obtained from Selleckchem and from" exact="Merck" post="(Darmstadt, Germany), respectively. Cell lines The HER2-overexpressing SKBR3 and"/>
   <result pre="Mol Cell Biol. 2001; 2: 127– 137. 11252954 10 Rubin" exact="BP" post=", Duensing A . Mechanisms of resistance to small"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4706127/results/search/funders/results.xml">
   <result pre="Oncology Division and Center for Investigational Therapeutics, Huntsman Cancer Institute," exact="University of Utah" post="School of Medicine, 2000 Circle of Hope, Suite 2100,"/>
   <result pre="Center for Investigational Therapeutics, Huntsman Cancer Institute, University of Utah" exact="School of Medicine," post="2000 Circle of Hope, Suite 2100, Salt Lake City,"/>
   <result pre="panitumumab is fully humanized, premedication is not recommended per US" exact="Food and Drug Administration" post="(FDA) label since infusion reactions rarely occur (1%–5%). 31"/>
   <result pre="wild-type patients in the National Comprehensive Cancer Network (NCCN) and" exact="European Society for Medical Oncology" post="guidelines. This recommendation is based on extrapolating data from"/>
   <result pre="https://www.clinicaltrials.gov/ct2/show/NCT02164916. NLM identifier: NCT02164916 Accessed October 28, 2015 56 collab:" exact="Novartis" post="Pharmaceuticals Study of LGX818 and cetuximab or LGX818, BYL719,"/>
   <result pre="predict response to anti-epidermal growth factor receptor monoclonal antibody therapy:" exact="American Society of Clinical Oncology" post="Provisional Clinical Opinion Update 2015 J Clin Oncol Epub"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4706528/results/search/funders/results.xml">
   <result pre="A randomized, double-blind, placebo-controlled phase II trial of the Sarah" exact="Cannon" post="Research Institute (SCRI). J Clin Oncol 2012;30:abstr 1018. 51"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4706584/results/search/funders/results.xml">
   <result pre="dose HER2 NONMEM Population pharmacokinetics modeling Trastuzumab Funding F. Hoffmann-La" exact="Roche" post="Ltd Genentech, Inc. Introduction Trastuzumab is a humanized immunoglobulin"/>
   <result pre="data included in the analysis AEs were graded according to" exact="National Cancer Institute" post="Common Terminology Criteria for Adverse Events (NCI-CTCAE V3.0) ["/>
   <result pre="(DOCX 771 kb) The study was funded by F. Hoffmann-La" exact="Roche" post="Ltd, Basel, Switzerland, and Genentech, Inc., a member of"/>
   <result pre="Ltd, Basel, Switzerland, and Genentech, Inc., a member of the" exact="Roche" post="Group, South San Francisco, CA, USA. The authors also"/>
   <result pre="writing assistance for this manuscript was provided by F. Hoffmann-La" exact="Roche" post="Ltd. References References 1. Sliwkowski MX Lofgren JA Lewis"/>
   <result pre="Pharmacol 2013 53 192 201 10.1177/0091270012436560 23436264 6. F. Hoffmann-La" exact="Roche" post="Ltd. Data on file 7. Bittner B Richter WF"/>
   <result pre="study Ann Oncol 2015 26 320 325 10.1093/annonc/mdu524 25403587 15." exact="National Cancer Institute" post="Common Terminology Criteria for Adverse Events version 3.0. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4707213/results/search/funders/results.xml">
   <result pre="Correspondence: Doo Ho Choi, MD, PhD, Department of Radiation Oncology," exact="Samsung" post="Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro,"/>
   <result pre="Choi, MD, PhD, Department of Radiation Oncology, Samsung Medical Center," exact="Sungkyunkwan University" post="School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea."/>
   <result pre="PhD, Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University" exact="School of Medicine," post="81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea. Tel: +82-2-3410-2436, Fax:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4708008/results/search/funders/results.xml">
   <result pre="under diverse conditions were prepared by washing with ice-cold PBS." exact="Total" post="RNA was isolated using Trizol reagent (iNtRON Biotechnology). Total"/>
   <result pre="PBS. Total RNA was isolated using Trizol reagent (iNtRON Biotechnology)." exact="Total" post="RNA was treated with 2 units of RNase-free DNase"/>
   <result pre="cells were treated with apigenin (0–60 μM) for 24 h." exact="Total" post="proteins were analysed by western blotting with anti-Bcl-2, anti-BAX"/>
   <result pre="was supported by the Basic Science Research Program through the" exact="National Research Foundation" post="of Korea (NRF) funded by the Ministry of Science,"/>
   <result pre="NRF-2015R1C1A2A/1/51539]; and the Traditional Korean Medicine R&amp;amp;D Project of the" exact="Ministry of Health" post="&amp;amp; Welfare [grant numbers HI12C1889 and HI11C2110]. Abbreviations AIF"/>
   <result pre="16850126 34 Kute T. Lack C.M. Willingham M. Bishwokama B." exact="Williams" post="H. Barrett K. Mitchell T. Vaughn J.P. Development of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4708174/results/search/funders/results.xml">
   <result pre="Samit 4 [1], [2], [3], [4], [5], Correspondence: Cristian Massacesi," exact="Novartis" post="Oncology, 10 Rue Lionel Terray, Rueil-Malmaison, Paris 92500, France,"/>
   <result pre="the PI3Kα-selective inhibitor alpelisib (BYL719), currently in clinical development by" exact="Novartis" post="Oncology, may therefore be effective as anticancer agents. Early"/>
   <result pre="PI3K inhibitors? This review summarizes the strategies being employed by" exact="Novartis" post="Oncology to help maximize the benefits of clinical studies"/>
   <result pre="the first PI3K inhibitor licensed for the treatment of cancer." exact="Novartis" post="Oncology has been investigating the PI3K–AKT–mTOR pathway for many"/>
   <result pre="been investigating the PI3K–AKT–mTOR pathway for many years. Indeed, the" exact="Novartis" post="mTOR complex 1 inhibitor everolimus is now approved for"/>
   <result pre="demonstrating the potential for PI3K–AKT–mTOR pathway inhibition in cancer. Other" exact="Novartis" post="compounds in clinical development include the pan-PI3K inhibitor buparlisib"/>
   <result pre="describe the range of clinical study designs being used by" exact="Novartis" post="Oncology to maximize the potential of this promising new"/>
   <result pre="Figure 2 summarizes the study designs currently in use by" exact="Novartis" post="Oncology in the following tumor types. Breast cancer PI3K–AKT–mTOR"/>
   <result pre="pharmaceutical companies and academic institutions, including a wide range of" exact="Novartis" post="Oncology trials of buparlisib and alpelisib. Unanswered questions remain"/>
   <result pre="future of cancer care. Disclosure All authors are employees of" exact="Novartis" post="Pharmaceuticals Corporation or Novartis Pharma AG. Medical editorial assistance"/>
   <result pre="Disclosure All authors are employees of Novartis Pharmaceuticals Corporation or" exact="Novartis" post="Pharma AG. Medical editorial assistance was provided by Kate"/>
   <result pre="Gaffey, PhD and Alex Coulthard, BSc, and was funded by" exact="Novartis" post="Pharmaceuticals Corporation. References References 1 Dienstmann R Rodon J"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4717619/results/search/funders/results.xml">
   <result pre="breast cancer stem-like cells by activating Notch signalling in brain" exact="EMBO" post="Mol Med 2013 5 384 96 10.1002/emmm.201201623 23495140 36."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4717845/results/search/funders/results.xml">
   <result pre="of the mobile phase. Mass spectrometry was performed in a" exact="Thermo Scientific" post="Exactive Benchtop LC/MS Orbitrap Mass spectrometer ( Chaneton et"/>
   <result pre="Ward P.S. Yen K.E. Liau L.M. Rabinowitz J.D. Cantley L.C." exact="Thompson" post="C.B. Vander Heiden M.G. Su S.M. Cancer-associated IDH1 mutations"/>
   <result pre="135 5 2014 Sep 1 1060 1071 24531984 Ward P.S." exact="Thompson" post="C.B. Metabolic reprogramming: a cancer hallmark even Warburg did"/>
   <result pre="Pfeiffer H.K. Nissim I. Daikhin E. Yudkoff M. McMahon S.B." exact="Thompson" post="C.B. Myc regulates a transcriptional program that stimulates mitochondrial"/>
   <result pre="article: LINK LINK Acknowledgments This work was supported by the" exact="Cancer Research UK" post="Manchester Institute (ref: C5759/A12328), Cancer Research UK (ref: A17240),"/>
   <result pre="supported by the Cancer Research UK Manchester Institute (ref: C5759/A12328)," exact="Cancer Research UK" post="(ref: A17240), the Wellcome Trust (WT1005X) and the Cancer"/>
   <result pre="Manchester Institute (ref: C5759/A12328), Cancer Research UK (ref: A17240), the" exact="Wellcome Trust" post="(WT1005X) and the Cancer Research UK Beatson Institute (ref:"/>
   <result pre="Research UK (ref: A17240), the Wellcome Trust (WT1005X) and the" exact="Cancer Research UK" post="Beatson Institute (ref: 12477). Appendix A Supplementary data related"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4718910/results/search/funders/results.xml">
   <result pre="of ≥6 months; recovery from any grade 3 (according to" exact="National Cancer Institute" post="Common Terminology Criteria for Adverse Events [NCI CTCAE] version"/>
   <result pre="(HPLC–MS/MS) assay at the Department of Drug Metabolism and Pharmacokinetics," exact="Boehringer Ingelheim" post="Pharma GmbH and Co. KG, Biberach, Germany. Letrozole plasma"/>
   <result pre="1 Demographics and characteristics of treated patients N (%) a" exact="Total" post="number 28 (100) Sex Female 28 (100) Age (years)"/>
   <result pre="1 (7.7) 0 0 1 (3.6) 1 (3.6) NCI CTCAE" exact="National Cancer Institute" post="Common Terminology Criteria for Adverse Events (version 3.0) Six"/>
   <result pre="approved the final manuscript. Acknowledgements This study was supported by" exact="Boehringer Ingelheim." post="We gratefully acknowledge the patients, their families and their"/>
   <result pre="participation in this study. Medical writing assistance, supported financially by" exact="Boehringer Ingelheim," post="was provided by Julie Fleming, of Ogilvy Healthworld, and"/>
   <result pre="board fees from Novartis; HDMS, MUF, KP, SW: employees of" exact="Boehringer Ingelheim." post="Role of the funding source This study was supported"/>
   <result pre="Role of the funding source This study was supported by" exact="Boehringer Ingelheim." post="The authors were fully responsible for all content and"/>
   <result pre="letrozole monotherapy. Poster presentation at 46th Annual Meeting of the" exact="American Society of Clinical Oncology," post="4–8 June, 2010, Chicago, IL. Abstract no. 1072. References"/>
   <result pre="solid tumors. European Organization for Research and Treatment of Cancer," exact="National Cancer Institute" post="of the United States, National Cancer Institute of Canada"/>
   <result pre="Treatment of Cancer, National Cancer Institute of the United States," exact="National Cancer Institute" post="of Canada J Natl Cancer Inst 2000 92 205"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4720061/results/search/funders/results.xml">
   <result pre="Korea Correspondence: Eun Sook Lee, MD, PhD Center for Breast Cancer," exact="National Cancer Center," post="323 Ilsan-ro, Ilsandong-gu, Goyang 410-769, Korea Tel: 82-31-920-1503 Fax: 82-31-920-1511"/>
   <result pre="included consecutive breast cancer patients who received NAC at the" exact="National Cancer Center," post="Korea, between August 2002 and June 2011, and had"/>
   <result pre="database for records of consecutive patients who underwent NAC at" exact="National Cancer Center," post="Korea, between August 2002 and June 2011. Diagnostic core"/>
   <result pre="was reviewed and approved by the Institutional Review Board of" exact="National Cancer Center," post="Korea. Results 1. Patient characteristics Of 4,460 patients who"/>
   <result pre="This work was supported by a research grant from the" exact="National Cancer Center" post="(NCC-1410690-2), Republic of Korea. References References 1 Wolmark N"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4720106/results/search/funders/results.xml">
   <result pre="Lee, MD, PhD Division of Medical Oncology, Department of Internal Medicine," exact="Yonsei University" post="College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea Tel:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4722889/results/search/funders/results.xml">
   <result pre="9) and MESO4 ( 9) cell lines were purchased from" exact="RIKEN" post="BRC through the National Bio-Resource Project of the MEXT"/>
   <result pre="Grant (25–34), the Ryobi Teien Research Grant and The Okayama" exact="Medical Foundation" post="(to R.O.), and the Strategic Research Foundation Grant-aided Project"/>
   <result pre="the Strategic Research Foundation Grant-aided Project for Private Universities from" exact="Ministry of Education," post="Culture, Sport, Science and Technology (to M.N.). Abbreviations MPM"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4728453/results/search/funders/results.xml">
   <result pre="↑ ↑ *   Plasma volume ↓ ↑ §  " exact="Total" post="body water ↓ ↑ §   Intra-/extracellular body fluid"/>
   <result pre="15 CL: −50% * Vss: −57% * T ½: −17%" exact="Total" post="paclitaxel: Cmax: −5% AUC: +16% CL: −20% * Lichtman"/>
   <result pre="by Piazza et al. CL of distribution phase: −30% *" exact="Total" post="CL: −23% Dobbs 1995 Doxorubicin &amp;lt;25 m–100 mg/m 2"/>
   <result pre="(h); ECOG = Eastern Cooperative Oncology Group score; FDA =" exact="Food and Drug Administration;" post="iv = intravenous; MC = mamma carcinoma; MRT ="/>
   <result pre="Drug Registration—E4 European Medicines Agency London, UK 1994 9. collab:" exact="Food and Drug Administration" post="Guidance for Industry: Exposure-Response Relationships—Study Design, Data Analysis and"/>
   <result pre="older JAMA 2001 285 885 892 10.1001/jama.285.7.885 11180731 20. collab:" exact="Food and Drug Administration" post="Taxotere (docetaxel), NDA 020449Adriamycin RDF (Doxorubin Hydrochloride), NDA 050467"/>
   <result pre="Analytics Thomson Micromedex, Greenwood Village, CO, USA 2015 45. collab:" exact="Food and Drug Administration" post="Adriamycin RDF (Doxorubin Hydrochloride), NDA 050467 2013 46. Dobbs"/>
   <result pre="Oncol. Tumor Pharmacother. 1992 9 75 80 1341719 55. collab:" exact="Food and Drug Administration" post="Ellence (Epirubicin Hydrochloride), NDA 050778 2014 56. collab: Food"/>
   <result pre="Drug Administration Ellence (Epirubicin Hydrochloride), NDA 050778 2014 56. collab:" exact="Food and Drug Administration," post="Center for Drug Evaluation and Research Clinical Pharmacology and"/>
   <result pre="Clin. Pharmacokinet. 1991 20 194 208 10.2165/00003088-199120030-00002 2025981 59. collab:" exact="Food and Drug Administration" post="Lyophilized Cytoxan (Cyclophosphamide), NDA 012142 2013 60. collab: DRUGDEX"/>
   <result pre="476 10.1007/s00228-002-0506-x 12389069 64. Lush R.M. McCune J.S. Tetteh L." exact="Thompson" post="J.A. Mahany J.J. Garland L. Suttle A.B. Sullivan D.M."/>
   <result pre="Anticancer Drugs 2002 13 473 480 10.1097/00001813-200206000-00005 12045458 68. collab:" exact="Food and Drug Administration" post="Navelbine (Vinorelbine), NDA 020388 2014 69. Depierre A. Freyer"/>
   <result pre="Healthcare products Regulatory Agency London, UK 2014 85. Seymour M.T." exact="Thompson" post="L.C. Wasan H.S. Middleton G. Brewster A.E. Shepherd S.F."/>
   <result pre="controlled trial Trials 2015 16 238 10.1186/s13063-015-0753-7 26021722 95. collab:" exact="Food and Drug Administration" post="Medical Review: Xeloda (Capecitabine) FDA Rockville, MD, USA 1998"/>
   <result pre="Review: Xeloda (Capecitabine) FDA Rockville, MD, USA 1998 96. collab:" exact="Food and Drug Administration" post="Xeloda (Capecitbine), NDA 020896 2015 97. Gieschke R. Burger"/>
   <result pre="Ann. Oncol. 2012 23 1845 1853 10.1093/annonc/mdr539 22104575 106. collab:" exact="Food and Drug Administration" post="Paraplatin (Carboplatin), NDA 020452 2004 107. Merino-Sanjuán M. Monteiro"/>
   <result pre="CBG-MEB SmPC Platinol CBG-MEB Utrecht, The Netherlands 2011 111. collab:" exact="Food and Drug Administration" post="Platinol (Cisplatin), NDA 018057 2015 112. collab: Medicines and"/>
   <result pre="Pharmacol. Ther. 2012 29 3499 511 10.1038/clpt.2011.74 21633346 121. collab:" exact="Food and Drug Administration" post="Kadcyla (Ado-Trastuzumab Emtansine), BLA 125427 FDA Rockville, MD, USA"/>
   <result pre="Emtansine), BLA 125427 FDA Rockville, MD, USA 2015 122. collab:" exact="Food and Drug Administration" post="Drug Approvals: Kadcyla (Ado-Trastuzumab Emtansine) FDA Rockville, MD, USA"/>
   <result pre="Metab. Dispos. 2012 40 313 321 10.1124/dmd.111.042762 22041109 128. collab:" exact="Food and Drug Administration" post="Halaven (Eribulin Mesylate), NDA 201532 2014 129. collab: European"/>
   <result pre="(Erybulin Mesylate) European Medicines Agency London, UK 2015 130. collab:" exact="Food and Drug Administration," post="Center for Drug Evaluation and Research Clinical Pharmacology and"/>
   <result pre="Analytics Thomson Micromedex, Greenwood Village, CO, USA 2015 132. collab:" exact="Food and Drug Administration" post="Afinitor (Everolimus), NDA 022334 2015 133. Motzer R.J. Escudier"/>
   <result pre="Oudard S. Hutson T.E. Porta C. Bracarda S. Grünwald V." exact="Thompson" post="J.A. Figlin R.A. et al. Efficacy of everolimus in"/>
   <result pre="trial Lancet 2008 372 449 456 10.1016/S0140-6736(08)61039-9 18653228 134. collab:" exact="Food and Drug Administration," post="Center for Drug Evaluation and Research Clinical Pharmacology and"/>
   <result pre="Analytics Thomson Micromedex, Greenwood Village, CO, USA 2015 137. collab:" exact="Food and Drug Administration" post="Tykerb (Lapatinib Ditosylate), NDA 022059 2015 138. Scheffler M."/>
   <result pre="Clin. Pharmacokinet. 2011 50 371 403 10.2165/11587020-000000000-00000 21553932 139. collab:" exact="Food and Drug Administration," post="Center for Drug Evaluation and Research Clinical Pharmacology and"/>
   <result pre="With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer:" exact="American Society of Clinical Oncology" post="Clinical Practice Guideline J. Clin. Oncol. 2014 32 1"/>
   <result pre="Epidermal Growth Factor Receptor 2-Negative (or unknown) Advanced Breast Cancer:" exact="American Society of Clinical Oncology" post="Clinical Practice Guideline J. Clin. Oncol. 2014 32 3307"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4729711/results/search/funders/results.xml">
   <result pre="Breast cancer Hormonal therapy Molecular-targeted therapy CT MRI Funding http://dx.doi.org/10.13039/100005625" exact="RSNA Research and Educational Foundation" post="(US) Introduction A paradigm shift has occurred over the"/>
   <result pre="dimerization inhibitor) that has been approved by the United States" exact="Food and Drug Administration" post="(FDA) for use in metastatic breast cancer. Other targeted"/>
   <result pre="% [ 30]. Hepatocyte-specific contrast agents, including gadoxetate disodium (Eovist/Primovist;" exact="Bayer" post="HealthCare, Leverkusen, Germany) and gadobenate dimeglumine (MultiHance; Bracco Diagnostics"/>
   <result pre="with ethical standards Disclosures The investigator A.B.S was awarded a" exact="Radiological Society of North America" post="(RSNA) research grant beginning July, 2014. The remaining authors"/>
   <result pre="Oncol 2009 27 5685 5692 10.1200/JCO.2008.21.4577 19884557 9. Spielmann M" exact="Roche" post="H Delozier T et al. Trastuzumab for patients with"/>
   <result pre="solid tumors. HER2ean Organization for Research and Treatment of Cancer," exact="National Cancer Institute" post="of the United States, National Cancer Institute of Canada"/>
   <result pre="Treatment of Cancer, National Cancer Institute of the United States," exact="National Cancer Institute" post="of Canada J Natl Cancer Inst 2000 92 205"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4730993/results/search/funders/results.xml">
   <result pre="Genetic and Molecular Toxicology, National Center for Toxicological Research, US" exact="Food and Drug Administration," post="3900 NCTR Rd, Jefferson, AR 72079, USA, Tel +1"/>
   <result pre="in the USA, with ~40,000 deaths per year. 1 The" exact="American Cancer Society" post="estimates 232,000 new cases of invasive breast cancer and"/>
   <result pre="the foundation of personalized cancer medicine. According to the US" exact="Food and Drug Administration" post="(FDA) guidance document for industry and FDA staff, &quot;In-Vitro"/>
   <result pre="inhibitors, are preferred over chemotherapy as a first-line treatment. Recent" exact="American Society of Clinical Oncology" post="(ASCO) guidelines 22 recommend that tamoxifen therapy should be"/>
   <result pre="(Ventana Medical Systems, Inc., Tucson, AZ, USA), and 3) Bond" exact="Oracle" post="HER2 IHC system (Leica Biosystems, Wetzlar, Germany). The remaining"/>
   <result pre="US Food Drug Administration In Vitro Companion Diagnostic Devices US" exact="Food and Drug Administration" post="2014 3 Lerner HJ Band PR Israel L Leung"/>
   <result pre="Sentinel lymph node biopsy for patients with early-stage breast cancer:" exact="American Society of Clinical Oncology" post="clinical practice guideline update J Clin Oncol 2014 32"/>
   <result pre="24663048 8 Caudle AS Hunt KK Tucker SL et al." exact="American College of Surgeons" post="Oncology Group (ACOSOG) Z0011: impact on surgeon practice patterns"/>
   <result pre="Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer:" exact="American Society of Clinical Oncology" post="clinical practice guideline focused update J Clin Oncol 2014"/>
   <result pre="2015. 62 Harris L Fritsche H Mennel R et al." exact="American Society of Clinical Oncology" post="2007 update of recommendations for the use of tumor"/>
   <result pre="Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs) US" exact="Food and Drug Administration" post="2014 Available from: http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm416685.pdf Accessed January 8, 2016 64"/>
   <result pre="Laboratories, and Staff: In Vitro Diagnostic Multivariate Index Assays US" exact="Food and Drug Administration" post="2007 Available from: http://www.fda.gov/downloads/MedicalDevices/…/ucm071455.pdf Accessed January 8, 2016 65"/>
   <result pre="Systems, Inc. P100027 2011 2015 Automated, quantitative, dual-color DISH Bond" exact="Oracle" post="HER2 IHC System Leica Biosystems P090015 2012 2015 Automated,"/>
   <result pre="in situ hybridization; DISH, dual in situ hybridization; FDA, US" exact="Food and Drug Administration;" post="FISH, fluorescent in situ hybridization; HER2, human epidermal growth"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4734963/results/search/funders/results.xml">
   <result pre="[2], Korea [3], Korea Corresponding Author Jae-Ho Cheong, MD, PhD" exact="Department of Surgery," post="Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul"/>
   <result pre="Korea Corresponding Author Jae-Ho Cheong, MD, PhD Department of Surgery," exact="Yonsei University" post="College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea"/>
   <result pre="GC. GC has been classified according to histo-morphologic features. The" exact="World Health Organization" post="(WHO) classifies GC into papillary, tubular, mucinous, and poorly"/>
   <result pre="grant of the Korea Health Technology R&amp;amp;D Project through the" exact="Korea Health Industry Development Institute" post="(KHIDI), funded by the Ministry of Health &amp;amp; Welfare,"/>
   <result pre="the Korea Health Industry Development Institute (KHIDI), funded by the" exact="Ministry of Health" post="&amp;amp; Welfare, Republic of Korea (HI3C2162), and by the"/>
   <result pre="(HI3C2162), and by the National R&amp;amp;D Program for Cancer Control," exact="Ministry of Health" post="and Welfare, Republic of Korea (1020390, 1320360). References REFERENCES"/>
   <result pre="cancer Clin Cancer Res 2015 21 2453 61 25712685 31" exact="Amgen" post="announces termination of all amgen-sponsored clinical studies of rilotumumab"/>
   <result pre="Clin Cancer Res 2012 18 5992 6000 22977193 64 collab:" exact="U.S. Food and Drug Administration" post="Trastuzumab [Internet]. Office of Medical Products and Tobacco [Internet]"/>
   <result pre="Cancer Res 2012 18 5992 6000 22977193 64 collab: U.S." exact="Food and Drug Administration" post="Trastuzumab [Internet]. Office of Medical Products and Tobacco [Internet]"/>
   <result pre="[Internet]. Office of Medical Products and Tobacco [Internet] Silver Spring" exact="U.S. Food and Drug Administration" post="2010 [cited 2015 Oct 1]. Available from: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm230418.htm 65"/>
   <result pre="Office of Medical Products and Tobacco [Internet] Silver Spring U.S." exact="Food and Drug Administration" post="2010 [cited 2015 Oct 1]. Available from: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm230418.htm 65"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4735094/results/search/funders/results.xml">
   <result pre="research Biomarkers Patient profiling Randomized trials Breast cancer Funding http://dx.doi.org/10.13039/100009009" exact="Novartis" post="Pharmaceuticals Canada Background Breast cancer (BC) is a significant"/>
   <result pre="research in the United States (US) each year by, the" exact="National Cancer Institute" post="alone (National Cancer Institute 2013), and female BC has"/>
   <result pre="Triple-negative or BRCA-positive [n (%)] Other or unselected [n (%)]" exact="Total" post="[n (%)] Total, n (proportion by subtype, %) 79"/>
   <result pre="Categories Neoadjuvant [n (%)] Adjuvant [n (%)] Advanced [n (%)]" exact="Total" post="[n (%)] Total [n (proportion by setting, %)] 68"/>
   <result pre="(%)] Adjuvant [n (%)] Advanced [n (%)] Total [n (%)]" exact="Total" post="[n (proportion by setting, %)] 68 (24.3) 66 (23.6)"/>
   <result pre="Established targeted-drugs, defined as those with at least one US" exact="Food and Drug Administration" post="(FDA)-approved BC indication as of September 4, 2013, are"/>
   <result pre="factor receptor ER estrogen receptor ET endocrine therapy FDA US" exact="Food and Drug Administration" post="FGFR fibroblast growth factor receptor GpNMB glycoprotein NMB HER2"/>
   <result pre="BMS, payment for travel, accommodations or other expenses from BMS," exact="Roche" post="Farmaceutica Quimica, Celldex and Astra-Zeneca and has received fellowship"/>
   <result pre="Quimica, Celldex and Astra-Zeneca and has received fellowship support from" exact="Genomic Health." post="Christine Simmons has received honoraria from and has been"/>
   <result pre="AZ, payment for travel, accommodations or other expenses from Roche," exact="Amgen" post="and Novartis and has received research funding from Roche,"/>
   <result pre="for travel, accommodations or other expenses from Roche, Amgen and" exact="Novartis" post="and has received research funding from Roche, Novartis, Amgen,"/>
   <result pre="Amgen, GSK and AZ. Jean-Francois Boileau is a consultant for" exact="Roche" post="and Genomic Health, has received honoraria from Roche and"/>
   <result pre="and AZ. Jean-Francois Boileau is a consultant for Roche and" exact="Genomic Health," post="has received honoraria from Roche and Genomic Health, payment"/>
   <result pre="consultant for Roche and Genomic Health, has received honoraria from" exact="Roche" post="and Genomic Health, payment for travel, accommodations or other"/>
   <result pre="Roche and Genomic Health, has received honoraria from Roche and" exact="Genomic Health," post="payment for travel, accommodations or other expenses from Roche"/>
   <result pre="Genomic Health, payment for travel, accommodations or other expenses from" exact="Roche" post="and Dr. Boileau’s institution has received research funding from"/>
   <result pre="of Immunogen, Seattle Genetics, and Celdex, received research funding from" exact="Novartis" post="and has consulted for sanofi. Ilidio Martins is an"/>
   <result pre="agent of Kaleidoscope Strategic, which has received research funding from" exact="Novartis" post="for the preparation of this manuscript. Maureen Trudeau has"/>
   <result pre="received research funding from Amgen, Astra-Zeneca, Novartis, Pfizer, RNA Diagnostics," exact="Roche" post="and sanofi. Funding source This work was funded through"/>
   <result pre="366 2 109 119 10.1056/NEJMoa1113216 22149875 Baselga J Segalla JG" exact="Roche" post="H Del Giglio A Pinczowski H Ciruelos EM Filho"/>
   <result pre="Steering Committee on Cancer Statistics (2013) Canadian cancer statistics 2013." exact="Canadian Cancer Society," post="Toronto, ON. http://www.cancer.ca/~/media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/canadian-cancer-statistics-2013-EN.pdf. Accessed 23 Aug 2013 Cardoso F"/>
   <result pre="growth factor receptor 2 immunohistochemical score and comparison with the" exact="Genomic Health" post="recurrence score in early breast cancer J Clin Oncol"/>
   <result pre="Quinn E Salter J Wale C Cuzick J Houghton J" exact="Williams" post="N Mallon E Bishop H Ellis I Larsimont D"/>
   <result pre="breast cancer indication for AVASTIN (bevacizumab): decision of the commissioner." exact="Department of Health" post="and Human Services, U.S. Food and Drug Administration. http://www.fda.gov/downloads/NewsEvents/Newsroom/UCM280546.pdf."/>
   <result pre="decision of the commissioner. Department of Health and Human Services," exact="U.S. Food and Drug Administration." post="http://www.fda.gov/downloads/NewsEvents/Newsroom/UCM280546.pdf. Accessed 28 May 2014 Harris CA Ward RL"/>
   <result pre="of the commissioner. Department of Health and Human Services, U.S." exact="Food and Drug Administration." post="http://www.fda.gov/downloads/NewsEvents/Newsroom/UCM280546.pdf. Accessed 28 May 2014 Harris CA Ward RL"/>
   <result pre="J Clin Pathol 2005 123 1 21 27 10.1309/4WV79N2GHJ3X1841 15762276" exact="National Cancer Institute" post="(2012) Cancer trends progress report—2011/2012 update: costs of cancer"/>
   <result pre="(2012) Cancer trends progress report—2011/2012 update: costs of cancer care." exact="National Cancer Institute," post="NIH, DHHS. http://progressreport.cancer.gov/doc_detail.asp?pid=1&amp;amp;did=2009&amp;amp;chid=95&amp;amp;coid=926&amp;amp;mid=. Accessed 19 May 2014 National Cancer"/>
   <result pre="National Cancer Institute, NIH, DHHS. http://progressreport.cancer.gov/doc_detail.asp?pid=1&amp;amp;did=2009&amp;amp;chid=95&amp;amp;coid=926&amp;amp;mid=. Accessed 19 May 2014" exact="National Cancer Institute" post="(2013) A snapshot of breast cancer. http://www.cancer.gov/researchandfunding/snapshots/breast#footnote1. Accessed 19"/>
   <result pre="A snapshot of breast cancer. http://www.cancer.gov/researchandfunding/snapshots/breast#footnote1. Accessed 19 May 2014" exact="National Cancer Institute" post="(2014) NCI dictionary of cancer terms: targeted therapy. http://www.cancer.gov/dictionary?cdrid=270742."/>
   <result pre="Oncol 2011 29 25 3366 3373 10.1200/JCO.2011.35.0868 21768458 Perez EA," exact="Thompson" post="EA, Anderson SK, Asmann YW, Kalari KR, Eckel-Passow J,"/>
   <result pre="Ross DT Johnsen H Akslen LA Fluge O Pergamenschikov A" exact="Williams" post="C Zhu SX Lonning PE Borresen-Dale AL Brown PO"/>
   <result pre="Bogaerts J Delaloge S Veer LV Rubio IT Viale G" exact="Thompson" post="AM Passalacqua R Nitz U Vindevoghel A Pierga JY"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4736909/results/search/funders/results.xml">
   <result pre="for the treatment of advanced gastric cancer by the US" exact="Food and Drug Administration" post="(FDA) in November 2010 and by the Chinese version"/>
   <result pre="approved for the treatment of non-small-cell lung cancer by China's" exact="Food and Drug Administration" post="(CFDA) supervision bureau in 2005. Ling et al.'s study"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4738716/results/search/funders/results.xml">
   <result pre="(Agilent Whole Human Genome Microarray 4 × 44 k v2). IPA" exact="Core" post="Analysis function was used to examine which biological processes"/>
   <result pre="using LightCycler Taqman Master Kit (Roche Applied Science, Penzberg, Germany)." exact="Roche" post="Applied Science software was used to design the structure"/>
   <result pre="cancer, we analyzed our data using IPA software. We ran" exact="Core" post="Analysis for BC versus CTR, ER−PR−HER2− versus CTR, ER+PR+HER2−"/>
   <result pre="carcinomas distinguish tumor subclasses with clinical implications Proceedings of the" exact="National Academy of Sciences" post="of the United States of America 2001 98 19"/>
   <result pre="subtypes in independent gene expression data sets Proceedings of the" exact="National Academy of Sciences" post="of the United States of America 2003 100 14"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4739616/results/search/funders/results.xml">
   <result pre="( https://www.ncn.gov.pl/), funding received by AK. Publication supported by the" exact="European Commission" post="from the FP7 project MOBI4Health, GA 316094; funding received"/>
   <result pre="Science Centre No. 2011/03/B/NZ7/06144. Open access publication supported by the" exact="European Commission" post="from the FP7 project MOBI4Health, GA 316094. References References"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4740402/results/search/funders/results.xml">
   <result pre="Research), partner site Hamburg/Kiel/Lübeck, Hamburg, Germany [2], Molecular Medicine Section," exact="National Heart and Lung Institute," post="Faculty of Medicine, Imperial College London, London, United Kingdom"/>
   <result pre="Medicine Section, National Heart and Lung Institute, Faculty of Medicine," exact="Imperial College London," post="London, United Kingdom [3], Department of Clinical Chemistry/Central Laboratories,"/>
   <result pre="Germany [4], Center for Translational Medicine, Cardiology Division, Temple University" exact="School of Medicine," post="Philadelphia, Pennsylvania, 19140, United States of America Lee Jung"/>
   <result pre="19140, United States of America Lee Jung Weon Editor []," exact="Seoul National University," post="REPUBLIC OF KOREA Competing Interests: The authors have declared"/>
   <result pre="autophagic flux. Funding This study was supported by funds from" exact="Deutsche Herzstiftung" post="(F/13/10), the German Research Foundation (DFG Es 88/12-1), the"/>
   <result pre="Research and Education (DZHK, German Centre for Cardiovascular Research), the" exact="European Commission" post="with FP7 Projects Angioscaff and Biodesign. fig-count: table-count: page-count:"/>
   <result pre="was performed with 60 μl extraction buffer per EHT (M-PER," exact="Thermo Scientific" post="#78501, Mini-Complete protease inhibitor, Roche 11837580001; PhosSTOP, Roche 04906837001)."/>
   <result pre="buffer per EHT (M-PER, Thermo Scientific #78501, Mini-Complete protease inhibitor," exact="Roche" post="11837580001; PhosSTOP, Roche 04906837001). Tissue was lysed with the"/>
   <result pre="(M-PER, Thermo Scientific #78501, Mini-Complete protease inhibitor, Roche 11837580001; PhosSTOP," exact="Roche" post="04906837001). Tissue was lysed with the Qiagen Tissue Lyser."/>
   <result pre="vs. baseline, two-way ANOVA and Bonferroni's multiple comparison post-test. (B)" exact="Total" post="therapeutic plasma concentration (TPC), toxic threshold concentration (TTC: TKI"/>
   <result pre="data file. We thank Melanie Neumann and Kristin Hartmann (HEXT" exact="Core" post="Facility Mouse Pathology, Institute of Neuropathology, University Medical Center"/>
   <result pre="6 Herman EH , Knapton A , Rosen E ," exact="Thompson" post="K , Rosenzweig B , Estis J , et"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4741577/results/search/funders/results.xml">
   <result pre="of Shemyakin &amp;amp; Ovchinnikov Institute of Bioorganic Chemistry of the" exact="Russian Academy of Sciences." post="Animals were kept in well-ventilated polypropylene cages with a"/>
   <result pre="grateful to V.I. Plekhanov (Institute of Applied Physics of the" exact="Russian Academy of Sciences," post="Nizhny Novgorod) for technical assistance and valuable ideas when"/>
   <result pre="well as E.N. Lebedenko (Institute of Bioorganic Chemistry of the" exact="Russian Academy of Sciences," post="Moscow) for helpful advice and critical reading of the"/>
   <result pre="immunotoxin and cell studies, and project no. 14.Z50.31.0022 of the" exact="Ministry of Education" post="and Science of the Russian Federation in the part"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4741657/results/search/funders/results.xml">
   <result pre="AND METHODS Patients We conducted a prospective study at the" exact="Samsung" post="Medical Center (SMC) from March 2013 to November 2014."/>
   <result pre="grant from the Korea Health Technology R&amp;amp;D Project through the" exact="Korea Health Industry Development Institute" post="(KHIDI), funded by the Ministry of Health &amp;amp; Welfare,"/>
   <result pre="the Korea Health Industry Development Institute (KHIDI), funded by the" exact="Ministry of Health" post="&amp;amp; Welfare, Republic of Korea (grant number : HI13C2096)."/>
   <result pre="number : HI13C2096). This work was also supported by the" exact="Samsung" post="Biomedical Research Institute (grant number SMO1131841). CONFLICTS OF INTEREST"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4742525/results/search/funders/results.xml">
   <result pre="conduct of this project; i.e. decision no. 1110/94/EC of the" exact="European Parliament" post="and of the Council (OJL126 18,5,94), the Helsinki Declaration"/>
   <result pre="Society AC. Global Cancer Facts &amp;amp; Figures 2nd Edition Atlanta:" exact="American Cancer Society;" post="2011 [cited 2011]. 2nd:[Available from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027766.pdf. 4 Lauwers GY"/>
   <result pre="7 Cunningham D , Allum WH , Stenning SP ," exact="Thompson" post="JN , Van de Velde CJ , Nicolson M"/>
   <result pre=", Steyerberg EW , van Berge Henegouwen MI , Wijnhoven" exact="BP" post=", et al. Preoperative chemoradiotherapy for esophageal or junctional"/>
   <result pre="and survival in solid tumors: a meta-analysis. Journal of the" exact="National Cancer Institute." post="2013; 105( 4): 266– 73. doi: 10.1093/jnci/djs501 . 23221996"/>
   <result pre="gastric cancer. Clinical cancer research: an official journal of the" exact="American Association for Cancer Research" post=". 2008; 14( 23): 7843– 9. doi: 10.1158/1078-0432.CCR-08-1064 ."/>
   <result pre="cancer therapy. Clinical cancer research: an official journal of the" exact="American Association for Cancer Research." post="2010; 16( 5): 1373– 83. doi: 10.1158/1078-0432.CCR-09-1218 ; PubMed"/>
   <result pre="outcome . Journal of clinical oncology: official journal of the" exact="American Society of Clinical Oncology" post=". 2011; 29( 22): 3030– 6. doi: 10.1200/JCO.2010.33.6313 ."/>
   <result pre="cancer . Clinical cancer research: an official journal of the" exact="American Association for Cancer Research" post=". 2012; 18( 21): 5992– 6000. doi: 10.1158/1078-0432.CCR-12-1318 ."/>
   <result pre="adenocarcinoma . Journal of gastrointestinal surgery: official journal of the" exact="Society for Surgery of the Alimentary Tract" post=". 2004; 8( 4): 448– 53. doi: 10.1016/j.gassur.2004.01.006 ."/>
   <result pre="chemoradiotherapy . Clinical cancer research: an official journal of the" exact="American Association for Cancer Research" post=". 2003; 9( 17): 6461– 8. . 14695149 34"/>
   <result pre="epidermal growth factor signaling by combinatorial receptor interactions . The" exact="EMBO" post="journal. 1996; 15( 10): 2452– 67. ; PubMed Central"/>
   <result pre="patients . Journal of clinical oncology: official journal of the" exact="American Society of Clinical Oncology" post=". 2006; 24( 10): 1612– 9. doi: 10.1200/JCO.2005.03.4900 ."/>
   <result pre="0127 . Journal of clinical oncology: official journal of the" exact="American Society of Clinical Oncology" post=". 2006; 24( 30): 4922– 7. doi: 10.1200/JCO.2006.07.1316 ."/>
   <result pre="trial . Journal of clinical oncology: official journal of the" exact="American Society of Clinical Oncology" post=". 2010; 28( 25): 3945– 50. doi: 10.1200/JCO.2010.29.2847 ."/>
   <result pre="II study . Annals of oncology: official journal of the" exact="European Society for Medical Oncology" post="/ ESMO . 2010; 21( 11): 2213– 9. doi:"/>
   <result pre="response . Clinical cancer research: an official journal of the" exact="American Association for Cancer Research" post=". 2007; 13( 19): 5869– 75. doi: 10.1158/1078-0432.CCR-06-1970 ."/>
   <result pre="tumors . Clinical cancer research: an official journal of the" exact="American Association for Cancer Research" post=". 2013; 19( 11): 3078– 87. doi: 10.1158/1078-0432.CCR-12-3051 ."/>
   <result pre="inhibition of the HER2 tyrosine kinase . Proceedings of the" exact="National Academy of Sciences" post="of the United States of America. 2011; 108( 12):"/>
   <result pre="52. . 7821892 66 Jarde T , Kass L ," exact="Staples" post="M , Lescesen H , Carne P , Oliva"/>
   <result pre="studies. Cancer epidemiology, biomarkers &amp;amp; prevention: a publication of the" exact="American Association for Cancer Research," post="cosponsored by the American Society of Preventive Oncology ."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4743179/results/search/funders/results.xml">
   <result pre="cancer colorectal cancer immunotherapy INTRODUCTION Every year, one goes to" exact="American Society of Clinical Oncology" post="(ASCO) to hear what is new and happening in"/>
   <result pre="Based on improvement in overall survival, Eribulin has recently received" exact="Food and Drug Administration" post="(FDA) approval for the treatment of women with heavily"/>
   <result pre="in triple-negative breast cancer (TNBC): Preliminary toxicity of a Sarah" exact="Cannon" post="Research Institute phase III trial J Clin Oncol 2011"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4745781/results/search/funders/results.xml">
   <result pre="bevacizumab-based combinations [ 5, 6], on November 14, 2014, the" exact="Food and Drug Administration" post="(FDA) approved bevacizumab in combination with chemotherapy for the"/>
   <result pre="were from Invitrogen (Gaithersburg, MD, USA). Protein A-Sepharose was from" exact="GE Healthcare" post="Life Sciences (Piscataway, NJ, USA). Carboplatin and cisplatin were"/>
   <result pre="Life Sciences (Piscataway, NJ, USA). Carboplatin and cisplatin were from" exact="Pfizer" post="(Madrid, Spain). Docetaxel was from Hospira UK Ltd (Warwickshire,"/>
   <result pre="purchased from a local pharmacy and pertuzumab was obtained from" exact="Genentech" post="(San Francisco, CA). Other generic chemicals were purchased from"/>
   <result pre="(San Francisco, CA). Other generic chemicals were purchased from Sigma," exact="Roche" post="Biochemicals or Merck (Darmstadt, Germany). The antibodies against Abl,"/>
   <result pre="Other generic chemicals were purchased from Sigma, Roche Biochemicals or" exact="Merck" post="(Darmstadt, Germany). The antibodies against Abl, CSF-1R, EphA2, FAK,"/>
   <result pre="containing short hairpin RNA (shRNA) for HER2 were obtained from" exact="Thermo Scientific" post="(Waltham, MA, USA). A minimum of 5 different shRNA"/>
   <result pre="Chicago, IL). SUPPLEMENTARY FIGURES LINK FUNDING Work supported by the" exact="Ministry of Economy" post="and Competitiveness of Spain (BFU2012–39151), the Instituto de Salud"/>
   <result pre="the Ministry of Economy and Competitiveness of Spain (BFU2012–39151), the" exact="Instituto de Salud Carlos III" post="through the Spanish Cancer Centers Network Program (RD12/0036/0003), the"/>
   <result pre="is recipient of a doctoral contract from the MINECO. The" exact="Cancer Research Institute" post="and the work carried out at A.P. laboratory receive"/>
   <result pre="Stewart M Katsaros D Sismondi P Love S Scott WN" exact="Williams" post="AR Lessells AM Macleod KG Smyth JF Miller WR"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4747990/results/search/funders/results.xml">
   <result pre="by use of MEDLINE, from materials from meetings of the" exact="American Society of Clinical Oncology" post="National Comprehensive Cancer Network, and from European Society of"/>
   <result pre="(MASCC)/European Society of Medical Oncology (ESMO) [ 2], and the" exact="American Society of Clinical Oncology" post="(ASCO) [ 3]. However, application of these guidelines in"/>
   <result pre="clinical use in Japan. Subsequently, in November 2011, the Japanese" exact="Ministry of Health," post="Labour, and Welfare approved the intravenous NK1 receptor antagonist,"/>
   <result pre="category Treated area High emetic risk (emetic frequency: &amp;gt;90 %)" exact="Total" post="body Moderate emetic risk (emetic frequency: 30–90 %) Upper"/>
   <result pre="Taiho Pharmaceutical Co., Ltd. Kazuhiko Nakagawa received lecture fees from" exact="Astellas Pharma" post="Inc. and research fundings from Taiho Pharmaceutical Co., Ltd/Ono"/>
   <result pre="Pain Symptom Manage 2004 28 381 388 10.1016/j.jpainsymman.2004.01.009 15471656 18." exact="Cancer Care Ontario." post="The role of neurokinin-1 receptor antagonists in the prevention"/>
   <result pre="ABC-02 trial). J Clin Oncol 27:15s (suppl; abstr 4503) 21." exact="Williams" post="SD Birch R Einhorn LH et al. Treatment of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4750533/results/search/funders/results.xml">
   <result pre="MK-2206 perifosine triciribine 1. Introduction Cancer is defined by the" exact="American Cancer Society" post="as a group of diseases characterized by the uncontrolled"/>
   <result pre="by the uncontrolled growth and spread of abnormal cells. The" exact="World Health Organization" post="(WHO) states that one defining feature of cancer is"/>
   <result pre="corresponds to 13% of all deaths worldwide. Data from the" exact="Cancer Research UK" post="indicated that in 2012, approximately 14.1 million new cases"/>
   <result pre="in new cancer cases over the next two decades. The" exact="American Cancer Society" post="released the analysis for 2015, projecting that there will"/>
   <result pre="manner with PIT-1 ( 119). Purine derivatives Screening of the" exact="National Cancer Institute" post="(NCI) Diversity Set led to the identification of API-2"/>
   <result pre="M Esteva FJ Sahin AA Klos KS Li P Monia" exact="BP" post="Nguyen NT et al. PTEN activation contributes to tumor"/>
   <result pre="15231645 121 Sampath D Malik A Plunkett W Nowak B" exact="Williams" post="B Burton M Verstovsek S Faderl S Garcia-Manero G"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4751719/results/search/funders/results.xml">
   <result pre="documented in Table 1. Table 1 Patient characteristics Characteristics Data" exact="Total" post="number of patients 190 Age, yr 51 (18–84) Menopausal"/>
   <result pre="type, TNM stage, and grade were assessed according to the" exact="World Health Organization" post="classification of breast tumors [ 59] and the Sixth"/>
   <result pre="Tumor cells after NACT Tumor cells before NACT Negative Positive" exact="Total" post="Total 96 22 (19 %) 118  DTC-negative 73 14"/>
   <result pre="cells after NACT Tumor cells before NACT Negative Positive Total" exact="Total" post="96 22 (19 %) 118  DTC-negative 73 14 87"/>
   <result pre=" DTC-negative 73 14 87  DTC-positive 23 8 31 (26 %)" exact="Total" post="82 10 (11 %) 92  CTC-negative 58 9 67"/>
   <result pre=" CTC-negative 58 9 67  CTC-positive 24 1 25 (27 %)" exact="Total" post="39 9 (19 %) 48  slCTC-negative 18 1 19"/>
   <result pre="between clinical data and DTCs, CTCs, and slCTCs before therapy" exact="Total" post="DTC-positive, n (%) p Value Total CTC-positive, n (%)"/>
   <result pre="and slCTCs before therapy Total DTC-positive, n (%) p Value" exact="Total" post="CTC-positive, n (%) p Value Total slCTC-positive (%) p"/>
   <result pre="n (%) p Value Total CTC-positive, n (%) p Value" exact="Total" post="slCTC-positive (%) p Value Tumor size 139 37 (27)"/>
   <result pre="between clinical data and DTCs, CTCs, and slCTCs after therapy" exact="Total" post="DTC-positive, n % p Value Total CTC-positive, n %"/>
   <result pre="and slCTCs after therapy Total DTC-positive, n % p Value" exact="Total" post="CTC-positive, n % p Value Total slCTC-positive, n %"/>
   <result pre="n % p Value Total CTC-positive, n % p Value" exact="Total" post="slCTC-positive, n % p Value Tumor size 163 33"/>
   <result pre="only system for CTC enumeration in BC approved by the" exact="U.S. Food and Drug Administration" post="[ 7]. However, despite the prognostic impact of CTC"/>
   <result pre="system for CTC enumeration in BC approved by the U.S." exact="Food and Drug Administration" post="[ 7]. However, despite the prognostic impact of CTC"/>
   <result pre="K Biology, detection, and clinical implications of circulating tumor cells" exact="EMBO" post="Mol Med. 2014 7 1 11 10.15252/emmm.201303698 25398926 8."/>
   <result pre="al. Tavassoli FA Devilee P et al. Invasive breast carcinoma" exact="World Health Organization" post="classification of tumours: tumours of the breast and female"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4752991/results/search/funders/results.xml">
   <result pre="However, due to incomplete understanding of the biology of the" exact="FOX" post="family of transcription factors that has complex regulatory mechanisms,"/>
   <result pre="prevent age-related proliferation defects in regenerating liver Proceedings of the" exact="National Academy of Sciences" post="of the United States of America 2001 98 20"/>
   <result pre="replication and mitosis during mouse liver regeneration Proceedings of the" exact="National Academy of Sciences" post="of the United States of America 2002 99 26"/>
   <result pre="Z. et al. Deregulation of FoxM1b leads to tumour metastasis" exact="EMBO" post="Molecular Medicine 2011 3 1 21 34 10.1002/emmm.201000107 21204266"/>
   <result pre="carcinomas distinguish tumor subclasses with clinical implications Proceedings of the" exact="National Academy of Sciences" post="of the United States of America 2001 98 19"/>
   <result pre="Discovery of a biologically active thiostrepton fragment Journal of the" exact="American Chemical Society" post="2005 127 43 15042 15044 10.1021/ja0552803 16248640 75 Kwok"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4758093/results/search/funders/results.xml">
   <result pre="KH der Elisabethinen, Ethikkommission des Landes Salzburg, Ethikkommission der Medizinsiche" exact="Universität Wien," post="Etická komise FN Olomouc, Etická komise Všeobecné fakultní nemocnice,"/>
   <result pre="Wien, Etická komise FN Olomouc, Etická komise Všeobecné fakultní nemocnice," exact="Medical Research Council" post="Ethics Committee for Clinical Pharmacology, National Medical Ethics Committee"/>
   <result pre="Medical Dictionary for Regulatory Activities (MedDRA) and assessed according to" exact="National Cancer Institute" post="Common Terminology Criteria for Adverse Events (NCI-CTCAE version 4.0)."/>
   <result pre="n (%) Grade 3 n (%) Grade 4 n (%)" exact="Total" post="n (%) Diarrhea 20 (17.1) 1 (0.9) 0 (0)"/>
   <result pre="lapatinib. Competing interests CZ has received advisory board honoraria from" exact="Roche" post="and GSK; TB has received lecture fee from GSK;"/>
   <result pre="GSK; RB received lecture honoraria and travel support from GSK," exact="Roche" post="and Pierre-Fabre; MB received honoraria for speech and advisory"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4758788/results/search/funders/results.xml">
   <result pre="Wang, Department of Surgical Oncology, The First Affiliated Hospital of" exact="Wenzhou Medical University," post="Wenzhou 325000, Zhejiang, People’s Republic of China, Tel +86"/>
   <result pre="by the Ethics Committee of the First Affiliated Hospital of" exact="Wenzhou Medical University," post="Wenzhou, Zhejiang, People’s Republic of China. Seven breast cancer"/>
   <result pre="study is summarized in Table S1. RNA extraction and sequencing" exact="Total" post="RNA was extracted from tissue samples using the TRIzol"/>
   <result pre="The cDNA libraries for single-end sequencing were prepared using Ion" exact="Total" post="RNA-Seq Kit v2.0 (Life Technologies) according to the manufacturer’s"/>
   <result pre="the human genome (version: GRCH37) using the MapSplice program (v2.1.6," exact="University of Kentucky," post="Lexington, KY, USA). We applied EBseq algorithm to screen"/>
   <result pre="a more central location of a gene within a network." exact="Core" post="regulatory factors were determined by the k-core difference (difk-core)"/>
   <result pre="Science and Technology Innovation Team of Zhejiang Province (2013TD10) and" exact="National Natural Science Foundation of China" post="(Number 81372380). Disclosure The authors report no conflicts of"/>
   <result pre="scoring, and we highlight the highest k-core-scoring hub. ( C)" exact="Core" post="LncRNAs in HER-2-enriched subtype breast cancer are listed by"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4759568/results/search/funders/results.xml">
   <result pre="D668– 672 10.1093/nar/gkj067 ( 2006). 16381955 Pence H. E. &amp;amp;" exact="Williams" post="A. Chemspider: An online chemical information resource. Journal of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4763414/results/search/funders/results.xml">
   <result pre="Keywords ERBB4 Triple negative breast cancer nCounter expression assay Funding" exact="Samsung" post="Biomedical Research Institute SBRI GL1-B2-251-1-2 Im Young-Hyuck Background Triple"/>
   <result pre="breast cancer who received adjuvant chemotherapy after curative surgery at" exact="Samsung" post="Medical Center between 2000 and 2004. Women who were"/>
   <result pre="records of breast cancer patients who received curative surgery at" exact="Samsung" post="Medical Center from 2005 to 2010. The institutional review"/>
   <result pre="Center from 2005 to 2010. The institutional review board of" exact="Samsung" post="Medical Center, Seoul, Korea approved our study protocol and"/>
   <result pre="the final manuscript. Acknowledgements This research was funded by the" exact="Samsung" post="Biomedical Research Institute (SMO 11311841). References References 1. Foulkes"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4763476/results/search/funders/results.xml">
   <result pre="Im Young-Hyuck Park Yeon Hee * [], Department of Medicine," exact="Samsung" post="Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"/>
   <result pre="Yeon Hee * [], Department of Medicine, Samsung Medical Center," exact="Sungkyunkwan University" post="School of Medicine, Seoul, Korea Sung Shian-Ying Editor [],"/>
   <result pre="* [], Department of Medicine, Samsung Medical Center, Sungkyunkwan University" exact="School of Medicine," post="Seoul, Korea Sung Shian-Ying Editor [], Taipei Medical University,"/>
   <result pre="University School of Medicine, Seoul, Korea Sung Shian-Ying Editor []," exact="Taipei Medical University," post="TAIWAN Competing Interests: The authors have declared that no"/>
   <result pre="2013. Data were obtained from the breast cancer database of" exact="Samsung" post="Medical Center. Results Among the 806 patients selected for"/>
   <result pre="grant of the Korea Health Technology R&amp;amp;D Project through the" exact="Korea Health Industry Development Institute" post="(KHIDI), funded by the Ministry of Health &amp;amp; Welfare,"/>
   <result pre="the Korea Health Industry Development Institute (KHIDI), funded by the" exact="Ministry of Health" post="&amp;amp; Welfare, Republic of Korea (grant number: HI14C1234). fig-count:"/>
   <result pre="2013. Data were obtained from the breast cancer database of" exact="Samsung" post="Medical Center. We excluded patients with local and/or contralateral"/>
   <result pre="Declaration of Helsinki and approved by Institutional Review Board of" exact="Samsung" post="Medical Center. The patient records /information was anonymized and"/>
   <result pre="1 Characteristics according to biological subtype (n = 806). Variable" exact="Total" post="HR+ HER2+ TNBC P n = n = 410"/>
   <result pre="the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines." exact="American Society of Clinical Oncology" post="Growth Factors Expert Panel . J Clin Oncol. 2000;"/>
   <result pre="283. 17962200 25 Tevaarwerk AJ , Gray RJ , Schneider" exact="BP" post=", Smith ML , Wagner LI , Fetting JH"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4764922/results/search/funders/results.xml">
   <result pre="5 Boissière-Michot Florence 6 Lopez-Crapez Evelyne 6 Theillet Charles 5" exact="Roche" post="Serge a 1 Benistant Christine b 1 2 [1],"/>
   <result pre="France). Anti-rabbit IgG-HRP (1:5,000) and anti-mouse IgG-HRP (1:5,000) were from" exact="GE Healthcare" post="(Fairfield, USA). Anti-rabbit and anti-mouse IgG coupled to Alexa-Fluor"/>
   <result pre="specific for mouse TOLLIP, mouse and human MT1-MMP were from" exact="GE Healthcare" post="(Dharmacon), Fairfield, USA. Migration and invasion assays Cell migration"/>
   <result pre="microscopie électronique, plateforme Montpellier RIO Imaging, 80 Rue Augustin Fliche" exact="BP" post="7410334091 Montpellier cedex 5). We also thank the Réseau"/>
   <result pre="animal tissues and immunostainings.This work was supported by INCa, La" exact="Ligue Contre le Cancer" post="(Labellisation Ligue 2014), CNRS and the University of Montpellier."/>
   <result pre="W. Participation of Tom1L1 in EGF-stimulated endocytosis of EGF receptor." exact="EMBO" post="J. 28, 3485– 3499 ( 2009). 19798056 Collin G."/>
   <result pre=", Franco M. , Simon V. , Benistant C. &amp;amp;" exact="Roche" post="S. The Tom1L1-clathrin heavy chain complex regulates membrane partitioning"/>
   <result pre=", Vigy O. , Orsetti B. , Urbach S. &amp;amp;" exact="Roche" post="S. Analysis of SRC oncogenic signalling in colorectal cancer"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4769490/results/search/funders/results.xml">
   <result pre="chloride hexahydrate from Sigma Aldrich (Schnelldorf, Germany); trastuzumab (Herceptin®) from" exact="Roche" post="(San Francisco, CA, USA); and ZVAD pan-caspase inhibitor z-VAD-fmk"/>
   <result pre="Biol. 1995 128 1173 84 10.1083/jcb.128.6.1173 7896880 18. Oltvai ZN" exact="Milliman" post="CL Korsmeyer SJ Bcl-2 heterodimerizes in vivo with a"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4770148/results/search/funders/results.xml">
   <result pre="Mech DMM dmm Disease Models &amp;amp; Mechanisms 1754-8403 1754-8411 The" exact="Company of Biologists" post="Ltd pmcid: 4770148 pmid: 26721874 doi: 10.1242/dmm.023143 DMM023143 :"/>
   <result pre="William J. 4 Brunton Valerie G. 1 ‡ [1], Edinburgh" exact="Cancer Research UK" post="Centre, University of Edinburgh Crewe Road South, Edinburgh EH4"/>
   <result pre="Pathology Department Western General Hospital Edinburgh EH4 2ZD UK [3]," exact="AstraZeneca" post="Oncology iMed Alderley Park, Macclesfield SK10 4TG UK [4],"/>
   <result pre="Park, Macclesfield SK10 4TG UK [4], Goodman Cancer Research Center," exact="McGill University" post="Montreal Canada H3A 1A3 * Present address: AstraZeneca Innovative"/>
   <result pre="Center, McGill University Montreal Canada H3A 1A3 * Present address:" exact="AstraZeneca" post="Innovative Medicines &amp;amp; Early Development, Darwin Building, Cambridge Science"/>
   <result pre="EMT. KEY WORDS HER2 Breast cancer Resistance Epithelial-to-mesenchymal transition Funding" exact="Cancer Research UK" post="http://search.crossref.org/fundref?q=501100000321 C157/A15703 C157/A9148 C6088/A12063 Funding Medical Research Council http://search.crossref.org/fundref?q=501100001411"/>
   <result pre="transition Funding Cancer Research UK http://search.crossref.org/fundref?q=501100000321 C157/A15703 C157/A9148 C6088/A12063 Funding" exact="Medical Research Council" post="http://search.crossref.org/fundref?q=501100001411 G0900184-4/1 INTRODUCTION Human epidermal growth factor receptor 2"/>
   <result pre="TN, USA). All experiments were conducted in compliance with UK" exact="Home Office" post="guidelines. Nulliparous females were monitored twice weekly, using manual"/>
   <result pre="their maximal size (1.5 cm in one direction) as determined by" exact="Home Office" post="regulations, mice were sacrificed. Tumours were then collected and"/>
   <result pre="(1.5 cm in any direction) was reached as permitted under UK" exact="Home Office" post="regulations. For drug studies using paclitaxel, treatment was commenced"/>
   <result pre="and wrote the manuscript. Funding This work was supported by" exact="Cancer Research UK" post="grants [C157/A15703, C157/A9148 and C6088/A12063] and a Medical Research"/>
   <result pre="Hamilton P. , Clermont A. C. , Devasthali V. ," exact="Thompson" post="J. D. , Cheng J. H. , Bou Reslan"/>
   <result pre="tumour progression in mouse models of human breast cancer ." exact="EMBO" post="J. 27, 910- 920. 10.1038/emboj.2008.22 18273058 van Miltenburg M."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4772532/results/search/funders/results.xml">
   <result pre="of ovarian shutdown drugs that have been approved by the" exact="U.S. Food and Drug Administration" post="(FDA) are goserelin (Zoladex®) and leuprolide (Lupron®). (ii) Blocking"/>
   <result pre="ovarian shutdown drugs that have been approved by the U.S." exact="Food and Drug Administration" post="(FDA) are goserelin (Zoladex®) and leuprolide (Lupron®). (ii) Blocking"/>
   <result pre="makes difficult to interpret the treatment outcome. According to the" exact="World Health Organization" post="(WHO), there are at least 18 different histological subtypes"/>
   <result pre="Technology on Innovation on Neglected Diseases (INCT/IDN, CNPq, 573642/2008-7), the" exact="Canadian Breast Cancer Foundation," post="the Allard Foundation and the Alberta Cancer Foundation. References"/>
   <result pre="Diseases (INCT/IDN, CNPq, 573642/2008-7), the Canadian Breast Cancer Foundation, the" exact="Allard Foundation" post="and the Alberta Cancer Foundation. References References 1. Cecilio"/>
   <result pre="the Canadian Breast Cancer Foundation, the Allard Foundation and the" exact="Alberta Cancer Foundation." post="References References 1. Cecilio AP Takakura ET Jumes JJ"/>
   <result pre="challenges of personalised cancer medicine: a position paper by the" exact="European Society for Medical Oncology" post="(ESMO) Ann Oncol 2014 25 1673 1678 10.1093/annonc/mdu217 24950979"/>
   <result pre="Hugo H Ackland ML Blick T Lawrence MG Clements JA" exact="Williams" post="ED et al. Epithelial - mesenchymal and mesenchymal -"/>
   <result pre="Komurov K Zhou AY Gupta S Yang J et al." exact="Core" post="epithelial- to-mesenchymal transition interactome gene-expression signature is associated with"/>
   <result pre="410 10.1038/nrc3064 21606941 72. DeBerardinis RJ Lum JJ Hatzivassiliou G" exact="Thompson" post="CB The biology of cancer: Metabolic reprogramming fuels cell"/>
   <result pre="Metab 2008 7 11 20 10.1016/j.cmet.2007.10.002 18177721 73. Jones RG" exact="Thompson" post="CB Tumor suppressors and cell metabolism: a recipe for"/>
   <result pre="Nanobiotechnol 2015 7 3 387 407 10.1002/wnan.1321 141. Mortazavi A" exact="Williams" post="BA McCue K Schaeffer L Wold B Mapping and"/>
   <result pre="et al. Tavassoli FA Devilee P et al. Lobular Neoplasia" exact="World Health Organization" post="classification of tumours 2003 Lyon, France IARC Press 60"/>
   <result pre="drug sensitivity Nature 2012 483 603 607 10.1038/nature11003 22460905 209." exact="European Commission." post="Use of ‘-omics’ technologies in the development of personalised"/>
  </snippets>
 </snippetsTree>
</projectSnippetsTree>
